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Abstract 
 
South Asian ethnicity has long been considered a contributory factor in the 
development of atherosclerosis and cardiovascular disease. Endothelial dysfunction 
is considered to be the precursor of atherosclerosis, and South Asian ethnicity has 
been linked to endothelial progenitor cell dysfunction and impaired endothelium 
dependent vasodilatation. Endothelial progenitor cell (EPC) dysfunction may 
contribute to ineffective endogenous endothelial repair, although the exact 
mechanisms remain unclear. This project aimed to validate existing data, and 
identify signalling pathways and molecular mechanisms that may be involved in EPC 
dysfunction in healthy South Asian men when compared to matched white European 
controls. In addition, the study was designed to assess the impact of South Asian 
ethnicity on EPC function in vivo, and whether modifying the signalling pathways 
linked with EPC dysfunction improved EPC function. 
 
Early outgrowth EPC numbers were significantly lower in South Asian men. EPC 
numbers were significantly increased in both South Asian and white European 
groups by treating EPCs with Simvastatin in vitro. Functional parameters such as 
migration to VEGF, adhesion to fibronectin and endothelial tubule formation induced 
by EPC conditioned medium were also impaired in South Asian EPCs. Some 
aspects of functional impairment were improved by Simvastatin. Late outgrowth 
EPCs derived from South Asian men demonstrated reduced proliferation and 
increased senescence. Western blot analysis showed reduced basal Akt and 
endothelial Nitric Oxide Synthase (eNOS) expression in South Asian late EPCs. 
Vascular repair of injured conduit vessel following transfusion of South Asian late 
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EPCs was significantly impaired - this was rescued by increasing Akt activity using 
Lentiviral delivery of constitutively active Akt. Abnormal phosphotidyl-inositol-3-
kinase/Akt signalling may therefore contribute to EPC dysfunction in South Asian 
men. These data provide novel insights into mechanisms underlying EPC 
dysfunction which may contribute to increased atherosclerosis burden in people of 
South Asian origin. Future research avenues have been identified, which may guide 
development of novel strategies in preventing and treating cardiovascular disease. 
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1. General Introduction 
Despite advances in medicine and a reduction in cardiovascular mortality in the past 
5 years, variable outcomes have been noted between genders and ethnicities.1 
South Asian populations in particular have been demonstrated to exhibit a higher 
incidence and prevalence of cardiovascular disease (CVD), with studies showing a 
50-60% greater death rate from CVD compared to white European males.2 Given 
this group forms a significant portion of the population of the United Kingdom, it 
presents a significant burden on the healthcare system. Conventional risk factors 
such as smoking and hypertension may play an important role; however non-
conventional risk factors may also play a significant part in the pathogenesis of 
cardiovascular disease in this group. A detailed discussion of this concept follows. 
1.1 South Asian ethnicity and Cardiovascular risk 
1.1.1 Defining ‘South Asian’ ethnicity 
 
The Indian subcontinent represents one quarter of the developing world’s population, 
and so the South Asian ethnic group forms one of the largest ethnic groups in the 
world. Unlike race, whose definition relies heavily on physical attributes such as hair 
and skin colour, ethnicity is a complex concept that encompasses many 
components.3 Numerous factors play an important role in defining ethnicity, including 
geographic origin, religion, diet and other cultural practices. In short, clearly defining 
ethnicity is a difficult task, and most published studies define South Asian ethnicity 
based on geographic location alone i.e. those subjects hailing from India, Pakistan, 
Nepal, Bangladesh and Sri Lanka. This, however, does not include a homogenous 
group of individuals as geographic origin alone neglects numerous additional 
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aspects of ethnicity. Furthermore, within commonly defined ethnic groups exists 
many subgroups, each with distinct cultural practices. This has been observed in 
studies that have shown variable prevalence in disease between subgroups of 
subjects residing in Pakistan.2 When put into this perspective, South Asian 
population groups studied within the UK are likely to exhibit further diversity. Given 
the wide variability in the definitions of ethnicity in the relevant literature, for the 
purposes of this discussion, ‘South Asian’ is defined geographically as hailing from 
India, Pakistan, Nepal, Bangladesh and Sri Lanka unless stated otherwise. 
1.1.2 Epidemiology 
 
In 2004, the Health Survey for England observed a high prevalence of 
cardiovascular disease in South Asian populations, with the highest prevalence seen 
in Pakistani men (9.1%) when compared to the general population (7.9% IHD and 
stroke combined).1 Over a 5 year period, the prevalence had nearly doubled in both 
these groups, with an increase from 4.8% to 9.1% seen in Pakistani men, and 2.3% 
to 4.2% seen in Indian women.1 Age-standardised risk ratios demonstrated a similar 
pattern to these observed percentages. In particular, risk ratios for angina were high 
in South Asians, particularly Pakistani men (2.85) whose prevalence was 
significantly greater than the general population (1.0 by definition). Cardiovascular 
mortality has also been demonstrated to be significantly higher in subjects born in 
the Indian subcontinent, with values 15-60% greater than the entire population of 
England and Wales.4, 5  In a cross sectional survey assessing heterogeneity of 
various coronary heart disease risk factors within South Asian population groups, a 
number of potentially relevant differences were found in the risk factor profile 
between various groups.6 These differences between South Asians and white 
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Europeans aside, there were also differences noted in economic circumstances and 
anthropometric measurements between Bangladeshi, Pakistani and Indian groups. 
Smoking was more prevalent in Bangladeshis, who also had the highest triglyceride 
and fasting glucose concentrations. However, they were shorter than and had lower 
blood pressure than Indian and Pakistani men. This led the authors to the conclusion 
that risk factors between groups are not uniform, and could underlie varying 
prevalence of coronary artery disease within these groups. 
1.1.3 South Asian ethnicity, socio-economic class and health care provision 
 
The relationship between lower socio-economic class and poorer health outcomes 
has been extensively studied.7, 8 In India, cardiovascular disease (CVD) was initially 
considered to primarily affect the affluent class, though this trend seems to have 
changed since the 1990’s.9 Over time, it has become apparent that CVD mostly 
affects the socioeconomically disadvantaged groups.10 Within the UK, a similar trend 
has been noticed in migrant South Asian populations in keeping with the changes in 
India. Recent work by Tillin et al demonstrated an increased risk of CVD in South 
Asians within lower socioeconomic classes, defined by fewer years of education.11  
 
In a study conducted to identify issues related to lifestyle risk factors in a focus group 
of South Asians over the age of 40yrs in Leicester, UK, Farooqi et al demonstrated 
that language barrier played a key role in accessing appropriate healthcare in a 
clinical setting.12   
 
The 1991 UK census data, whilst showing similar proportions of general and South 
Asians populations in specific social classes, revealed higher all cause mortality and 
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mortality due to ischemic heart disease in South Asians within comparable classes.13 
This disproportionality was mostly driven by the higher disease rates in Bangladeshi 
men. Individual groups’ experiences in the UK health care system have been 
variable and conflicting in terms of investigations and management of cardiac 
disease. Earlier work has suggested that South Asians wait longer for referral 14 and 
treatment 15 of ischemic heart disease for reasons that are not very clear. However, 
the Whitehall II study showed a higher rate of coronary artery disease in South 
Asians despite appropriate utilisation of investigations and secondary prevention 
measures.16 Despite this conflict, South Asian populations have experienced similar 
improvements in outcome and a decline in mortality following myocardial infarction 
when compared to the white European population.17 
1.1.4 Pathogenesis 
 
A number of factors may play a role in the higher prevalence of CVD in South Asian 
populations groups. These are discussed below. 
1.1.4.1 South Asian ethnicity , Insulin resistance and Diabetes mellitus 
 
In a study of anthropometric and biochemical data in 3,754 South Asian, Afro-
Caribbean and European subjects between 40-69 years of age, McKeigue et al 
found a high prevalence of type 2 diabetes mellitus in the South Asian population 
groups, with values approaching 20% compared to 4% in white European 
counterparts.18 In India, urbanisation is thought to have had a significant impact in 
the prevalence of type 2 diabetes, with an age-standardised prevalence of 11.2% in 
urban population compared to 2.4% in rural population.19 Within the UK, South Asian 
subjects develop diabetes 10 years earlier than white Europeans.20  
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The pathogenesis of diabetes mellitus involves both pancreatic β-cell dysfunction 
and insulin resistance, though the actual prevalence of this may vary between ethnic 
groups. In South Asians, insulin resistance plays a key role in the pathogenesis of 
type 2 diabetes 21, while in Afro-Caribbeans pancreatic β-cell dysfunction may make 
a larger contribution.22  
 
Diabetes has been identified as an independent risk factor for the development of 
cardiovascular disease.23 However, numerous additional factors play a role, 
including smoking, obesity, hypertension, elevated plasma cholesterol and raised 
triglycerides, all of which are more prevalent in South Asians (see table 1).6, 21 
Clustering of these risk factors was initially described by McKeigue et al, who 
identified a relationship between glucose intolerance, hyperinsulinemia and intra-
abdominal fat distribution in South Asians.24 These risk factors put together form the 
‘metabolic syndrome’, and previous studies have shown that subjects with metabolic 
syndrome face a greater risk of all cause and cardiovascular mortality when 
compared to those without the syndrome.25 
 
 
White 
Europeans 
UK South asians 
Punjabi 
Sikh 
Punjabi 
Hindu 
Gujarati 
Hindu 
Muslim 
Cigarette 
Smoking (%) 
 
30 4 21 33 30 
Systolic BP 
(mmHg) 
 
121 128 126 122 120 
Total 
Cholesterol 
(mmol/L) 
 
6.1 6.1 5.9 5.5 6.0 
Diabetes (%) 
 
5 20 19 22 19 
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2 hr insulin 
(mU/L) 
 
19 39 42 49 43 
HDL 
Cholesterol 
(mmol/L) 
 
1.24 1.22 1.17 1.14 1.04 
 
Table 1: Prevalence of risk factors for coronary artery disease in South Asians vs. 
White Europeans6 
 
 
Insulin resistance describes a reduction in the signalling effects of insulin, which over 
time results in a phenotype of impaired glucoregulation. It manifests early in South 
Asians; Whincup et al have demonstrated that in children between ages 8-11 years, 
South Asians had a higher fasting and post-glucose insulin concentrations compared 
to their white European counterparts, despite lower body weight.26 Blood glucose 
concentrations were similar in the two groups. Asian Indians have significantly higher 
proportions of visceral and total abdominal fat, levels of which were found to be 
inversely related to glucose disposal rate and directly related to insulin resistance.18, 
27  Foetal under-nutrition is believed to play a part in these phenomena, with 
metabolic adaptations resulting in a ‘thrifty phenotype’ designed to preserve energy 
and promote brain growth in utero (see below).  
South Asian diets consist predominantly of carbohydrates 28, consumption of which 
are higher in India than in migrant Indians in the UK.29 A high carbohydrate diet has 
been shown to induce hyperinsulinemia in South Asian subjects 29 Dietary fat intake 
is higher in migrant South Asians 30, and interestingly intake of saturated fat does not 
correlate with degree of hyperinsulinemia.29 Vegetarian diets did not confer 
additional protection when compared to non-vegetarian diets, with reports 
suggesting a higher prevalence of truncal obesity and higher BMI in vegetarians.31, 32 
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However, the impact of a vegetarian diet on insulin sensitivity is yet to be extensively 
investigated. Higher post glucose load hyperinsulinemia has been reported in South 
Asian vegetarians when compared to white European counterparts.33  
 
Physical inactivity has a direct relationship to obesity and onset of hyperglycaemia. 
South Asians in particular lead a sedentary lifestyle when compared to other ethnic 
groups, which may contribute to higher insulin levels.34 To some extent, this has 
been due to urbanisation and migration patterns. However, there is insufficient data 
available at present to causally link this with insulin resistance in South Asian 
groups. 
 
The role of genetics in development of insulin resistance has been inadequately 
studied. In a study assessing the inter-relationship between truncal obesity and 
insulin resistance in Asian Indians, Chandalia et al found Asian Indians to be more 
insulin resistant than Caucasians, independent of generalised or truncal adiposity.35 
In a study assessing insulin resistance and cardiovascular risk in immigrant Asians, 
fasting insulin levels were measured followed by levels after 1 and 2 hours of an oral 
glucose load. Fasting insulin levels were significantly higher in British Asians and 
Indian Asians when compared to white European subjects. There was no difference 
between the two South Asian groups two hours after glucose load. This could 
suggest a genetic component to insulin resistance in this group.36 However, with 
respect to inheritance of coronary artery disease risk, recent genome wide 
association studies have failed to show material differences in effect size or allelic 
frequency of established susceptibility variants between European and South Asian 
cohorts.37  
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1.1.4.3 South Asian ethnicity, dyslipidemia and obesity  
 
Prospective studies have shown an increase in CAD amongst South Asians when 
compared with white Europeans, after accounting for insulin resistance, diabetes, 
metabolic syndrome and socio-economic status.2 Hyperinsulinemia and consequent 
insulin resistance is associated with reduced high density lipoprotein (HDL) 
cholesterol concentrations and hyper-triglyceridemia.38 In addition to this, South 
Asians also demonstrated elevated small-dense low density lipoprotein (LDL) 
concentrations.39 Small LDL particles are more atherogenic than normal sized 
particles and there is evidence that individuals with these particles are at a higher 
risk of developing coronary artery disease.40 Furthermore in South Asians, total HDL 
is usually low, and most HDL particles are small in size which renders them less 
protective.41 The abundance of HDL 2b, which is the most protective component of 
HDL, is significantly lower in Asian Indians when compared to non-Asian Indians.42 
 
Obesity, defined as a BMI >30 kg/m2 , is highly prevalent in migrant South Asian 
populations 18, and in urban populations in India.43 This pattern of obesity starts in 
childhood, and appears to increase with urbanisation and migration.44, 45 In addition, 
South Asians have a lower lean body mass and a relatively higher body fat, 
suggesting a BMI of < 25 kg/m2 may not necessarily reflect ‘normal’ body 
composition.46 The International Diabetes Federation guidance in defining metabolic 
syndrome uses a lower waist circumference cut off to measure central obesity in 
South Asians.47 Abdominal and intra-abdominal fat mass is high in South Asians as 
well, with thicker truncal skin folds.48, 49 However, despite this, waist to hip ratio 
remains comparable to white Europeans, primarily due to small waist size in South 
Asians.50 This combination of increased abdominal and intra-abdominal fat and body 
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fat patterning may be important determinants of dyslipidemia and insulin 
resistance.48, 49  
1.1.4.2 The ‘thrifty phenotype’ hypothesis 
 
The thrifty phenotype hypothesis, also termed ‘Foetal origin of Adult Disease 
(FOAD)’ proposes that foetal and infant under-nutrition induces permanent changes 
in metabolism, resulting in a predisposition to type 2 diabetes and cardiovascular 
disease in adulthood.51 These adaptations include a reduced capacity for insulin 
secretion and insulin resistance, which when combined with other risk factors such 
as obesity and physical inactivity, may be important determinants of the development 
of type 2 diabetes. The mean birth weight of South Asian babies is one of the lowest 
in the world at 2.6-2.8 kg, and remains so in UK South Asians.52 Low body weight in 
infancy is common, and adaptation of an urban lifestyle results in infants ‘catching 
up’, eventually leading to childhood and adult obesity and thus increasing their risk. 
This mismatch of ‘post natal plenty’ with ‘foetal thrift’ has been described as the 
‘adaptation-dysadaptation’ phenomenon.52 
 
1.1.4.3 Other conventional risk factors 
 
Smoking, hypertension and hypercholesterolemia are important risk factors in the 
development of CVD. The Health Survey for England 1999 provided useful insights 
into the prevalence of cardiovascular risk factors in ethnic minorities in the UK.53 
Indian and Pakistani men tended to smoke less, though Bangladeshi men were 60% 
more likely to smoke. Women tended to smoke less than men, which probably reflect 
traditional practices. Systolic blood pressure was comparable between South Asian 
and white European counterparts. However, this does not dismiss them as important 
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risk factors, as migration and adoption of local practices can have a significant 
impact on inter-ethnic risk profile. Patel et al demonstrated migrant South Asian 
populations demonstrated a higher body mass index (BMI), systolic blood pressure, 
blood glucose and serum cholesterol when compared to their siblings in India.54 
1.1.4.4 Non conventional risk factors 
 
A west London study demonstrated a 1.5 fold excess of pathological Q waves on 
ECG (indicative of a previous myocardial infarction) amongst South Asians after 
adjusting for age, smoking, diabetes, cholesterol, waist-hip ratio and glucose 
intolerance. This implies that conventional risk factors alone may not explain the 
higher prevalence of CVD in South Asians.55 Ethnic variations in inflammation, 
homocysteine concentrations, lipoprotein profiles and diet have been proposed as 
possible risk factors. 
 
Inflammation is a central feature of atherosclerosis.56 Inflammatory cytokines such as 
adipokines released from adipose tissue have been shown to play a role.57 They 
include TNF-alpha, C-reactive protein 58, leptin and resistin 59, and high 
concentrations of these markers have been found in healthy South Asians when 
compared to white Europeans. Alterations in adipokine production may therefore 
play a role in the increased cardiovascular risk observed in South Asians. In addition, 
high concentrations of Lipoprotein (a) 60 and homocysteine 61 have been noted in 
South Asians, and this are speculated to play a role in the higher incidence of CVD, 
but these associations are purely speculative. 
 
1.2 The Endothelium  
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The endothelium is the cellular monolayer lining all blood vessels that forms an 
interface between the circulating blood and the perfused tissues. Once considered 
just a simple barrier, the endothelium has now been demonstrated to possess a 
number of properties that affect numerous physiological processes.  
1.2.1 The Endothelium in health 
 
The vascular endothelium serves not merely as a passive barrier between flowing 
blood and the vascular wall, but plays a pivotal role in the maintenance of vascular 
tone. It produces a number of substances that mediate vasoconstriction (Endothelin-
1, Angiotensin-II and Thromboxane A-2) and dilatation (Nitric oxide, Prostacyclin, 
EDHF) in addition to modulating inflammatory cell extravasation, regulating 
thrombosis and fibrinolysis. The presence of an intact endothelium has been 
demonstrated to be essential for acetylcholine (ACh) induced vasodilatation of 
isolated arteries.62 Subsequent studies showed the substance mediating ACh 
induced vasodilatation to be nitric oxide (NO).63 NO is thought to be an important 
mediator of vasomotor endothelial function, and exerts numerous other effects 
including inhibition of platelet aggregation 64, impairing adhesion of leucocytes to 
endothelium 65 and inhibition of vascular smooth muscle migration and proliferation 
66, all of which may retard the progression of atherosclerosis. 
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Figure 1- Synthesis of NO and its actions 
 
Endothelium derived NO is synthesised by the enzymatic conversion of L-Arginine to 
L-Citrulline by endothelial Nitric Oxide Synthase (eNOS), using tetrahydrobiopterin 
(BH4), Flavin Adenine Dinucleotide (FAD) and Flavin Mononucleotide (FMN) as co-
factors (see figure 1). eNOS is predominantly located in ‘caveolae’ – flask shaped 
invaginations in the cell membrane that forms around 30% of the cell surface in 
capillaries.67 The caveolar coat protein Caveolin-1 interacts with eNOS through 
calmodulin and inhibits its activity. However, an increase in intracellular calcium in 
response to shear stress or certain vasodilatory stimuli results in displacement of 
caveolin-1 from calmodulin, thus releasing eNOS.68 The NO subsequently generated 
diffuses to the vascular smooth muscle and increases cyclic guanosine 
monophopshate generation, resulting in smooth muscle relaxation. NO appears to 
be a critical effector in a number of endothelial signalling pathways, and this is 
discussed in detail below. 
1.2.1.1 Endothelial intracellular signalling pathways 
 
1. eNOS signalling and Nitric Oxide production 
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As a principle modulator of vasoreactivity, NO has a number of downstream effects. 
The degree to which it exerts these effects depends on a delicate balance between 
its production and degradation. As NO production is dependent on eNOS activity, 
adequate transcription and translation of eNOS is essential to maintain NO 
synthesis. eNOS transcription is augmented by a number of stimuli ranging from 
shear stress 69, insulin 70, statins 71, VEGF 72, exercise 73 and low levels of oxidised 
LDL.74 This is in contrast to stimuli such as hypoxia 75 and inflammatory cytokines.76 
  
The eNOS protein consists of a reductase and an oxygenase domain which are 
connected to each other by a flexible protein strand. NADPH catalyses 
dehydrogenation of the reductase region, resulting in the production of electrons that 
transfer across the flexible protein strand to the oxygenase region. These electrons 
are required for nitric oxide generation.77 In addition to this, the oxygenase region 
binds tetrahydrobiopterin (BH4), an important cofactor in synthesis of NO. Deficiency 
of BH4 or even L-arginine can result in uncoupling of eNOS, resulting in superoxide 
(O2
-) and hydrogen peroxide radical production instead of NO.78 In conditions of 
oxidant stress, despite adequate production of NO, O2
- production can inactivate it 
rapidly. Interaction between NO and O2
- produces peroxynitrite, itself a reactive 
oxygen species, which can oxidise BH4 and deplete it.79 
The flexible protein strand of eNOS has a specific binding site, to which attaches 
calmodulin. Calmodulin is an essential activator of eNOS. When electrons essential 
for NO production are released from the reductase region of the eNOS protein, the 
transfer across to the oxygenase region is facilitated by binding of calcium to 
calmodulin. A deficiency of calmodulin can thus result in reduced NO production. 
31 
 
Agonists such as acetylcholine that increase intracellular calcium promote binding of 
calmodulin to eNOS, thus increasing its activity. 
 
Besides the above mechanisms, eNOS is also regulated through other post-
translational mechanisms which include phosphorylation at Serine 1177 (Ser1177). 
Phosphorylation of Ser 1177 is catalysed by Akt80 in addition to other kinases such 
as AMP-activated protein kinase (AMPK), and results in activation of eNOS by 
inhibiting calmodulin dissociation from eNOS.81, 82 This interaction results in 
increased NO production; a similar effect is seen following phosphorylation of Ser 
617 by Akt or PKA which renders eNOS more susceptible to activation by 
calmodulin.83 
 
2. The PI-3 kinase / Akt pathway and relationship to eNOS 
The PI-3 kinase / Akt signalling pathway has been shown to play a pivotal role in the 
phosphorylation of eNOS at serine 1177, resulting in an increase in endothelial NO 
production.80 Ziche et al demonstrated that VEGF stimulated an eNOS-dependent 
angiogenic response in a model of corneal angiogenesis, and eNOS mediated NO 
production was demonstrated by Dimmeler et al to be dependent on Akt signalling.80, 
84 Signalling via this pathway confers increased cell survival, reduced apoptosis and 
promotes angiogenesis.85  Indeed, infection of rabbit arterial endothelial cells by a 
viral vector encoding a constitutively-active Akt demonstrated increased blood flow 
and local NO-mediated vasodilatation, a process which was blunted when a virus 
encoding a dominant negative Akt was used.86 Similar results have been shown in a 
study of penile erection in rats, where Akt dependent eNOS phosphorylation was 
demonstrated to play a key role in maintaining erection- a process that was reduced 
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by wortmannin and LY294002  (inhibitors of PI3-kinase).87 Interestingly, amongst the 
Akt isoforms, Ackah et al demonstrated Akt-1 to be the crucial isoform in 
phosphorylation of eNOS and angiogenesis in mouse hind limb ischemia studies.88  
 
3. Reactive oxygen species 
Reactive oxygen species (ROS) are products of normal cellular metabolism. They 
are usually produced as a result of reactions catalysed by cellular enzyme systems, 
which include NADPH oxidase, xanthine oxidase, mitochondrial enzyme complexes, 
cytochrome P450 and uncoupled eNOS.89 Classically, ROS were considered to be 
products of cellular metabolism that exerted detrimental effects on numerous cellular 
structures.90 However, more recently, they have also been identified as critical 
regulators of a number of intracellular signalling pathways.91 Enhanced ROS 
production has  however been implicated in the pathogenesis of a number of 
cardiovascular risk factors including hypertension and diabetes mellitus.92 In 
particular, NADPH oxidases are a major source of ROS in the vasculature, with high 
levels of Nox2 and Nox 4 NADPH oxidases evident in atherosclerotic plaques in 
diseased coronary arteries.93 NO degradation is principally mediated by ROS, which 
react with NO and produce peroxynitrite, which in itself is a form of ROS. While 
NADPH oxidase plays a critical role in cell signalling processes, evidence suggests 
that excess NADPH oxidase activity is linked to worse cardiovascular outcomes.94 
Despite the wealth of evidence supporting the detrimental effects of ROS, certain 
groups have shown activation of endothelial NADP(H) oxidase by angiogenic factors 
such as VEGF promotes endothelial cell migration and proliferation, which in turn 
may contribute to postnatal angiogenesis in vivo.95 In keeping with available 
evidence, it appears physiological concentrations of reactive oxygen species appear 
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essential to maintain normal endothelial function, and concentrations higher than this 
appear to be detrimental. 
1.2.2 The Endothelium in disease  
1.2.2.1 Atherosclerosis and endothelial dysfunction 
 
Atherosclerosis has been described as a systemic inflammatory disease affecting 
the arterial wall.96 Atherosclerotic plaques mediate the mortality and morbidity of 
cardiovascular diseases, including angina, claudication, myocardial infarction and 
strokes. Cholesterol forms a major component of atherosclerotic plaques, and it is 
well established that hypercholesterolemia is an important risk factor in the 
development of atherosclerosis.97 However, atherogenesis is more than just lipid 
accumulation in the vessel wall, and the precursor event leading onto atherosclerosis 
is widely thought to be endothelial dysfunction, even in the absence of 
angiographically evident coronary disease.98 
 
The endothelium possesses innate antioxidant properties which are overwhelmed in 
the presence of high LDL. Oxidised LDL is a potent inducer of ROS generation that 
play a major role in the pathogenesis of atherosclerosis. Endothelial injury appears 
to be the triggering factor (‘response to injury’ hypothesis 56) and the resultant 
endothelial dysfunction results in a cascade of events that alter the homeostatic 
properties of the endothelium. Enhanced endothelial expression of luminal leukocyte 
surface adhesion molecules leads to increased adhesion of circulating monocytes. 
These release a number of pro-inflammatory cytokines, which promote smooth 
muscle cell proliferation in the tunica media, along with further monocyte recruitment. 
Monocytes cross the endothelium and differentiate into macrophages, which ingest 
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and oxidise free lipoproteins, resulting in the formation of ‘foam cells’. The 
accumulation of foam cells within the vessel wall forms fatty streaks which 
progressively grow and coalesce, with surrounding smooth muscle and fibrous tissue 
encapsulating the fatty streak to form more advanced plaques. Macrophages also 
release pro-inflammatory mediators which further stimulate atherogenesis. 
Eventually these plaques can obliterate the vessel lumen, causing a reduction in flow 
of blood flow and ischemia of target tissues, resulting in clinical syndromes such as 
angina and claudication. Ongoing inflammation destabilises the fibrous cap of the 
plaque predisposing to plaque rupture, which promotes overlying thrombosis and 
abrupt vessel occlusion, causing myocardial infarction and some forms of ischemic 
stroke (See figure 2).  
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Figure 2: Pathogenesis of atherosclerosis (Modified from Textbook Of Physiology, 
Arthur Guyton ) 
 
Atherogenesis begins early in life, and the conventional cardiovascular disease risk 
factors have all been linked with endothelial dysfunction.99 Cigarette smoking is 
potent inducer of endothelial dysfunction, with studies showing significant functional 
impairment in conjunction with hypercholesterolemia.100 Hypercholesterolemia is a 
well recognised risk factor in the development of atherosclerosis, and certainly 
oxidised LDL seems to play a major role in the pathogenesis of the atherosclerotic 
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plaque, as previously discussed. Studies have demonstrated a significant risk 
reduction in the major cardiovascular events following the reduction in levels of LDL 
cholesterol.101 Furthermore, a reduction in LDL cholesterol by HMG-CoA reductase 
inhibitors is associated with an improvement in endothelial function.102  Central 
adiposity is also recognised as important risk factor, and certainly a strong link has 
been established with endothelial dysfunction, as evidenced by blunted FMD in 
obese subjects.103  Central obesity is associated with altered release of adipokines 
that modulate fatty acid and glucose catabolism. While adipocyte products such as 
adipocyte-derived relaxing factor 104  and adiponectin 105 confer protection against 
development of atherosclerosis, the overall effect of increasing obesity is increased 
production of non-esterified free fatty acids and numerous pro-inflammatory 
cytokines including TNF-α, plasminogen activator inhibitor-1 (PAI-1) and C-reactive 
protein (CRP) to name a few. The free fatty acids deposit in ectopic sites such as the 
liver and muscle, eventually leading to insulin resistance and diabetes mellitus. 
Clustering all the above risk factors, Reaven coined the term ‘syndrome X’, 
establishing a link to insulin resistance.106 Over the years the definition has evolved 
and is termed ‘metabolic syndrome’, which clumps together abdominal obesity, 
atherogenic dyslipidemia (elevated triglycerides and low HDL), elevated blood 
pressure, insulin resistance and elevated pro-inflammatory and prothrombotic 
markers.107 It is now established that it is linked with increased risk of future 
cardiovascular events.108 
 
NO released from healthy endothelium plays an important role in retarding platelet 
aggregation and thrombus formation. In addition to this, dysfunctional endothelium 
secretes more plasminogen activator inhibitor -1, an inhibitor of fibrinolysis, which 
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contributes to an overall prothrombotic state.77 These form an important aspect in the 
pathogenesis of atherosclerosis. 
1.2.2.2 Insulin resistance and endothelial dysfunction 
 
It is well established that obesity, type II diabetes and insulin resistance are major 
risk factors in the development of atherosclerosis and subsequent cardiovascular 
disease.109, 110 Insulin regulates glucose disposal at a number of sites in the body, 
including muscle and adipose tissue. It does so by attaching to its cell surface 
receptor thus activating a cascade of downstream signalling molecules mediating its 
metabolic effects.  This is mediated by activation of the insulin receptor’s tyrosine 
kinase domain, which via a number of intermediaries promotes activity of the PI3 
kinase and MAP kinase pathways. The PI3 kinase molecule is essential for insulin 
stimulated GLUT-4 translocation, which is responsible for insulin-regulated glucose 
translocation into cells.111  
 
 In addition to its metabolic effects, insulin also plays a role in vascular endothelial 
NO production, leading to enhanced blood flow, vasodilatation and augmented 
skeletal muscle glucose disposal.112 Studies have demonstrated the presence of 
insulin receptors on the surface of the endothelium.113, 114 However, insulin signalling 
pathways that regulate endothelial NO production are similar to the insulin signalling 
pathways that regulate its metabolic effects in adipose tissue and skeletal muscle.115 
The relative contributors of whole body insulin resistance and endothelium specific 
insulin resistance to endothelial dysfunction and atherosclerosis remain unclear, 
although recent data indicate endothelium-specific insulin resistance is 
atherogenic.116  
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In the vascular endothelium, insulin receptor activation stimulates two major 
signalling cascades: the PI3 kinase pathway which is involved in NO production, and 
the MAP kinase pathway which is predominantly involved in cell growth / division. 
The activation of the PI3 kinase pathway is dependent on phosphorylation of insulin 
receptor substrate-1 (IRS -1), which appears to play a major role in mediating insulin 
stimulated endothelium-dependant vasorelaxation 117 (see figure 3). Following 
phosphorylation by the activated insulin receptor, IRS -1 binds and activates PI3 
kinase, which leads to generation of phosphoinositide (3,4,5) triphosphase which 
stimulates membrane localisation of phosphoinositide-dependent kinase 1 (PDK-1). 
PDK-1 is then able to phosphorylate and activate Akt 113, 118, which in turn 
phosphorylates eNOS at serine 1177, resulting in enhanced eNOS activity and NO 
production.80 However, phosphorylation is the not the only mechanism involved in 
regulating eNOS activity, and other post translational modifications have also been 
described.119, 120 
 
Insulin also stimulates the production of Endothelin-1 (ET-1), a potent 
vasoconstrictor. Work by Potenza et al 121 demonstrated the role of MAP kinase 
signalling in endothelial ET-1 secretion. By studying bovine aortic endothelial cells, 
they showed that insulin treatment induced an increase in ET-1 levels in conditioned 
medium, a process blocked by PD-98059 (a MAP kinase inhibitor) and not by 
wortmannin (a PI3 kinase inhibitor). A similar effect was seen in cell lysates, 
implicating regulation of ET-1 secretion by MAP kinase signalling and not PI3 kinase 
signalling.  
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Figure 3: Stimulation of insulin receptor and downstream effects on endothelium  
 
 In insulin resistant states, signalling via the PI3 kinase pathway is downregulated, 
while the MAP kinase signalling is overactive, resulting in ‘pathway-specific insulin 
resistance’, a term coined by Quon et al, as a contributor to the pathophysiology of 
endothelial dysfunction associated with insulin resistance.122, 123 At a molecular level, 
insulin resistance is accompanied by reduced insulin stimulated tyrosine 
phosphorylation of IRS-1, perhaps due to inhibitory phosphorylation of nearby serine 
residues.122 The MAP kinase pathway is activated normally by interaction between 
Grb-2/Sos and IRS-1 or Shc. However, in insulin resistant states, the former 
interaction is downregulated but the reduced phosphorylation of the IRS-1 receptor is 
sufficient enough to maintain a normal interaction between Grb-2/Sos and Shc, 
resulting in normal MAP kinase pathway activity.124  A number of factors seem to 
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play a role, including hyperglycemia and elevated free fatty acid levels. 
Hyperglycemia increases the production of ROS, which can activate transcription 
factors Nuclear Factor κB (NF-κB) and activator protein -1 (AP-1). These 
transcription factors can also be activated by lipopolysaccharides and free fatty 
acids. Once stimulated, they enhance transcription of proinflammatory cytokines (IL-
1, TNF-α), which results in insulin resistance by affecting insulin signalling via 
paracrine effects.125 Thus NF- κB  plays a pivotal role in inflammation mediated 
pathway-specific insulin resistance, and a recent study has corroborated this.126 
Metabolic insulin resistance is accompanied by compensatory hyperinsulinemia in 
order to maintain a euglycemic state. Hyperinsulinemia results in over-activity of 
MAP kinase dependent pathways, resulting in an imbalance between PI3-kinase and 
MAP kinase dependent effects of insulin. By doing so, molecules whose secretion is 
regulated by MAP kinases such as ET – 1 are over-expressed and molecules 
dependent on PI3 kinase activity (such as NO) are reduced, which is characteristic of 
endothelial dysfunction.  
 
By mimicking pathway specific insulin resistance via pharmacological inhibition of 
PI3 kinase pathway, Montagnani et al demonstrated enhanced mitogenic effects of 
insulin mediated via the MAP kinase pathway.127 This also results in increased 
expression of leukocyte adhesion molecules such as ICAM-1, VCAM -1 and E-
selectin due to greater availability of prenylated Rho and Ras proteins. These 
adhesion molecules are believed to play an important role in the initiation of 
atherogenesis.128 Furthermore, increased circulating concentrations of soluble 
adhesion molecules correlate strongly with future cardiovascular events.129, 130 
Reduction in NO production blunts vasodilatation in response to insulin – an effect 
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that is mediated by the PI3 kinase pathway.123 Similar effects are seen in obese 
subjects and patients with type 2 diabetes mellitus.131  
 
It is evident from the above discussion that insulin signalling pathways involving the 
PI3-kinase regulate GLUT-4 translocation and subsequent glucose uptake in 
adipose tissue and skeletal muscle. The same pathway regulates eNOS activation 
and NO production in the endothelium. Thus, metabolic insulin resistance and 
endothelial dysfunction appear to be pathophysiologically related to selective 
downregulation of the PI3-kinase signalling.115, 122 
  
Insulin resistance is particularly prevalent in South Asian population groups, and is 
associated with endothelial dysfunction.132 A non-invasive study of the endothelium-
dependent conduit vessel flow mediated dilatation in SA males suggested significant 
blunting when compared with WE counterparts and this was associated with insulin 
resistance.133 Insulin resistant patients have elevated ET-1 levels, and patients with 
hyperinsulinemia associated with metabolic syndrome also demonstrate elevated 
ET-1 levels.134 
1.2.3 Endothelial cell senescence 
 
In 1961, Hayflick and Moorhead first described senescence in human skin 
fibroblasts.135 The term ‘replicative senescence’ was coined; implying diploid cells 
had a limited capacity to divide in cell culture, eventually leading to an arrest in cell 
division. Numerous hypotheses were stated, including the belief that cellular 
senescence was an anticancer mechanism. At one point, senescence was believed 
to be the only marker of ageing – the loss of regenerative capacity of cells in vivo. 
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This meant that senescence had both beneficial and detrimental effects. Future 
studies conducted have shown that associated with these effects is a rather striking 
phenotypic change, which include apoptosis and altered gene expression. In 1995, 
Dimri et al demonstrated the histochemical marker beta-galactosidase detected 
senescent keratinocytes and fibroblasts in skin biopsies of elderly people.136 
Experiments conducted by Kurz et al have demonstrated, through beta-
galactosidase staining, deposition of senescent cells at site of denudation following 
balloon injury in rabbit carotid artery 137, confirming the occurrence of vascular 
senescence in vivo.   
 
A number of factors play a role in triggering cell senescence. The vasculature in 
humans is exposed to a circulating reactive oxygen species and other insults, 
including modified lipoproteins. These can result in rapid telomere damage and 
shortening, which can result in senescence.  
 
 
              Figure 4: Mechanism of senescence and resultant phenotype 
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In essence, telomere length is inversely related to endothelial cell age in vivo 138, and 
senescence is reached when the telomeres are shortened below critical length.139  
Previous work has demonstrated the presence of senescent endothelial cells in 
human atherosclerotic lesions but not in non-atherosclerotic lesions.140 However, the 
role of diabetes and insulin resistance in endothelial cell senescence is poorly 
understood. Hyperglycaemia, a feature of both insulin resistance and diabetes, can 
lead to oxidative stress, which in turn can result in premature senescence of normal 
endothelial cells.141  Studies examining the relationship between coronary artery 
disease and telomere length found that telomeres from endothelial cells derived from 
diseased portions of coronaries were shorter than the non-diseased regions.142 
 
1.3 Endothelial progenitor cells 
 
The first indication of the presence of endothelial progenitor cells dates back to the 
early 1930’s, when Heuper and Russell found capillary-like formations in leukocyte 
cultures143. In the early 1950’s, human patients with cardiovascular disease were 
having diseased segments of large blood vessels replaced by artificial vascular 
grafts, which upon later excision were covered in a layer of endothelial cells.144 For a 
number of years, the established theory regarding postnatal new vessel growth 
invoked proliferation and migration of fully differentiated endothelial cells from pre-
existing vessels – a process termed ‘angiogenesis’. However, in 1997, Asahara et al 
published a landmark study suggesting the presence of circulating cells bearing the 
CD34 (or the KDR) surface marker that possessed some properties of endothelial 
cells when cultured in vitro with angiogenic growth factors.145 Furthermore, these 
cells promoted in vivo angiogenesis when transplanted into murine hind limb 
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ischemia models.145 These cells were termed ‘Endothelial cell Progenitors’ or 
‘angioblasts’, and were believed to form blood vessels de novo – a process called 
‘vasculogenesis’, initially thought to occur only in utero. However, these data have 
been extrapolated by many other investigators to suggest the in vivo presence of 
‘endothelial progenitor cells’, defined by the co-expression of CD34 and KDR 
(though no cell culture modification). However, the in vivo role of such cells has 
never been proven, and this has resulted in controversy and confusion in the field of 
vascular repair. Notwithstanding these concerns, Asahara’s initial findings and 
subsequent studies have resulted in a paradigm shift in our understanding of 
endothelial injury and repair. A delicate balance between endothelial damage and 
repair is now thought to influence the development of atherosclerosis, and hence 
modulating repair mechanisms could represent a novel way retarding, or reversing 
atherogenesis.  
1.3.1 Defining endothelial progenitor cells 
 
To date, there is no clear consensus on the definition of an endothelial progenitor 
cell (EPC) and the term is still used interchangeably to describe circulating cells 
bearing CD34 with or without other markers, or various types of cell-culture derived 
populations. The former group is perhaps better defined as circulating progenitor 
cells (CPC), acknowledging our ongoing uncertainty as to their role in vivo. CPC will 
be used from now on in this thesis to describe circulating cells counted with flow 
cytometry, whereas EPC will be used to denote culture derived cells with typical 
functional properties. Phenotypic characterisation of CPC has been controversial, 
and attempts by numerous groups to successfully define these cells have been 
confounded by the presence of circulating endothelial cells (CEC).146 Furthermore, 
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CECs and CPCs form only 0.01% and 0.0001% respectively of cells in peripheral 
blood, making isolation and thus further characterisation of these cells difficult.147  
Circulating endothelial cells are believed to be derived from mature vascular 
endothelium following mechanical disruption or apoptosis 148, though a small subset 
of these cells may be derived from bone-marrow derived progenitors.149 Their 
numbers are increased in various conditions that are associated with vascular injury, 
including septic shock 150 and systemic lupus erythematosus.151 In order to ascertain 
the origin of CECs further, Lin et al conducted novel experiments on blood samples 
derived from recipients of gender-mismatched bone marrow transplants. They 
demonstrated  that in vitro endothelial cell colonies appearing within nine days were 
of a recipient phenotype thus arising from CECs, while those arising later were of 
donor origin suggesting the possibility of bone marrow derived CECs or EPCs.152 
Furthermore, CECs derived from the bone marrow are thought to form only a small 
fraction of the total CEC count.152   
 
Identifying the specific cellular origin of EPCs is difficult given the various cell types 
in the blood that can differentiate into cells with endothelial-like gene expression in 
vitro.  These include hematopoietic stem cells, monocyte-macrophages and 
CECs.153 However, there are a variety of measures that can help assist in isolation 
and quantification of EPCs. These include identifying cell surface phenotype using 
flow cytometry with subsequent flow sorting and in vitro culture. Cells for analysis 
can be derived from whole blood or by density layered centrifugation.  
 
Preliminary work conducted by Asahara et al 145 identified that transfused culture- 
modified murine CD34+ or Flk1+ cells localised to areas of neoangiogenesis in vivo. 
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This led them to hypothesise that circulating CD34+ and Flk-1+ mononuclear cells 
may contribute to neoangiogenesis in adult mice. Following this, Peichev et al 154 
attempted to differentiate circulating endothelial cells (sloughed mature endothelial 
cells) and CPCs using cell surface markers.  Identifying that HSCs strongly 
expressing CD34 and CD133 cell surface markers are downregulated during HSC 
differentiation, they postulated that cells expressing these markers may represent 
immature progenitor cells. Furthermore, they postulated that cells expressing CD133 
co-expressed KDR, and that this could be used to differentiate between mature 
endothelial cells and CPCs. Of all the samples analysed, they found that only 2% of 
mobilised peripheral blood CD34+ cells co-expressed CD133 and KDR. This was not 
seen in umbilical cord derived endothelial cells, which only expressed CD34+ and 
KDR+, but did not express CD133. Based on this information, it was concluded that 
circulating CD34+KDR+CD133+ cells may represent a putative immature CPC 
phenotype. Examination of luminal surfaces of left ventricular assist devices 
implanted in humans identified the presence of cells expressing all three surface 
markers, though they only constituted 3% of the total mononuclear cells on the 
surface.154 Based on all the above evidence, the authors concluded that CD34+ cells 
in the circulation that co-expressed CD133 and KDR could be defined as ‘circulating 
EPCs’ (or CPCs), and quantification of these cells could provide valuable information 
of their role in diseased states. In addition, we now understand that late outgrowth 
EPCs are not derived from CD133 cells.155  
 
In addition to identifying CPCs in vivo, a number of groups have attempted to identify 
putative EPCs in vitro. Initial work by Asahara et al identified CD34+ expressing cells 
as putative EPCs in vitro, after a period of culture modification whilst adherent to 
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fibronectin coated plates.145  These cells formed clusters of round cells surrounded 
by spindle shaped cells when co-cultured with CD34+ depleted mononuclear cells, 
and expressed ‘endothelial’ surface marker proteins. Ito et al 156 expanded on this 
work and isolated human peripheral blood mononuclear cells and plated them on 
fibronectin. The non-adherent cells were removed after 24 hours in order to deplete 
the population of monocytes, macrophages and any circulating endothelial cells, and 
were re-plated onto fibronectin coated dishes. A number of similar clusters were 
identified as EPC colonies 7 days after plating. 
 
The definition of an EPC remained unclear. Hur et al 157 recognised this lack of 
clarity and attempted to demonstrate the heterogeneity of EPCs based on culture 
properties. In a series of experiments using human peripheral blood, they identified 
two types of EPCs in culture. The spindle shaped cells that appears 3-5 days 
following plating were termed ‘early EPCs’, and were akin to the EPCs initially 
described by Asahara. Following an increase in their number over 2 weeks, a decline 
in their number was later observed with their gradual disappearance in 4 weeks. 
During the early EPC decline, another cell type with a similar appearance to 
endothelial cells was identified, with the capability to rapidly proliferate over 
numerous population doublings without senescence (see figure 5). These were 
called late-outgrowth EPCs and ingested acetylated LDL and bound to lectin in a 
similar fashion to early EPCs.  Another interesting observation noted was the 
proliferation rate of late EPCs was greater than mature endothelial cells (gastro-
epiploic artery endothelial cells – GEA EC), which could imply the origin of late EPCs 
was not simply via vessel wall detachment. 
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Figure 5 - Different growth curves of early and late EPC and mature endothelial cells 
(Modified from Hur et al 157) 
 
 
 In 2003, Hill et al demonstrated a technique of culturing EPCs purported to avoid 
subculture of circulating mature endothelial cells.158 PMNCs were placed on 
fibronectin, and after 24-48 hours non adherent cells were removed and re-plated. 
After 7 days in culture, colonies formed which were counted. These colonies had a 
central core of round cells with spindle shaped cells around the periphery. Work by 
Hur et al has shown the central core to be composed of T-lymphocytes 159, while the 
spindle shaped cells in the periphery to be macrophages bearing some non-specific 
endothelial surface markers.   
1.3.2 Identifying Endothelial Progenitor Cells in vitro  
 
1.3.2.1 Morphology in vitro 
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It is now apparent that Asahara’s initial work described early outgrowth EPCs, 
sometimes referred to by other groups as circulating angiogenic cells. These cells 
when derived from peripheral blood mononuclear cells remain adherent to fibronectin 
4-7 days following plating. They are spindle shaped cells with limited proliferative 
capacity, and rarely survive beyond 2-3 weeks in culture.160 When co-cultured with 
endothelial cells, they promote angiogenesis in a paracrine fashion, though they do 
not form vascular networks in isolation. This is achieved by a number of pro-
angiogenic factors released by these cells, which include VEGF, MMP-9 and IGF-1 
161, concentrations of which are significantly higher compared to the conditioned 
medium of late outgrowth EPCs.157 Work conducted by Rohde et al has shown these 
early EPCs to be culture derived monocytes 162, and the expression of endothelial 
surface markers has been demonstrated to be via phagocytosis of platelet derived 
mricroparticles generated from debris in the culture plate.163  
 
As outlined earlier, the other form of early outgrowth EPC is the colony-forming units 
(CFU-Hill). These colonies are derived by plating PBMCs in fibronectin coated plates 
with modified growth medium for 2 days, following which the non-adherent cells are 
extracted, re-plated and grown for a further 3 days. A typical CFU appears on day 5 
and consists of a cluster of spherical cells surrounded by spindle shaped cells (see 
figure 6). The central core has been demonstrated to be strongly positive for the 
surface marker CD-3, indicating a T-lymphocyte-rich core.159 These T-lymphocytes 
release numerous angiogenic growth factors including VEGF, IL-8 and TNF-α, 
towards which the surrounding monocytes migrate. These surrounding monocytes 
are akin to early outgrowth EPCs described by Asahara, and express endothelial 
antigens.  
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Figure 6: Different subsets of endothelial progenitor cells derived from culture of 
PBMCs. 
 
When PBMCs are cultured for prolonged periods, late outgrowth EPC colonies of 
cells appear after 7-21 days. These cells exhibit a cobblestone pattern in culture, 
have a high proliferative potential, being capable of serial passages, and express 
typical endothelial surface markers. When placed in matrigel plugs, these cells can 
form capillary-like networks in contrast to early outgrowth EPCs that are incapable of 
doing so.160 Seminal work by Ingram et al has demonstrated that some individual 
late outgrowth cells can form secondary late outgrowth colonies that exhibit high 
proliferative capacity; this proliferative hierarchy is considered a feature of ‘true 
progenitor’ populations.164 Hence, late outgrowth EPCs are considered by some to 
be the true EPC, and share similar gene expression profiles to HUVECs.157, 165  
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1.3.2.2 Uptake of DiI-Ac-LDL 
 
In 1990, Voyta et al 166 incubated endothelial and smooth muscle cells with a 
fluorescently tagged acetylated LDL cholesterol molecule DiI-Ac-LDL, for 4 hours 
and visualised them with fluorescence microscopy. Endothelial cells were highly 
fluorescent, while the smooth muscle cells only demonstrated mild fluorescence 
when compared to the background, and so this method was adopted to identify 
endothelial cells, and later EPCs.167 We now understand that acetylated LDL is taken 
up by endothelial cells via the ‘scavenger cell pathway’ of metabolism of LDL.166 
However, high uptake is also seen in monocytes and macrophages, and hence this 
assay in isolation is not specific for the endothelial phenotype.  
 
1.3.2.3 Binding to UEA-1 lectin 
 
Ulex Europeus 1 agglutinin (UAE-1) is a lectin that binds to certain glycol-
compounds present in cells and can be visualised under fluorescence microscopy 
when conjugated with fluorescent molecules such as FITC. Studies have shown that 
it binds to endothelial cells lining blood vessels 168; however, more recent work has 
shown that UEA-1 also binds to other cell types 169, and so  binding of UEA-1 alone 
is a non-specific assay of endothelial phenotype. Combined assessment of UEA-1 
with that of DiI-Ac-LDL binding may improve specificity for endothelial phenotype 167, 
and so can be used in defining early EPCs. However we now understand these cells 
to be of monocyte origin, so highlighting the poor specificity of this assay. 
 
 
52 
 
1.3.3. EPCs, CPCs and cardiovascular outcomes 
 
Despite the numerous methods to culture and identify EPCs in vitro, it is unclear 
whether these culture-derived cells exist in vivo, and if so whether they are reflected 
by circulating progenitor cells in vivo. This is primarily due to the lack of a unique 
identifier that is present within EPCs. This makes interpreting and correlating 
cardiovascular outcome data regarding EPCs and CPCs difficult. Previous work has 
demonstrated an inverse relationship between circulating progenitor cell number and 
cardiovascular risk factors.170 The number of circulating progenitor cells has also 
been shown to independently predict future major cardiovascular events in patients 
suspected of having coronary artery disease by Werner et al.171 Similar findings have 
been seen in patients with congestive cardiac failure.172 Cultured EPC-CFU numbers 
have been demonstrated to correlate with endothelial dysfunction and Framingham 
cardiovascular risk index.158  
 
The relationship between CPCs linked to cardiovascular outcome by Werner et al 171 
and cell-culture derived EPC remain unclear. Recent research has shown that within 
CD34+CD45- CPCs are the cells that give rise to late outgrowth EPCs, although not 
all CD34+CD45- cells possess this potential.155  This work has also showed that late 
outgrowth EPCs lack CD133, a primitive cell surface marker, and that CD133+  cells 
cannot form late outgrowth EPCs in vitro. Timmermans et al also demonstrated that 
CD34+CD45- cells which eventually generated late EPCs lacked CD133. In contrast 
to this, some groups have shown that purified CD133+ cells can generate endothelial 
cells.173 
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It is evident from the above discussion that a unique marker of an EPC is lacking, 
and whether or not results obtained from ex vivo work with EPCs are relevant to in 
vivo observations remains unclear.  
 
1.3.4 Functional properties of EPCs 
1.3.4.1 Endothelial Progenitor Cell mobilisation 
The bone marrow is home to a stem cell niche which consists of fibroblasts, 
osteoblasts and endothelial cells, and provides an environment of self renewal and 
differentiation of stem and progenitor cells. Progenitor cells are mobilised from the 
bone marrow into the circulation in response to a number of cytokines and growth 
factors which include Vascular Endothelial Growth Factor (VEGF), Stromal-cell 
Derived Factor (SDF), angiopoetin -1 and erthyropoeitin.174 These cytokines can 
stimulate the cleavage of molecules mediating retention of progenitor cells in the 
bone marrow by activating proteases such as matrix metalloproteases (e.g. MMP-9) 
and cathepsins.175 Both VEGF and SDF-1 up-regulate bone marrow MMP-9 activity, 
which cleaves the progenitor cell membrane bound kit-ligand, resulting in progenitor 
mobilisation into the vascular zone of the bone marrow.174 Nos3-/-   (eNOS-/-) mice 
have greatly reduced basal activity of pro-MMP-9 resulting in a reduction in sKitL 
release from mKitL. Consequently progenitors fail to mobilise in Nos3-/-  mice in 
response to physiological stimuli, a phenomenon that was rescued by infusion of 
sKitL. This establishes a mechanistic link between VEGF signalling and MMP-9 in 
bone marrow stroma.174 NO released by the bone marrow stromal cells as a result of 
VEGF signal transduction promotes nitrosylation of MMP-9, and is an absolute 
requirement for VEGF stimulated EPC mobilisation.176  
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Tissue hypoxia appears to be a major stimulus for VEGF release, mostly due to 
increased VEGF messenger RNA levels in response to hypoxia inducible factor -1 
(HIF-1).177 Animal studies have demonstrated increased mobilisation of circulating 
progenitors and EPCs in response to VEGF.178 Similar results have been seen in 
human studies, with numbers of EPCs increasing following burn injuries 179 and 
myocardial infarction 180 mirroring increased VEGF levels. Other cytokines that 
mobilise EPCs include granulocyte colony stimulating factor (G-CSF) and 
granulocyte monocyte colony stimulating factor (GM-CSF).  However, recent 
evidence has shown these to be pro-inflammatory and possibly contributory towards 
plaque instability and has questioned their therapeutic use in patients with the sole 
aim to progenitor cell mobilisation.181  Erythropoietin is another cytokine that 
mobilises EPCs in vivo.182, 183 Numerous other stimuli result in release of EPCs from 
bone marrow, and these have been listed in the figure below. 
 
Figure 7: Factors affecting various stages in EPC mobilisation 
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Endothelial NO synthase is essential to maintain EPC mobilisation in response to 
various stimuli.133, 176, 178, 184 More specifically, NO is a critical molecule in EPC 
mobilisation from the bone marrow. Mice deficient in eNOS show reduced EPC and 
stem cell mobilisation from the bone marrow176. Numerous other stimuli such as 
exercise133 and statins 167 have been demonstrated to mobilise EPC in a NO 
dependent mechanism. This would imply a reduction in NO production, as noted in 
patients with endothelial dysfunction, would lead to impaired mobilisation of CPCs.170 
Recent work conducted by our group assessing the effect of moderate intensity 
exercise on mobilisation of CPCs provided the first proof of a pivotal role for NO in 
mobilisation of CPCs in humans.133  
 
1.3.4.2 EPC adhesion and transmigration 
 
In order for EPCs to participate in vascular repair, it is essential for them to adhere to 
the vasculature at the sites of ischemia or injury.185 Integrins have been 
demonstrated to mediate adhesion of leukocytes to extracellular matrix proteins and 
endothelial cells. In particular, β1 integrins are expressed on the surface of 
endothelial cells, while β2 integrins are expressed on hematopoietic stem cells.
185 β2 
integrins are also expressed on the surface of peripheral blood derived EPCs, and 
are required for EPC adhesion to endothelial cells and trans-endothelial migration in 
vitro.186 Furthermore, HSCs lacking  β2 integrins demonstrate impaired homing and 
reduced capacity to improve post-ischemic neovascularisation.187 In denuded 
arteries, reendothelialisation may be mediated to an extent by β1 integrins’ role in 
adhering EPCs to extracellular matrix.188 However, studies have shown that the αvβ3- 
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and αvβ5-integrins play a major role in mediated adhesion of EPCs to denuded 
vessels.189  
1.3.4.3 EPC chemotaxis and migration 
 
Given the small number of circulating progenitor cells released in response to tissue 
injury and ischemia, it is necessary to have a sufficient concentration of chemo-
attractant factors to facilitate recruitment to the injured tissue. VEGF has been 
demonstrated to act as a chemo-attractant factor to EPCs190, 191 In addition to this, 
SDF-1 has also been shown to be a potent chemotactic factor and stimulates 
recruitment of progenitor cells to ischemic tissues.192 IGF-1 has also been 
demonstrated to exert similar effects193, and is itself released from ischemic 
tissues.194 
1.3.4.4 EPCs and angiogenesis  
 
As previously discussed, early outgrowth EPCs release numerous mediators that 
can stimulate capillary growth, though they themselves do not directly or 
permanently contribute to vascular endothelial networks.195 These results have been 
noted in both in vitro and in vivo studies.196  
 
In 2001, Kocher et al 197 mobilised CD34+ cells from the bone marrow using G-CSF, 
purified them, labelled them with DiI-Ac-LDL and injected them into rats where the 
main coronary artery had been ligated (to cause myocardial infarction) 48 hours 
earlier. Significantly enhanced neoangiogenesis was noted at the site of the infarct, 
with 20-25% of the new vessels co-localising with labelled cells. Also noted was an 
improvement in left ventricular ejection fraction. This improvement was not seen with 
CD34- cells. Other groups have also shown similar results.198 Transplantation of ex 
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vivo expanded EPCs into a mouse model of hind limb ischemia demonstrated 
successful promotion of neovascularisation with a 50% reduction in limb necrosis 
and auto-amputation.199 This preliminary work has demonstrated the possible role of 
bone marrow derived progenitor cells in neoangiogenesis in vivo, though cannot 
confirm the direct formation of endothelial cells from transplanted bone marrow cells. 
 
Since then, work has demonstrated that neoangiogenesis may occur from interplay 
between EPCs and mature endothelium. In 2003, Rehman et al demonstrated that 
endothelial progenitor cells secreted a number of angiogenic factors, including 
VEGF.195  Other groups have shown that CD14+ and CD34+ EPCs also release 
numerous other growth factors such as insulin – like growth factor-1 (IGF-1) and 
basic fibroblast growth factor (bFGF).200, 201 Work by Hur et al demonstrated early 
outgrowth EPCs, when co-cultured in vitro with HUVECs on Matrigel, were 
incorporated into tubular network structures, though not to the extent seen with late 
outgrowth EPCs.160 This indicated the involvement of early outgrowth EPCs in vitro 
in the formation of new blood vessels, and is likely to be secondary to the numerous 
growth factors released which generate a pro-angiogenic environment. However, 
there is much scepticism regarding in vitro assays of angiogenesis using Matrigel, as 
cells that have no angiogenic potential in vivo may also induce tubulogenesis.202  
In order to account for this problem, Sieveking et al 201 performed a tubulogenesis 
assay specific for endothelial cells using co-cultures of differentiated endothelial cells 
(which included HUVECs, coronary artery and microvascular ECs) or non-
endothelial cells with monolayers of human fibroblasts. They showed via 3D 
immune-fluorescence microscopy that early EPCs do not directly participate in 
tubulogenesis, but in fact release mediators in a paracrine fashion that facilitate tube 
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formation by differentiated ECs. Further analysis of late outgrowth EPCs 
demonstrated direct participation in both de novo tubulogenesis and direct 
incorporation into pre-formed EC tubules, without exerting a paracrine effect. As 
previously discussed, this suggests that late outgrowth EPCs are true EC 
progenitors. 
 
Clearly, more research is required to identify all the relevant paracrine mediators of 
tube formation. By isolating and delivering these paracrine mediators, potential future 
therapeutic strategies may be developed in patients suffering from CAD and vascular 
disease. 
1.3.5 Endothelial Progenitor Cell signalling pathways 
 
The functional properties of EPCs described above are dependent on a number of 
critical signalling pathways and molecules. The following section discusses these 
important molecules. 
 
1. Nitric oxide 
Endothelial regeneration may be dependent on the normal functioning of EPCs in 
response to ischemia or injury, requiring mobilisation, homing and eventually 
endothelial repair. These steps are all critically dependent on NO. NO is produced in 
EPCs by eNOS, via the same molecular signalling mechanisms as endothelial 
cells.203 Aicher et al demonstrated in a hind limb ischemia model in eNOS-deficient 
mice (Nos3 -/-), infusion of wild type EPCs, but not Nos3 -/-  EPCs rescued the 
phenotype of defective neovascularisation, indicating the role of eNOS beyond 
simply mobilising EPCs.176 In human subjects with type 2 diabetes, early EPCs 
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demonstrate impaired migration in vitro, a phenomenon that was reversed by 
addition of a NO donor drug; further studies suggested a role for NO in EPC 
cytoskeletal plasticity and so migration properties 204. These findings indicate a 
strong and essential role for EPC-derived NO in many of its biological functions. 
Coupled with its requirement for progenitor mobilisation and endothelial 
homeostasis, NO is likely to be a critical mediator in vascular repair. 
 
2. PI3K/Akt signalling pathway 
The PI3K/Akt pathway augments the production of NO through stimulatory 
phosphorylation of eNOS at its serine residue 1177 in mature endothelial cells – a 
phenomenon that has also been demonstrated in EPCs.167  The pathway’s activity is 
stimulated by a number of factors including VEGF, exercise and drugs such as 
statins.167  As NO plays a significant role in EPC mobilisation, the PI3K/Akt pathway 
may play an important role in this process, as discussed below. 
 
Experiments conducted by Ackah et al have shown Akt 1 to play a pivotal role in 
progenitor mobilisation and EPC function. They demonstrated that infusion of Akt1-/-  
EPCs following hind-limb ischemia had no significant effect on tissue perfusion, 
which was in stark contrast with wild-type EPCs.88 A number of other functional 
properties, such as EPC homing and migration have also been linked to PI3 kinase 
Akt pathway.205 In particular, the γ subunit of the PI3K molecule is thought to play an 
important role in regulation of EPC function, with PI3Kγ−/− EPCs showing a defect in 
proliferation, survival, integration into endothelial networks, and migration toward 
SDF-1.206 Pharmacological agents such as statins have been demonstrated to 
enhance EPC mobilisation and migration, a phenomenon that is PI3K/Akt-pathway 
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dependent.167 Similarly, homing of EPC toward chemotactic ligands such as VEGF 
and SDF-1 released in response to tissue hypoxia are PI3K/Akt dependent.88, 207  
 
Despite the overwhelming evidence in support of the PI3K/Akt pathway in regulating 
EPC function, recent work has demonstrated a possible detrimental role of Akt in 
EPC function and survival. Wang et al have postulated that chronic upregulation of 
Akt may result in enhanced apoptosis and impaired angiogenesis.208 Furthermore, 
Nishi et al observed impaired angiogenesis in VEGFR-1 haploinsufficient mice as a 
result of uninhibited VEGFR-2 signalling. This effect was mediated by excessive Akt 
activation.209 It thus appears that many of EPC functional properties are mediated via 
PI3K/Akt signalling, though hyper-stimulation of the pathway may be detrimental. 
 
3. MAP kinases 
Mitogen activated protein kinases (MAP kinases) are a family of serine/threonine 
kinases that comprise 3 majors subgroups – extracellular signal regulated kinases 
(ERK) which includes p42/44, p38 MAPKs and c-Jun N-terminal kinases (JNK). They 
co-ordinate and regulate cell proliferation and differentiation in response to stimuli 
such as TNF-α in different cell types.210 The MAP kinase pathway broadly promotes 
cell proliferation. Pathway specific insulin resistance results in hyper stimulation of 
MAP kinase pathways, leading to cell apoptosis and senescence.122  Previous work 
has demonstrated the p38 MAP kinase signalling pathway to be hyper stimulated by 
high glucose concentrations 211, indicating a role in EPC dysfunction in diabetes. 
When compared to healthy subjects, patients with CAD and underlying EPC 
dysfunction have demonstrated profound upregulation in p38 phosphorylation. A 
similar effect has been noted when EPCs derived ex vivo are cultured with TNF-α or 
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glucose.212 Oxidised LDL has also been demonstrated to reduce EPC number and 
function by inducing p38 MAPK in a time and dose dependent manner.213 
Interestingly, inhibition of p38 MAPK is associated with enhanced angiogenesis.214, 
215 Thus, by targeting p38 MAPK, potential therapies could be designed to halt 
premature senescence and thus promote vascular repair. 
 
4.  Reactive oxygen species and oxidative stress 
For a long time now, ageing and disease has been partially attributed to endogenous 
reactive oxygen species.216 As previously discussed, ROS have also been implicated 
in the pathogenesis of numerous cardiovascular risk factors.92 Recent evidence has 
shown ROS to serve as a secondary intracellular messenger, playing an important 
role in cellular processes including differentiation, senescence and cell apoptosis.217 
While detrimental effects are primarily seen at high concentrations of reactive 
oxygen species, lower concentrations have been shown to play a critical role in 
mobilisation and homing of EPCs, thus playing a key role in neovascularisation 
following ischemic injury.218 An alteration in ROS generation may thus alter EPC 
function and modulate cardiovascular risk. 
 
Studies have demonstrated that defective endothelial repair is closely linked to 
oxidative stress in disease states. In subjects with type 2 diabetes, a reduction in 
EPC mobilisation and number has been attributed to uncoupling of eNOS, resulting 
in the production of superoxide anion (O2
-) instead of NO.219 In addition, Sorrentino 
et al demonstrated enhanced NADP(H) oxidase catalysed superoxide anion 
production as a possible aetiological factor in the impaired in vivo re-
endothelialisation capacity of EPCs derived from patients with diabetes.220 Similar 
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results have been seen in recent work by other groups, with high NADP(H) oxidase 
activity and superoxide levels seen in EPCs derived from diabetic subjects.221 
Hyperglycaemia induced EPC dysfunction was rescued by superoxide dismutase 
and by restoration of BH4 levels.219, 222, 223 However, excess ROS in isolation cannot 
explain EPC dysfunction in diabetes, and mechanisms such as increased activation 
of p38 MAP kinase have also been postulated.212  
 
Despite enhanced ROS production in conditions of stress such as injury and 
ischemia, EPCs still manage to facilitate vascular repair, suggesting a possible 
resistance to ROS-induced toxicity. Work performed by Dernbach et al demonstrated 
that EPCs derived from healthy donors were rich in antioxidants superoxide 
dismutase and glutathione peroxidise when compared to HUVECS.224 This could 
potentially augment their ability to repair vasculature, although whether these 
defences are diminished by insulin resistance or diabetes is unclear.   
 
5.  Inflammation  
As previously discussed, atherosclerosis is a systemic inflammatory disease. 
Mediators released by inflammation such as C-reactive protein can have a 
detrimental effect on endothelial progenitor cell function, resulting in impaired 
survival and differentiation.225 However views supporting the contrary exist, and a 
study assessing circulating EPCs and EPC-CFUs in patients with anginal syndromes 
demonstrated a positive correlation between CRP levels and both CPC and EPC-
CFU numbers, suggesting inflammation can promote CPC mobilisation.226 The 
authors did however acknowledge the small sample size. Recent evidence has 
shown that acute systemic inflammation alone is insufficient to mobilise EPCs, and 
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vessel wall injury is also required. The group showed that systemic inflammation 
induced by Salmonella typhus increased levels of VEGF, however failed to cause 
mobilisation of progenitor cells.227 
 
6.  Insulin resistance and EPCs 
A number of studies, both human and animal, have demonstrated abnormalities in 
EPC biology, ranging from reduced numbers, impaired mobilisation and impaired 
function in insulin resistant states.228, 229 Studies have also shown subjects with type 
2 diabetes to have reduced numbers of circulating EPCs.230, 231 Furthermore, a 12 
week course of Rosiglitazone increased EPC numbers and migratory function in 
newly diagnosed type 2 diabetic patients , independent of its glucoregulatory 
properties.232  Unpublished work by our group has already shown a negative 
correlation between homeostasis model assessment of insulin resistance (HOMA-IR) 
and number of circulating EPCs  
 
Studies linking EPC function and insulin resistance have mostly been conducted in 
subjects with diabetes. Teasing out the effect of insulin resistance alone on EPC 
function from all other facets in a diabetic phenotype is difficult. Recently our group 
performed a series of experiments on normoglycemic mice with whole body haplo-
insufficiency of the insulin receptor (insulin receptor knockout IRKO), assessing the 
impact of whole body insulin resistance alone on progenitor function.233 CPCs 
derived from IRKO mice demonstrated impaired endothelial repair following vascular 
injury - in addition IRKO had absent VEGF induced CPC mobilisation and their EPCs 
showed impaired paracrine functionality. Transfusion of wild type CPCs into IRKO 
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mice significantly enhanced vascular repair, providing novel insights into the effect of 
insulin resistance on vascular repair, progenitor biology and EPC function. 
 
Insulin resistance aside, impaired EPC function in individuals with diabetes can be 
partly explained by a direct glucotoxic effect on the cells. Hyperglycaemia is a 
feature of insulin resistance and diabetes, and plays in important role in the 
pathogenesis of vascular complications in patients with diabetes mellitus. EPCs 
derived from patients with type 2 diabetes demonstrate impaired adhesion, 
proliferation and incorporation into vascular structures.234 Chronic incubation of early 
and late outgrowth EPCs with high glucose dose-dependently reduces the 
proliferation, migration and colony forming numbers, effects not seen with the 
comparable osmotic control mannitol.235 In addition to this, Krankel et al 
demonstrated that hyperglycaemia resulted in the induction of protein phosphatase 
2A (PP2A – an eNOS de-phosphorylator at serine1177), which resulted in a decline of 
eNOS phosphorylation and NO production in EPCs. Impaired Akt activation was 
proposed as a possible additional mechanism, though PP2A inhibition did not restore 
Akt activity completely, indicating other possible hyperglycaemia-mediated 
mechanisms in EPC dysfunction.236 
1.3.6 Endothelial Progenitor Cells and vascular re- endothelialization 
 
An important phenomenon in the pathogenesis of atherosclerosis, in-stent re-
stenosis and vascular conduit failure is endothelial damage/dysfunction and neo-
intimal proliferation. By accelerating healthy re-endothelialisation following 
endothelial insult by ischemia or injury, neo-intimal proliferation could be prevented 
thus resulting in improved vessel wall healing and reduced atherosclerosis. 
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Transfusion of EPCs derived from splenic mononuclear cells into splenectomised 
mice following arterial injury demonstrated enhanced re-endothelialisation and 
reduced neo-intima proliferation.237 In balloon denuded rabbit carotid arteries, 
transfusion of bone marrow derived rabbit MNCs has shown similar results.238 
Hypercholesterolemia plays an important role in atherogenesis, and certainly spleen-
derived EPCs transfused from wild type mice into high-fat diet fed splenectomised 
Apo E-/- mice restored endothelium dependent dilatation, though the effects were not 
as pronounced as spleen derived MNCs.239 Furthermore, chronic treatment of aged 
Apo E-/- mice with bone-marrow derived progenitor cells from young Apo E-/- mice or 
wild type mice prevented the development of atherosclerotic lesions.240 This effect is 
enhanced by statins, and certainly bone marrow derived progenitor cells harvested 
from C57/BL6 mice treated for 10 days with Rosuvastatin demonstrated increased 
reendothelialisation and decreased neointimal formation when compared to 
controls.241 Similar results have also been demonstrated by other groups.189, 242  
 
In subjects with type 2 diabetes mellitus, Sorrentino et al demonstrated that in vivo 
reendothelialisation of injured carotid arteries in nude mice following transfusion of 
EPCs derived from these subjects is significantly impaired - a phenomenon that is 
improved by Rosiglitazone, implying the role of oxidant stress and NAD(P)H 
oxidases in the EPC dysfunction.220 Similar effects have been demonstrated in rats 
with type 1 diabetes mellitus, with insulin administration restoring NO-mediated 
inhibition of neointimal hyperplasia.243 Certainly, insulin has a vaso-protective effect, 
and improves re-endothelialization and decreased neointimal growth following 
arterial injury.244  Furthermore, a recent study by Kahn et al demonstrated impaired 
endogenous vascular repair in insulin receptor knock out (IRKO) mice when 
66 
 
compared to wild type (WT) mice. This effect was normalized when IRKO mice were 
transfused with EPCs derived from insulin-sensitive animals but not from insulin-
resistant animals.233 Despite the available evidence, the effect of insulin resistance 
per se on in vivo re-endothelialisation in humans requires further investigation. 
Furthermore, studies assessing the relevance of these observations in South Asian 
people are lacking. 
 
1.3.7 South Asian ethnicity and endothelial progenitor cells 
 
Data confirming a direct relationship between endothelial progenitor cell dysfunction 
and South Asian ethnicity is limited. So far, I have discussed the increased 
propensity of South Asians to develop atherosclerosis, and have linked endothelial 
dysfunction to the pathogenesis of atherosclerosis.  The work of Murphy et al  
assessed endothelial function in South Asian men (n=24) in comparison with 
matched  white European men (n=25).132 Ethnicity was defined as subjects, or both 
of their parents, having been born in India, Pakistan, Sri Lanka or Bangladesh. 
Brachial artery flow mediated dilatation (FMD) and fore-arm vascular response to 
intra-arterial injection of Levo-N-monomethyl arginine (LNMMA – a nitric oxide 
synthase antagonist) was used to assess endothelial dysfunction. South Asian men 
demonstrated significantly reduced FMD (6.9% vs. 8.5%; p=0.003) and reduced 
response to LNMMA, implying impaired NO mediated endothelium-dependent 
vasodilatation at baseline and in response to shear stress. Furthermore, CPC 
numbers and EPC-CFU colony numbers were significantly reduced. However as 
limited functional assays were performed in a small subset of the study group, more 
67 
 
detailed studies in a larger cohort are required. Also, no data regarding the 
mechanisms of dysfunction were published.  
 
Since then, our group has conducted further work assessing the effect of exercise on 
circulating progenitor cells in South Asian men. We assessed basal CPC numbers in 
15 South Asian and 15 matched white European men.133 Basal CPC numbers were 
significantly lower in South Asian men. The study went on to assess the effects of 
exercise on CPC mobilisation, and demonstrated a significant increase in CPC 
numbers following exercise, though this was blunted in South Asian men in a NO 
dependent manner.  
 
To date, this is the only available published evidence linking South Asian ethnicity 
and endothelial progenitor cell number and function.  
 
1.4. Statins, the Endothelium and Progenitor cells 
1.4.1 Introduction 
 
In 1971, Akira Endo and Masao Kuroda commenced research into inhibitors of 
HMG-CoA reductase. Their work looked into the microbial metabolites that would 
inhibit this rate limiting enzyme in cholesterol synthesis.245 They subsequently 
discovered Mevastatin, which they derived from a strain of Penicillium citrinum, a 
subclass of fungi. Since then a number of statins have been developed with variable 
potency and pharmacokinetics. Statins are a class of drugs used clinically to lower 
serum cholesterol. They act by inhibiting the enzyme Hydroxy-methyl-glutaryl 
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Coenzyme A reductase (HMG CoA reductase), which catalyses the rate limiting step 
in hepatic cholesterol synthesis. In particular, this group of drugs reduce serum low 
density lipoprotein (LDL) concentrations, which studies have shown to be a major 
risk factor in the development of coronary artery disease.246 Meta-analyses studying 
the effects of statins on future coronary events and cardiovascular mortality have 
demonstrated a significant reduction in major coronary events independent of gender 
and the presence of hypertension and diabetes.247 Reductions in cardiovascular 
mortality persist in insulin resistant populations.248 
1.4.2 Statins and atherosclerosis 
 
As has been discussed previously, inflammation plays a key role in the development 
of atherosclerosis. Besides their cholesterol lowering properties, statins possess a 
number of pleiotropic effects, which are speculated to contribute to their clinical 
efficacy. They have been demonstrated to exhibit anti-inflammatory properties by 
modulating immune cell activation and subsequently reducing the number of 
inflammatory cells in the atherosclerotic plaque.249 In addition to this, they retard the 
formation of oxidised LDL, which plays a major role in plaque formation. A number of 
mechanisms have been postulated, including preservation of superoxide dismutase 
(an endogenous antioxidant) 250 and alterations in macrophage handling of oxidised 
LDL.251 Statins also decrease the expression of the endothelial cell leukocyte 
adhesion molecules VCAM-1 and E-selectin, which are important mediators in the 
initiation of atherosclerosis.252 
 
The pleiotropic effects of statins include an effect on endothelial dysfunction, with 
restoration of vasomotor function seen at early stages of treatment.102, 253 A number 
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of mechanisms have been postulated, ranging from increased NO production254 to 
complex signalling.255  
1.4.3 Statins and endothelial cell signalling pathways 
1.4.3.1 Enhanced eNOS expression 
 
NO is a labile-freely diffusing molecule that not only exerts its effects on the cell it is 
synthesised within, but also on the surrounding cells and molecules.256 Reduced 
bioavailability of NO is a hallmark of endothelial dysfunction. One of the primary 
mechanisms through which NO production is reduced in endothelial dysfunction is 
through reduced expression and activation of eNOS. A study on the effects of statins 
on cerebral ischemia in mice demonstrated that statins up-regulated eNOS 
expression and activity.257 Studies conducted in dogs 258 and primates 259 have 
yielded similar results. In humans, the increase in eNOS expression by statins has 
been shown to be independent of its cholesterol lowering effect 260, with increases 
noted as early as 2 weeks following commencement of oral therapy.261 This increase 
in eNOS expression is reversed by geranyl geranyl pyrophosphate (GGPP) and not 
farnesyl pyrophosphate (FPP), implicating the involvement of small GTPases in this 
process (see section 1.4.3.3 below). However, there is no clear understanding as to 
how statins activate eNOS and increase NO production. A number of hypotheses 
exist, including decreased caveolin-1-eNOS interaction 262  to stimulation of the 
PI3K/Akt activity 254 and enhanced formation of eNOS-Hsp90-Akt complex in 
endothelial cells.263 These effects are clearly seen at lower doses of statins; higher 
doses have been shown to be detrimental to migratory and angiogenic properties of 
mature endothelial cells due to induction of apoptosis 264 (see section 1.4.5).  
70 
 
1.4.3.2 Stimulation of PI3-kinase-Akt pathway 
 
Statins have been shown to increase NO production through the PI3 kinase-Akt 
pathway (see figure 8). Stimulation of this pathway results in rapid phosphorylation of 
eNOS, with subsequent increased NO production. This process is blocked by 
wortmannin and LY294002, inhibitors of PI3-kinase. Statin-induced Akt activation is 
reversed by mevalonate, indicating the role of the HMG CoA reductase pathway in 
Akt activation and subsequent eNOS activation.254 Exposure of human umbilical vein 
endothelial cells  to 0.1microM of Simvastatin results in increased Akt 
phosphorylation, peaking after around one hour.254 Similar results have been seen 
with Atorvastatin, which also induces a time and dose dependent increase in early 
outgrowth EPC number and adhesive capacity.167 Dimmeler et al further extended 
this data by administering Simvastatin (20mg/kg daily) to mice for 3 weeks, and 
demonstrated an increase in early outgrowth EPCs. Further work concluded that 
statins exhibited these effects through the PI3-kinase/Akt dependent manner.167  
 
Figure 8: Mechanisms through which statins stimulate eNOS activity and increase 
NO production. 
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1.4.3.3 Statins and isoprenylated proteins  
 
Statins have been also shown to increase eNOS abundance through isoprenylated 
proteins (see figure 8). During cholesterol synthesis, a number of isoprenoid 
derivatives such as farnesylpyrophosphate (FPP) and geranylpyrophosphate (GPP) 
are produced. These are intermediates that serve as important lipid attachments for 
post translational modification of various cell signalling proteins. These cell signalling 
proteins include members of the Rho and Ras GTPase family, and appear to be 
important targets for inhibition by statins. Translocation of inactive Rho from the 
cytosol to the membrane depends on geranyl-geranylation. Once activated, they can 
negatively influence eNOS mRNA half-life, and by disrupting this statins prolong 
eNOS mRNA half life.255, 265 Rho proteins regulate the actin cytoskeleton, changes 
within which can affect mRNA stability and gene transcription.266 In mouse models of 
ischemic stroke, inhibition of RhoA by statins increased eNOS expression and 
reduced severity of cerebral ischemia.267 
1.4.4 Statins and Endothelial Progenitor Cell function  
 
Studies assessing the effect of statins on EPC biology in vitro have demonstrated a 
significant increase in EPC number and an improvement in function.167  Enhanced 
mobilisation, migration and increased EPC survival has also been shown following in 
vivo administration of statins.242  
 
In experiments conducted by Llevadot et al, simvastatin was added to a chemotaxis 
buffer along with recombinant human VEGF (rhVEGF) and murine GM-CSF in the 
lower chamber of modified Boyden chamber apparatus. Human peripheral blood-
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derived early outgrowth EPC chemotactic activity was increased by simvastatin in a 
dose dependent manner.242 A similar increase in EPC migration has been 
demonstrated with mevastatin and atorvastatin, an effect that was reversed by 
mevalonate and LY294002, a PI3 kinase inhibitor.264 Enhanced migration was 
noticed with increasing concentrations of atorvastatin, an effect that was not seen 
with mature endothelial cells.264 Studies assessing EPC function in response to oral 
atorvastatin in subjects with coronary artery disease showed a significant increase in 
migratory capacity following a 4 week course of Atorvastatin 40mg.268 This 
augmentated migratory capacity paralleled an increase in EPC numbers. EPC 
migration has been shown to be dependent on PI3 kinase- Akt signalling 269, and 
statins have been shown to enhance the activity of this pathway.167 However, work 
by other groups has shown that in improvement in functional properties of EPCs may 
also be dependent on its lipid lowering properties, particularly its ability to reduce 
LDL and thus ox-LDL.270 Incubation of EPCs with ox-LDL resulted in impaired 
cellular migration; an effect that was reversed when cells were pre-treated with 
Lovastatin.270 However, given ox-LDL reduces the PI3 kinase-Akt signalling, the 
mechanism(s) of statin induced effects on EPC function remain debated. 
 
As previously discussed, once mobilised from the bone marrow, EPCs home to sites 
of injury or ischemia and adhere to the vessel wall, eventually promoting 
angiogenesis and vascular repair. Statins have been demonstrated to significantly 
enhance adhesive properties of EPCs in vitro, an effect that could be explained by 
upregulation of αv and β5  integrin subunits.
189  
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Studies assessing the in vivo effects of statins have shown similar results. In a study 
assessing the effects of statins on reendothelialisation in carotid artery balloon-
injured Sprague-Dawley rats, Walter et al demonstrated a significant increase in 
circulating EPCs in response to simvastatin therapy, an effect that  was sustained 
through 4 weeks of therapy.189 Similar effects have been seen in humans EPCs.167 
These effects have been demonstrated to be dependent on the PI3 kinase Akt 
pathway and eNOS.167, 271  
 
1.4.5 Statins and angiogenesis 
 
A number of animal studies have demonstrated promotion of angiogenesis by low 
dose statins.254, 272 In a murine model of corneal injury, simvastatin augmented 
corneal neovascularisation via increased PI3 kinase Akt signalling.242 Similar results 
have been obtained with low dose atorvastatin.273 
 
Angiogenic effects have been described to be dose dependent, with low dose statins 
exerting a pro-angiogenic effect, while higher doses exert an anti-angiogenic 
effect.274 Described as a ‘double edged sword’, the pro-angiogenic effects of low 
dose atorvastatin on early outgrowth EPCs seems to be maintained at a higher dose; 
an effect that was not seen with HUVECs, which showed anti-angiogenic effects at 
higher doses.264 Similar results have been obtained with cerivastatin, which was anti-
angiogenic at higher concentrations on mature endothelial cells.275 This variable 
effect is likely to be due to a differing dose-response curve between the two cell 
types. At higher doses, statins induce endothelial cell apoptosis, an effect that is not 
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seen at equivalent doses in early outgrowth EPCs.242, 264 Furthermore, increased 
stimulatory Akt phosphorylation is observed in EPCs when compared to ECs with 
high dose statins, which could explain the difference in apoptotic sensitivity.264 
However, what this effect translates to in vivo is not fully clear as we are unsure if 
culture derived EPCs are in fact generated in vivo: furthermore, the doses of statin 
administered are orders of magnitude greater than pharmacological doses. Urbich et 
al demonstrated that at therapeutically relevant concentrations of atorvastatin, the 
overall effect upon early outgrowth EPCs was pro-migratory and pro-angiogenic. 
Vincent et al’s study assessing cerivastatin would translate to a 10-fold higher 
plasma concentration than maximal therapeutic dose, perhaps explaining the anti-
angiogenic effects described. In short, this would mean the low concentration of 
statins in vivo associated with standard clinical doses of statin therapy would 
resemble low concentration in vitro, producing an overall beneficial effect on EPC 
function and neovascularisation.  
 
1.4.6 Statins, South Asians and endothelial progenitor cells 
 
As previously discussed, atherosclerotic cardiovascular disease is highly prevalent in 
South Asian population groups. There are no published studies looking at the effects 
of statins on EPCs derived from South Asian men. However, post-hoc analysis of the 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT ) has shown Atorvastatin to 
reduce LDL levels to a similar extent in white Europeans, Blacks (Afro-Caribbean 
and African) and South Asians,276  though how this translated into changes in EPC 
number is unclear. Work performed by our group has assessed basal CPC and EPC 
number and function, and the effect of exercise on CPC mobilisation.132, 133 We have 
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demonstrated reduced CPC number and impaired EPC number/function in South 
Asian men, and in particular shown a blunted mobilisation of CPCs after exercise. 
However, contradictory reports have been published, and work by Hughes et al 
demonstrated no difference between circulating progenitor cells, late outgrowth 
colony numbers and non-senescent EPCs between European and South Asian 
subjects. However the study had a number of limitations; in particular some subjects 
were on regular medications such as aspirin and antihypertensive agents, 
suggesting that confounding factors may interfere with the assessment of links 
between South Asian ethnicity and EPC number/function.277  
 
This thesis aims to probe a number of outstanding questions noted in the 
introduction regarding endothelial progenitor dysfunction in South Asian men, its 
underlying pathophysiology, and to evaluate the effects of statins on these 
parameters. 
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Chapter 2 
Aims and 
hypotheses 
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2. Aims and hypotheses 
As has been discussed extensively in the above introduction, South Asian ethnicity is 
associated with impaired indices thought to reflect endogenous endothelial repair 
mechanisms and which are linked with increased prevalence of atherosclerosis and 
subsequent coronary artery disease. However, there are only two studies that have 
studied this in more detail, both of which have been performed by our group. While 
the data is undoubtedly useful and insightful, a clear mechanistic explanation into 
this dysfunction is lacking. In order to address this, we have planned this project to 
focus on the following broad themes: 
1. Is the finding of South Asian ethnicity being associated with reduced basal in vitro 
EPC numbers reproducible?  
2. Is early outgrowth EPC function (migration, adhesion, and tube forming capacity) 
impaired in South Asian men? 
3. Do pharmacological stimuli (e.g. Simvastatin) improve early outgrowth EPC 
functional properties? 
4.  Are late outgrowth EPCs derived from South Asian men dysfunctional? 
5. What are the molecular mechanisms underlying EPC dysfunction in South Asian 
men? 
6. Are South Asian EPCs also dysfunctional when assessed using in vivo models of 
vascular injury? 
7. Can molecular mechanisms involved in EPC dysfunction in South Asian men be 
modulated to improve their functional properties? 
 
In essence, these objectives are aimed at validating previous findings and expanding 
on a small body of evidence supporting impaired EPC function in South Asian men. 
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Furthermore, by studying the molecular mechanisms involved in this dysfunction, 
potential therapeutic strategies may be studied in the future. 
 
Based on the above aims, the following key null hypotheses can be made, which will 
be addressed in the respective subsections of the results chapter. The first aspect 
covers early outgrowth EPCs and effect of Simvastatin on their function. 
1. Early outgrowth EPC function is not impaired in South Asian men 
2. Simvastatin does not improve the function of early outgrowth EPCs from South 
Asian men 
 
The second aspect deals with late outgrowth EPCs. 
1. Late outgrowth EPC function in vitro is not impaired in South Asian men 
2. Late outgrowth EPC function in vivo is not impaired in South Asian men  
3. Dysfunction of late outgrowth EPC from South Asian men is not amenable to 
restoration by manipulation of key intracellular signalling cascades. 
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3. Materials 
3.1 Demographics and biochemical assessment 
 Human Insulin ELISA – Mercodia #10-1113-10 
 Sphygmomanometer – Omron MX3 plus 
 Blood analyses was performed in the biochemistry laboratory of Leeds 
General Infirmary: 
o Full blood count 
o Renal function tests 
o Liver function tests 
o Fasting plasma glucose 
o Thyroid function tests 
o Fasting lipid profile including total cholesterol, HDL and LDL 
3.2 General laboratory supplies 
 Phosphate buffered saline – Sigma 
 Ficoll paque plus – GE healthcare 
 Fetal calf serum – Biosera 
3.3 Endothelial progenitor cell culture 
 Biocoat fibronectin coated plastic culture vessels in 6-well, 24-well, T25 flask 
and T75 flask format – Becton Dickinson 
 Polycarbonate Boyden chambers with 8µm pore size - Becton Dickinson 
 Trypsin EDTA 0.025% solution – Gibco BRL 
 EGM-2 culture medium ± EBM2 Singlequots growth factor supplements – 
Lonza 
 Vascular Endothelial Growth Factor-165 – R&D systems 
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 Olympus CKX41 Fluorescence microscope with ‘Cell F’ software 
 Cryomedium (CryoSFM) – Promocell 
 Haematoxylin and Eosin – Sigma 
 Formalin 4% (b/v) in distilled water – Sigma 
 Dil-AcLDL – Invitrogen 
 Ulex Europeus-FITC conjugate – Invitrogen 
 CM-Dil CellTracker C-7001 - Invitrogen 
3.4 EPC intracellular and protein assessment (Western blot)  
 BCA protein assay ELISA kit (Thermo-scientific) 
 Phospho-eNOS(ser 1177) rabbit mAb – Cell signalling 
 eNOS rabbit mAb – Cell signalling 
 Phospho-Akt (ser 473) rabbit mAb – Cell signalling 
 Akt rabbit mAb – Cell signalling 
 Immobilon Western Chemiluminiscent HRP substrate - Millipore  
3.5 EPC senescence assay 
 Senescence β-galactosidase staining kit – Cell signalling 
3.6 EPC in vitro angiogenesis assay 
 Matrigel (growth factor reduced) - BD biosciences #356231 
3.7 Simvastatin 
 Simvastatin 5mg – Sigma 
3.8 Western blot assay 
 TBS tween 
o 20 mM Tris-HCl, pH 7.4 
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o 500mM NaCl 
o 0.05% Tween 20 
 Stripping buffer 
o Thermo Scientific Restore Western Blot stripping buffer #21059 
 Running buffer 
o 25 mM Tris base 
o 190 mM glycine 
o 0.1% SDS 
 Radioimmunoprecipitation assay (RIPA) buffer 
o 150 mM NaCl 
o 0.1% Triton X-100 
o 0.5% sodium deoxycholate 
o 0.1% SDS (sodium dodecyl sulphate) 
o 50 mM Tris-HCl pH 8.0 
 Protease Inhibitors 
o Leupeptin 10 mg/mL (1000x) 
o Aprotinin 10 mg/mL (1000x) 
o Phenylmethylsulfonyl flouride, 200mM in ethanol (100x) 
 Phosphatase inhibitors 
o 100 mM NaF 
o 50 mM NaVanadate 
o 800 mM ß-glycerol phosphate 
 Non-fat dried milk 
 Chemiluminiscent substrate 
o Millipore – Immobilon Western Chemiluminiscent  HRP substrate 
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3.9 Mouse model of femoral artery injury 
 Microscopes 
o Nikon SMZ1500 Stereo microscope for dissecting tissue 
o Olympus SZ61 with up to 45x magnification with QiCam Olympus 
digital camera 
 Fluovac Anaesthetizing chamber with gas scavenging system, Harvard 
apparatus  
 Compact Anaesthesia System   AN001 (Vet Tech Solutions Ltd, UK) Fluovac 
system, Harvard apparatus 
 Isoflurane Key fill applicator  AN003B    
 Heating plate (Vet Tech Solutions Ltd, UK)              
 Thermal cage  (HE-011(Vet Tech Solutions Ltd, UK)              
 Light source Schott KL1500 LCD 
 Guide Wire 0.014’’ (0.010’’(0.25mm) at 3 cm on the top) (Hi-Torque Cross-IT 
200XT, AbbotVascular, USA) 
 Micro serrifine curved (Inter Focus, #18055-05) 
 Forceps type clip applicator (Inter Focus, #18057-14) 
 Needle holder (World Precision Instrument, #14109) 
 Forceps and scissors: 
o Vannas scissors (WPI, #501778) for making arteriotomy 
o Vannas scissors (Inter Focus, #91501-09) for cleaning vessels 
o Fine Iris scissors (Inter Focus, #14094-11) for making skin cut 
o Tweezers Dumont, WPI (500339) 
o Tweezers Dumont, WPI (500234) 
 Syringes 
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o Terumo Insulin syringe 0.3ml with needle 29G x 13mm   613-4900 
o Terumo Insulin syringe 0.5ml with needle 27G x 13mm   TERUBS -
05M2713 
o Terumo Insulin syringe 1ml    with needle 29G x 13mm   613-4904  
 Surgical sutures 
o VICRYL absorbable surgical suture, 6-0, ETHICON, W9575, (Johnson 
& Johnson) 
o VICRYL absorbable surgical suture, 8-0, ETHICON, W9577, (Johnson 
& Johnson) 
 Microscope slide (Cell Path, #MAE-1000-03P) 
 Microscope Cover-slip 22 x 22 mm (SLS, # MIC 3114) 
 Others 
o Cotton buds 
o Gauze 
o Veet hair removal cream 
o Hair shaver 
o Seller tape 
 Reagents 
o Isoflurane-Vet (Merial Animal Health Ltd, Essex, UK; Code: 
AP/DRUGS/220/96)  
o Euthanal (Pentobarbital sodium Ph.Eur.)  
o 1% DPBS 
o 0.9% NaCl (saline) 
o 4% paraformaldehyde (Paraformaldehyde, Fisher (P/0840/53) 
o Surgical scrub Providone-Iodine (Vetasept®, Animal Care, York) 
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o Rodent No.1 maintenance diet RM1(E); code 801002, SDS (Specialist 
Diet Service), UK 
o Evans Blue (Fluka, 46160) 
o Buprenorphine (Buprenorphine 0.3 mg/ml as hydrochloride (Ph.Eur.) 
Alsatoe Anima Health, York, UK 
 
3.10 Lentiviral Transduction of constitutively active Akt 
 QuickTiter™ Lentivirus Titer Kit #VPK-107- Cell Biolabs 
 Akt Kinase assay kit #9840 - Cell signalling 
 FuGENE® HD transfection reagent - Promega #E2311 
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4. Methods 
4.1 Subject identification and recruitment 
Ethical approval for subject recruitment was obtained from the Leeds (East) 
Research Ethics committee (Ref No 08/H1306/27). Recruitment posters were 
displayed over the University campus. South Asian ethnicity was defined as 
individuals who identified themselves as of Indian, Pakistani, Bangladeshi, Nepalese 
or Sri Lankan origin based on UK National Health Service approved lists.278 
 
Healthy South Asian male subjects with no previous medical history were recruited. 
All subjects were between the ages of 18 to 40 years, and were non smokers with no 
diabetes mellitus (defined by the WHO as fasting plasma glucose > 7 mmol/l), 
obesity (defined as BMI > 30) hypertension (defined as a blood pressure over 140 
mmHg systolic and/or 90 mmHg diastolic) or hypercholesterolemia (total 
cholesterol>7mmol/L). These exclusions were applied to avoid the impact of their 
confounding influence upon EPC function.170, 279, 280 Due to the effects of the 
menstrual cycle and estrogens on EPC number and function,281 females were not 
recruited in any of the studies. All potential subjects were screened for the presence 
of any of the exclusion criteria through a questionnaire, clinical examination and 
blood tests.  
 
Blood tests were performed after an overnight fast, and included a full blood count, 
full lipid profile, liver function, renal function, thyroid function, insulin and blood 
glucose. Blood pressure, BMI (weight in kg/height in m2) and waist: hip ratio was 
obtained. All samples other than the fasting insulin levels were analysed in the Leeds 
Teaching Hospitals NHS Trust chemical pathology laboratory at Leeds General 
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Infirmary. Insulin concentrations were obtained using Human insulin ELISA kit as per 
manufacturer’s instructions. Standard curve calibration was only accepted if R>0.99 
with samples analysed in duplicate; intra-assay coefficient of variation (CV) was 
required to be <10% for optical density >0.1 arbitrary units. In house quality controls 
were used in all experiments to ensure inter-assay CV <5%. The homeostasis index 
of insulin resistance (HOMA-IR) score was calculated using the formula insulin 
(mU/L) x fasting glucose (mmol/L) / 22.4 282, with higher values indicating greater 
degree of insulin resistance. 
 
4.2 Early outgrowth EPCs and Simvastatin 
4.2.1 Culture of Early outgrowth EPC’s 
 
Whole peripheral blood was drawn from subjects into EDTA coated tubes and 
transferred to 50ml Falcon tubes. An equal volume of Dulbecco Phosphate buffered 
saline (DPBS) was added, and the resultant mixture was layered onto Ficoll paque 
plus. As per manufacturer’s instructions, density gradient centrifugation was carried 
out, and peripheral blood mononuclear cells (PBMCs) were aspirated from the buffy 
coat layer. These were washed and re-suspended with DPBS and subject to re-
centrifugation at 300g for 10 min at 18°C. The cell pellet obtained was suspended in 
EGM2 growth medium with EGM-2 single quot bullet kits  and 10%  fetal calf serum 
(FCS) (v/v), with an equivalent of 5 million cells per 2 ml of medium placed per well 
of a 6-well fibronectin coated plate. Cells were then incubated at 37°C with 5% CO2. 
After 3 days, cells were washed with DPBS and fresh medium replaced. The non-
adherent cells were thus removed, leaving behind cells firmly adherent to the 
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fibronectin. The cells firmly adherent between 4 - 7 days were predominantly early 
outgrowth EPCs. The phenotype of early EPC’s was confirmed by assessing co-
staining with Dil - AcLDL and Ulex Europeus lectin – FITC conjugate using 
fluorescence microscopy (see section 4.2.2.3). 
4.2.2 In vitro exposure of endothelial progenitor cells to Simvastatin 
 
In order to assess the effect of statins on endothelial progenitor cell number and 
function, Simvastatin at 0.1 µM was added to each culture well as described below. 
Previous experiments conducted with Simvastatin and EPCs have used varying 
concentrations of Simvastatin ranging from 0.01 µM to 1 µM.167, 242 On reviewing the 
pharmacokinetic data of Simvastatin283, an oral dose of 40mg (normally prescribed 
for therapeutic effect in hypercholesterolemia) achieves a maximum concentration of 
16.2 ng/ml at 2.3 hours. Based on this data, and taking into consideration the 
molecular weight of Simvastatin of 418, a 40 mg oral dose equivalent would amount 
to an in vitro concentration 0.04 µM. When pilot work was performed with 0.1 µM and 
1 µM of Simvastatin with early outgrowth EPCs, cell death was seen with 1 µM 
concentrations (see section 5.2). Given the use of 0.1 µM is broadly comparable to 
pharmacological concentration, and cell death was seen at higher concentrations, 
we opted to use 0.1 µM in our experiments. 
4.2.2.1 Preparation of Simvastatin 
 
Simvastatin was purchased from Sigma-Aldrich. 4mg Simvastatin was dissolved in 
100 µL ethanol. 150 µL of 0.1M sodium hydroxide (NaOH) was added to this, and 
the mixture was incubated in a water bath at 50 ◦C for 2 hours. Following this the 
solution was returned to pH 7 with hydrochloric acid (HCl) and the stock solution was 
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made up to 1 ml with ethanol to obtain a final concentration of 4mg/ml. 0.5 µL of this 
solution added to 2ml EGM-2 medium resulting in a concentration of 0.1 µM 
Simvastatin. In order to assess the effect of Simvastatin alone, vehicle solution was 
prepared for control experiments by incubating 100 µL ethanol with 150 µL of 0.1M 
NaOH in a water bath at 50 ◦C for 2 hours. Following this the solution was brought up 
to pH 7 with hydrochloric acid and the stock solution was made up to 1ml with 
ethanol. 
4.2.2.2 Cell culture assays 
 
PBMC’s were plated as described above into 6 well fibronectin coated plates at a 
concentration of 5 million cells / well. On day 3, control wells received standard 
medium with appropriate volume of vehicle, and intervention wells were exposed to 
0.1 µM Simvastatin in standard EGM-2 medium. On the following day, cells were 
enumerated and used in functional studies. 
4.2.2.3 Confirmation of early outgrowth EPC phenotype  
 
Following aspiration of culture medium, cells were washed twice with DPBS and 
stained with Dil - AcLDL 10 µg/ml in supplemented EGM-2 medium. The plate was 
incubated for 3 hours at 37°C with 5% CO2. Following two wash steps with DPBS, 
cells were fixed with 4% paraformaldehyde (v/v) for 15 minutes, and rewashed. 
Further staining with 10 µL Ulex Europeus Lectin - FITC conjugate in 990 µL in 
DPBS was performed for one hour, prior to washing with DPBS. Cells were then 
analysed using phase contrast microscopy, along with corresponding red (DiI) and 
green (FITC) fluorescence microscopy using an Olympus CKX-41 fluorescence 
microscope at 200x magnification and Olympus Cell F software. Cells appearing 
yellow on overlay images were defined as early outgrowth EPCs according to 
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standard definitions (see figure 9).145 Cells were counted in 10 random high power 
fields (200x) and expressed as number of cells per high power field. Mean inter-
assay CV in 3 identically prepared experiments was 10%. 
 
 
              
             
Figure 9: EPC enumeration assay. Images of early EPCs were taken 
 using phase contrast (A)  microscopy and DiI AcLDL (B) and Ulex Europeus lectin 
(C) fluorescent microscopy. Final EPC number was determined by counting cells 
seen in the overlaid image per high powered (200x) field (D). 
 
4.2.2.4 Migration assay 
 
Early EPC’s treated with vehicle or simvastatin were suspended in un-supplemented 
EGM-2 and 5 x 104 cells in 500 µL medium placed in the upper compartment of 
modified Boyden chambers with a polycarbonate membrane base and 8 μm pores. 
The chambers were placed in a non-coated 24 well plate, each well containing 750 
A 
C 
B 
D 
100 μm 
100 μm 100 μm 
100 μm 
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µL of un-supplemented medium in triplicate in control wells; 50 ng/ml Vascular 
Endothelial Growth Factor in EGM-2 was used as chemotactic stimulus to migration 
in the remaining wells. Cells were incubated for 24 hours at 37◦C with 5% CO2, and 
then fixed with 70% ethanol for 1 hour at -20◦C. After removing the cells from the 
upper surface of the membrane and washing with DPBS, membranes were stained 
with Haematoxylin and Eosin for 30 seconds each. Migrant EPC’s per 10 high power 
fields (715 x 530 µm) were counted (200x) and results expressed as mean cell 
number per high power field. Pilot work in 3 identically prepared experiments 
performed previously by our group has shown an intra-experimental CV of 7.8%. 
 
 
 
Figure 10: Representative control, VEGF-stimulated and statin-treated EPC 
migration assays. Hematoxylin and Eosin stained EPCs adhere to the lower surface 
of the modified Boyden chamber. EPCs and pores are labelled. 
Control VEGF 
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100 μm 100 μm 
100 μm 
Pore 
EPC 
Control 
100 μm 
93 
 
4.2.2.5 Adhesion assay 
 
Both untreated and pre-treated (with Simvastatin or vehicle) early EPCs were 
suspended in EGM-2 with growth factors and plated in a 24-well fibronectin coated 
plate in triplicate at a concentration of 5 x 104 cells / well. These were incubated at 
37◦C with 5% CO2 for one hour. The non- adherent cells were then gently washed 
twice with DPBS, and the adherent cells were counted (10 high powered fields 715 x 
530 µm). Results were expressed as mean cell number per high powered field. Mean 
inter-assay CV in 3 identically prepared samples was 17%.  
 
 
Figure 11: Representative control and Simvastatin-treated EPC adhesion assays. 
Phase contrast microscopy shows EPCs adherent to fibronectin coated surface of 
culture plates. 
 
4.2.2.6 Tubule formation on matrigel 
 
Tubule formation on Matrigel was used to assess paracrine stimulation of in vitro 
angiogenesis by EPCs. Matrigel was thawed overnight on ice, and the following day 
300 µL of Matrigel was coated onto the surface of each well of a 24 well culture 
plate. The plate was incubated at 37◦C with 5% CO2 for 30 minutes to facilitate 
gelling of Matrigel. 5 x 104 HUVECs were suspended in 500 µL EPC conditioned 
Control Statin 
100 μm 100 μm 
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medium (derived from both pre-treated and untreated cells) and placed into wells in 
duplicate. The plate was incubated for 24 hours at 37◦C with 5% CO2 and tubules 
were counted in 5 high powered fields (x100 - 1430x1060µm). Results were 
expressed as the number of tubules per high powered field.  
 
 
Figure 12: Tubule formation on Matrigel 
4.3 Late outgrowth EPC culture and conduit vessel re-endothelialisation 
4.3.1 Culture of late outgrowth EPCs 
PBMC’s derived from 50ml whole blood were harvested as described above, and 
plated in 12 ml of EGM-2 medium with EGM-2 bullet kit and 10% FCS in T75 
fibronectin coated flasks. Cells were washed with DPBS and medium changed daily 
for the first week, followed by alternate day half medium changes over the next 3-4 
weeks. At approximately 3-4 weeks, larger cells with a cobblestone like morphology 
were noted to develop in colonies. Colonies were identified by their specific 
microscopic appearance of a spatially distinct group of cells.  
Tubule 
50 μm 
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Figure 13: Endothelial progenitor cell colony 
 
These cells eventually expanded into larger colonies and exhibited contact inhibition, 
with a capability of serial passaging as previously reported152. The endothelial 
phenotype of these cells has been previously confirmed by my colleague Dr Richard 
Cubbon (as a part of his PhD dissertation) using FACS analysis demonstrating co-
expression of KDR and CD31 in 89% of cells (figure 14). All specimens derived in 
this project underwent assessment for the presence of eNOS by Western blotting, 
also supporting their endothelial phenotype. Once confluent in a T75 flask, the cells 
detached with trypsin, suspended in cryopreservation medium and stored in liquid 
nitrogen for future use (see section 4.3.3). 
 
500 μm 
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Figure 14: FACS analysis of late outgrowth EPCs – co-expression of KDR (PE) and 
CD31 (FITC) is seen in 89.8% of cells (from unpublished work by Dr R M Cubbon) 
 
4.3.2 Population doubling time assay 
 
In order to calculate cell population doubling time, EPCs derived from PBMCs were 
counted at every passage until fourth passage (P4), then cryo-preserved. The time 
point at which the cells were passaged was noted as was the total cell number prior 
to each re-plating. Population doubling time was calculated using software available 
online capable of calculating doubling times over a series of cell passages and time 
points (www.doubling-time.com/compute.php). In brief, given two cell counts at 2 
separate time points, and assuming a constant growth rate, the population doubling 
time (Td) was calculated using the equation:  
 
Td= (t2 – t1) x [log (2) / log (q2/q1)] 
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where q1 is the cell count at time t1, and q2 the cell count at time t2. 
 
4.3.3 Cryostorage of late outgrowth EPC’s 
 
Growth medium was removed from T75 flasks, and cells were washed twice with 10 
ml DPBS in order to remove all latent trypsinases present in foetal calf serum. Pre-
warmed trypsin-EDTA 0.025% was added to the flask at 40 µL/ sq cm, and the flask 
was incubated at 37° C for 90 seconds. Once removed from the incubator, the flask 
was tapped gently on all sides for 30 seconds to dislodge any cells that remain 
weakly adherent. EGM-2 with additives and FBS was then added to deactivate the 
trypsin. The resultant cell suspension was centrifuged at 300g for 10 min at 18° C. 
The cell pellet obtained was washed with DPBS and then re-centrifuged. The final 
cell pellet obtained was re-suspended in cryomedium at a concentration of 1 x 106 
cells/ml and stored in cryo-vials. These were cooled at a rate of <1° C/min overnight 
(in order to reduce cell attrition from ice crystal formation) in a -80°C freezer, 
following which they were transferred to liquid nitrogen storage. When required, 
cryovials were removed from liquid nitrogen and rapidly warmed to 37°C in a water 
bath. Cells were then suspended in EGM-2 medium with EGM-2 bullet-kit and re-
plated on either a 6 well fibronectin coated plate or a fibronectin coated T75 flask. 
Medium was changed completely within 24 hrs in order to remove latent cryo-
medium which is potentially toxic to the cells. Cells stored in liquid nitrogen retained 
their proliferative capacity and functional properties after more than 6 months of 
storage.  
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4.3.4 Western Blot assay 
4.3.4.1 Cell harvesting 
 
Cells were serum deprived in un-supplemented EGM-2 with 1% FCS for 24 hours in 
order to assess basal signalling activity. Cells were then removed with a cell scraper 
following the addition of 70 µL of lysis buffer (containing  Tris 50mM, NaCl 150 mM, 
SDS 0.1 %, Na.Deoxycholate 0.5 %, Triton X 100 or NP40 1% and protease and 
phosphatase inhibitors). The procedure was performed on ice. Lysates were either 
stored at -80°C or subject to centrifugation. The supernatant was aspirated and 
transferred to a fresh eppendorf, and the pelleted debris discarded.  
4.3.4.2 Total protein quantification 
 
The sample total protein concentration was first estimated using the Bicinchoninic 
Acid assay to ensure equal protein loading when later performing Western Blot 
analysis. 8 µL of each lysate sample was diluted 8-fold with 56 µL of milliQ distilled 
water. The samples were vortexed to ensure optimum mixture, and 25 µL of the 
sample was loaded in duplicate on a 96 well plate. Standards were prepared by 
serial dilution of 1mg/ml BCS protein assay kit as per manufacturer’s instructions and 
loaded onto the same plate in duplicate. 200 µL of a 50:1 dilution of Bicinchoninic 
acid: 4% copper (II) sulphate was then pipetted into each of the wells with the 
standards and samples. This initiates a two-step reaction – the first reaction to occur 
is the ‘biuret reaction’ - chelation of copper in an alkaline environment resulting in a 
light blue complex. The second step results from the reaction of the cuprous cation 
produced from step one with bicinchoninic acid, resulting in a light purple coloured 
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complex. These reactions occur when the plate is incubated at 37°C for 30 minutes 
after covering with sealing foil. Absorption spectra are then measured by colorimetric 
assay at 562nm. The protein content is then calculated in reference to a standard 
curve generated with known concentrations of bovine serum albumin, with correction 
for the initial 8-fold dilution.  
4.3.4.3 Protein gel resolution and transfer 
 
From the protein concentrations obtained above, the volume of lysate containing 50 
µg of protein was calculated. Any shortfall in volume under 30 µL was made up with 
lysis buffer. Loading dye is added to achieve a 1:4 dilution, followed by reducing 
buffer to obtain a 1:10 dilution. The lysate was boiled at 95 degrees C for 5 min. The 
reduced samples were then cooled on ice, vortexed and pulse centrifuged, then 
loaded onto a 4-12% pre-cast polyacrylamide gel. One well was loaded with a 
protein standard ladder for reference. Running buffer was loaded into the gel running 
system and samples were resolved by electrophoresis at 160V for 1 hour. Once 
completed, the gel with resolved protein was removed from the gel-case and placed 
over the PVDF membrane pre-soaked in methanol and transfer buffer. These were 
then sandwiched between 3mm filter paper, ensuring firm contact, and then placed 
in a transfer cassette in an orientation which ensured correct direction of transfer. 
This is then connected to a power pack supplying a constant 100V for 45 min. Upon 
completion, the membrane was removed and air dried for future immunostaining.  
 
 
 
100 
 
4.3.4.4 Immunostaining 
 
When required, membranes were refreshed by washing in methanol for 10 seconds, 
and rinsing in distilled water. Stripping buffer was added for exactly 5 minutes. This 
was then washed with TBS Tween three times for 15 minutes in total. The 
membrane was then blocked using 5 ml of 5% milk buffer (25 ml TBS Tween + 1.25g 
dried skimmed milk powder) in a universal container on a roller for 1 hour. Blocked 
membranes were then transferred to new containers containing milk buffer and 
primary antibody (See table 2). These were probed overnight at 4°C on a roller. The 
following day, buffer and antibody were washed off with TBS Tween for 3 cycles of 5 
minutes each. Membranes were then probed by an appropriate secondary antibody 
conjugated to horseradish peroxidase (see table 2) for 1 hour. 
 
Antibody Target Antibody Type Source Dilution 
eNOS Monoclonal Mouse BD Biosciences 1:1000 
Serine1177 phospho-eNOS  
Monoclonal Mouse Cell Signaling 1:1000 
Akt Rabbit Cell Signaling 1:1000 
Serine473 phospho-Akt Monoclonal Rabbit Cell Signaling 1:1000 
β-actin Monoclonal Mouse AbCam 1:3000 
HRP conjugated 2◦ Ab Mouse / Rabbit Dako 1:1000 
p38 MAP kinase Rabbit Cell Signaling 1:1000 
p16 INK 4a Rabbit Cell Signaling 1:1000 
 
Table 2: Antibodies directed toward specific antigens for Western blot protein assay 
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Once probed, the membranes are washed again with TBS Tween three times for 15 
minutes each followed by low salt TBS solution for 15 minutes (or even longer if 
desired) to remove excess antibody. The membrane was then covered with 
chemiluminiscent substrate solution for 5 minutes, after which the solution was 
allowed to run off and the membrane sandwiched between two translucent acetate 
films. This was then analysed with a digital camera and the band densities analysed 
with the accompanying proprietary software. In order to standardise results, all band 
densities were normalised to the corresponding sample beta-actin density.  
4.3.5 Senescence β-galactosidase assay 
EPC senescence was measured using a commercially available β-galactosidase 
assay kit. As confluent cells exhibit enhanced senescence due to contact inhibition, 
sub confluent late outgrowth endothelial progenitor cells in one well of a 6-well plate 
were washed twice with DPBS and then fixed with 1ml of supplied fixative (20% 
formaldehyde and 2% glutaraldehyde in 10x DPBS) for 15 minutes. While the cells 
were being fixed, the working staining solution was prepared using the supplied 
stock staining solution (400 mM citric acid/sodium phosphate (pH 6.0), 1.5 M NaCl, 
20 mM MgCl2), X-gal (5-bromo-4-chloro-3-indolyl-βD-galactopyranoside powder), 
staining solution A (500 nM potassium ferrocyanide) and staining solution B (500 nM 
potassium ferricyanide) as per manufacturer’s guidance. The fixative was then 
washed and replaced with a 1ml of working staining solution and the 6-well plate 
placed in an incubator overnight at 37°C with standard atmospheric air in order to 
maintain the pH of the solution at 6.  
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Figure 15: Beta-galactosidase staining of late outgrowth EPCs 
 
The following day, with the β-galactosidase still on the plate, cells were 
photographed at 200x magnification (715 x 530 µm) for the development of deep 
blue nuclear colour. Senescent cells were expressed as a percentage of blue cells in 
the total number of cells. As is seen in figure 15, cells that are senescent stain a 
deep blue, while the non-senescent cells stained a lighter shade of blue or did not 
stain at all. Acknowledging that this made analysis of the images subjective and 
could result in poor reproducibility, inter-observer agreement was assessed (see 
section 6.3).  
4.3.6 Polymerase chain reaction 
In order to study mRNA expression of Akt and eNOS, polymerase chain reaction 
(PCR) was performed. The experiments were performed with Dr Piruthivi Sukumar. 
Late outgrowth EPCs in 6 well plates were washed with DPBS, and lysed using 500 
µl TriReagent. The lysate was transferred to an eppendorf and stored at -80°C for 
future use.  
 Non senescent cell 
Senescent cell 
100 μM 
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The lysates were subject to centrifugation at 13000 rpm at 4°C for 10 min to pellet 
out the cell debris. The supernatant was mixed thoroughly with 50 µl of 
bromochloropropane and left at room temperature to allow phase separation. The 
mixture was then subject to centrifugation at 13000 rpm at 4°C for 15mins to 
complete phase separation. The topmost layer containing the RNA was carefully 
pipetted into a separate eppendorf, and the RNA was precipitated with isopropanol 
and glycogen by further centrifugation. The pellet is then washed with ethanol and 
dissolved in water. 
 
Following this stage, the sample was treated with DNase mastermix to remove 
genomic DNA content. The quantity of RNA was measured using Nanodrop 
controlled by ND-1000 software. 
 
In order to perform the reverse transcription stage of PCR, the quantity of the sample 
containing 1000ng of RNA was reverse transcribed by high capacity reverse 
transcriptases to cDNA mastermix. Using the forward and reverse primers specific to 
the Akt and eNOS gene, real-time PCR was performed with SYBR green base 
detection system in Applied Biosystems’ 7900HT controlled by SDS 2.2 software. 
Results were presented after normalising to house-keeping (β-actin) gene. Primer 
sequences were as follows - 
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eNOS forward, 5’-CTG-GAG-CAC-CCC-ACG-CT-3’ 
eNOS reverse, 5’-AGC-GGT-GAG-GGT-CAC-ACA-G-3’ 
Akt1 forward, 5’-CCT-TCC-TCA-CAG-CCC-TGA-AGT-3’ 
Akt1 reverse, 5’-CCG-GGA-CAG-GTG-GAA-GAA-C-3’ 
Beta-actin forward, 5’-CGT-GAA-AAG-ATG-ACC-CAG-ATC-A-3’ 
Beta-actin reverse, 5’-TGG-TAC-GAC-CAG-AGG-CAT-ACA-G-3’ 
 
4.4 Re-endothelialisation following mouse femoral artery wire injury 
 
In order to study the in vivo functional properties of late outgrowth EPCs derived 
from both SA and WE men, a series of transfusion experiments after femoral artery 
wire injury were conducted in nude mice. 
 
4.4.1 Deriving late outgrowth EPC 
Late outgrowth EPCs were derived as described in section 4.3.1. Cells were thawed 
from cryopreserved cell banks and placed in T75 flasks. Cells were harvested for 
transfusion studies once confluent. 
 
4.4.1.1 Harvesting late EPCs 
 
Prior to harvesting late EPCs from the T75 flasks, a fluorescent cell tracker solution 
was prepared by dissolving 50μg of CM-DiI in 50μL of DMSO, and then dissolving 
this in 50ml of standard supplemented EGM-2 growth medium. Medium was 
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discarded from the T75 flask, and replaced with cell tracker enriched medium for 5 
min. This medium was then discarded and the cells washed twice with DPBS, and 
subsequently removed from the plate using trypsin as described earlier. The total 
number of cells was counted, and the volume of medium containing 3.5 x 105 cells 
was aliquoted. These cells were then subject to centrifugation at 300G for 10 min at 
18°C. The cell pellet was then washed and suspended in 200μL of standard 
supplemented EGM-2 growth medium. This was drawn into a sterile 300μL 
microsyringe and transported in a sterile container on ice to the clinical sciences 
building at St. James’s hospital, where transfusion experiments were carried out. 
 
4.4.2 Vascular injury protocol 
 
Animal experiments were carried out under the regulation of the Animal (scientific 
procedures) Act 1986. Murine surgery was performed by Dr Nadira Yuldasheva.  
Male nude CD1-/- mice (9-11 weeks of age; weighing 26.5-32.0 g) were chosen as 
recipients of human LEPC in order to avoid alloimmune reactivity with donor 
material. Mice were fed a standard chow diet, and were given ad libitum access to 
food and water. All animals were in good health. Prior to vascular injury, and the later 
harvesting of vessels, the mice were anaesthetised with volatile isoflurane saturated 
with oxygen via nose mask. A regulator was used to titrate the content of Isoflurane 
(~1.5%) and oxygen. 
 
The mouse was placed in supine position with paws fixed on the mask tube and its 
lower extremities abducted and extended. It was given an intra-peritoneal injection of 
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0.25 mg/kg buprenorphine in 0.9% NaCl.   The lower abdomen and both groins are 
cleaned with   3%H2O2 and povidone-iodine. The operation performed with the 
assistance of surgical microscope (Nikon SMZ1500) under appropriate magnification 
(~ x7.2 to x19.2). A 1.2 cm longitudinal groin incision is made, crossing the inguinal 
ligament. The femoral vessels were exposed at two sites: near the inguinal ligament 
and distal to the bifurcation of the saphenous artery from the femoral artery. The 
structure between these two sites, particularly the fat pad containing the epigastric 
vessels was not dissected. Sparing these structures minimizes traumatic 
consequences and preserves collateral flow after injury. The segment below 
bifurcation of femoral artery (to the saphenous artery) was dissected free from vein 
and nerve and encircled with 8-0 vicryl suture (two ligatures). The external iliac artery 
and vein were occluded temporarily using an atraumatic vascular mini clamp placed 
just below inguinal ligament or external iliac artery, dissected from vein, or encircled 
with 8-0 vicryl suture. An arteriotomy was made approximately 1 mm distal to 
bifurcation of femoral artery. A 0.010’’ (0.25mm) guide wire was introduced into the 
arterial lumen, the clamp was removed (or ligature was freed) and then the wire was 
advanced ~1.5 cm, to the level of aortic bifurcation. The wire was advanced and 
pulled back three times through femoral artery, and the external iliac and common 
iliac were abraded three times over their entire length (≈1.5 cm). Prior to removal of 
the wire the blood flow was stopped and the arteriotomy site was ligatured by tying 
the proximal and distal sutures placed previously. The same procedure was carried 
out on the contra-lateral side without arteriotomy (sham operation). The skin incision 
was closed with continuous, 6-0 vicryl suture and povidone-Iodine was applied on 
the wound. The mouse was injected intra-peritoneally with 150 µl 0.9% NaCl 
solution.  
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4.4.3 Vessel harvesting, imaging and analysis of results 
 
On the fourth day following vascular injury, the mice were anesthetised with volatile 
isoflurane (as described above) and an incision was made on the linea alba to 
access the inferior vena cava (IVC). The IVC was then injected with 75µL of 5% 
Evans blue in 0.9% NaCl. After a few minutes, the thoracic cavity was opened and 
the mouse was perfused - fixed by injecting the left ventricle with 0.9% NaCl solution 
followed by 4% paraformaldehyde in DPBS (pH 7.0 to 7.2). The femoral, external 
iliac and common iliac arteries along with the distal aspect of the abdominal aorta (at 
the region of the common iliac bifurcation) were carefully dissected from the 
surrounding tissue. Arteries (injured and contralateral uninjured) were separated 
from attached fascia and fat by careful dissection, and a longitudinal incision 
extending from the exposed abdominal aorta to the femoral artery was made. The 
dissected vessel was then mounted between a histological slide and a cover slip. 
 
Figure 16: Estimation of re-endothelialisation of injured femoral artery following EPC 
transfusion. 
 
The specimen was digitally photographed and analysed using Image Pro software 
version 7.0 (Media Cybernetics, Bethesda, MD) to calculate the percentage of the 
stained and unstained area. The measured area was standardised for all samples as 
extending from 5mm from the proximal suture. Results were analysed using 
student’s t test.  
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4.4.4 Confocal microscopy 
 
Following en face assessment of the proportion of re-endothelialisation, confocal 
microscopic assessment of late EPCs adherent to the vessel wall was performed. 
The vessel was mounted with Vectashield DAPI prior to assessment using a 
confocal microscope (Zeiss LSM 510 META Axioplan 2).  
4.4.5 Akt transduction using Lentiviral vector  
 
In order to study the effect of augmenting Akt activity function of late outgrowth 
EPCs, transduction studies using lentiviral vector gene delivery of constitutively 
active Akt-1 mutant were performed.284, 285 The lentiviral vectors used are based on 
human immunodeficiency virus-1 (HIV-1) given its advantage and suitability of use in 
both dividing and non-dividing cells.  The experiments were performed with 
assistance from Dr Hema Viswambharan and Dr Sam Stephen, who performed the 
viral titration pilot work and lentiviral delivery of constitutively active Akt. 
 
a. SIN-Lentiviral production 
 
Recent reports have described mutation in AKT1 to be linked to various forms of 
human cancer.286 In particular, substitution of the glutamic acid by lyseine at amino 
acid 17 (E17K) results in altered morphology of the Pleckstrin Homology domain, 
promoting localisation of AKT1 to the plasma membrane and so subsequent 
phosphorylation of amino acids  serine 473 (Ser473) and threonine 308 (Thr308). In 
our experiments, the EGFP lentivirus, pSINCSGWdlNot1 was a kind gift of Dr. 
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Yashiro Idea (Mayo Clinic, Minnesota, USA). The E17K Akt mutant constructs was 
kindly donated by Dr JM Askham and SIN-lentiviral vector pHV-SLS 2 expressing 
E17K mutant was produced by Dr SL Stephen by cloning E17KAkt in place of the 
enhanced Green Fluorescent Protein (EGFP) cassette in pSINCSGWdlNot1. The 
SIN-Lentiviral vectors were generated as described by Zufferey et al.287 
 
b. Titration of Lentiviral samples 
 
The Lentiviral vectors were titred using a p24 ELISA kit as per manufacturer protocol 
(QuickTiter™ Lentivirus Titer Kit #VPK-107). In brief, for each lentiviral sample, the 
HIV p24 standard, blank and control medium were all assayed in duplicate. 100µL of 
inactivated lentiviral sample or p24 antigen standard was added to anti p24 antibody 
coated plate. This was incubated at 37 degrees C for 4 hours.  
 
The plate was then washed with supplied wash buffer and 100µL of diluted FITC-
Conjugated anti-p24 monoclonal antibody was added to each well. This was 
incubated for 1 hour at room temperature on an orbital shaker, and then washed 
three times with wash buffer. 100µL of diluted HRP-Conjugated anti-FITC 
Monoclonal antibody was added to all wells, and this was again incubated at room 
temperature for 1 hour, followed by a similar wash. The substrate solution was 
brought to room temperature and 100µL of this was added to all wells. Following 
incubation at room temperature for 30 minutes, 100µL of stop solution was then 
added, and the absorbance results were read immediately using a 
spectrophotometer at 450 nm. These data were then used to infer the concentration 
of lentiviral particles (infectious or non-infectious), as per manufacturer’s instructions. 
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c. Late outgrowth EPC culture 
 
Late outgrowth EPCs were cultured as described in section 4.3.1. In brief, PBMC 
were subject to density layered centrifugation and cells were placed on fibronectin 
coated plates. These were cultured for periods of 4 to 6 weeks till late outgrowth 
EPCs were obtained. Cells were cryo-stored for use at a later date. When required, 
cells were rejuvenated and plated at a concentration of 10 x 104 cells/ well in a 6 well 
fibronectin coated plate.  
 
d. Lentiviral transduction and Akt activity assay 
 
Late outgrowth EPCs were infected by lentiviral vectors encoding EGFP or 
constitutively active Akt (E17KAkt) in 6 well plates for a period of 72 hours.  
 
Pilot work was conducted to determine adequate multiplicity of infection (MOI) i.e 
ratio of viral agent to target late EPCs. Varying concentrations of virus was used to 
infect late EPCs, and Akt kinase activity was determined using western blotting (Cell 
signaling Akt Kinase assay kit #9840). In brief, Akt was immuno-precipitated from 
lysates, prior washing with recombinant Glycogen Synthase Kinase-3 (GSK-3) 
substrate and ATP; Akt activity is then defined by Western blotting for phospho-GSK-
3.The results are shown in figure 17. 
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Figure 17: A) Schema of pro-viral vectors pHVSLS2 and pSINCSGWdlNot1; B) 
Representative Akt activity data used to define viral load used in subsequent 
experiments (one arbitrary infectious unit per 105 LEPC), with Akt activity 
immunoblots corresponding to points on graph. 
 
Based on above results, one infectious unit defines as the volume of E17Akt 
lentiviral sample sufficient to enhance Akt kinase expression 3-fold, and this 
concentration was used for all subsequent experiments.  
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e. Transfusion of transduced late EPCs into nude mice 
 
Late outgrowth EPCs expressing EGFP and E17Akt were transfused into femoral 
arteries of nude mice as described previously. Femoral arteries were harvested on 
day 4 and re-endothelialisation was assessed by means of Evans blue staining as 
previously discussed. 
 
4.5 Statistical methods 
 
Continuous data are presented as arithmetic mean and standard error of the mean 
unless otherwise stated. Continuous data between the study cohorts are compared 
with Student’s t-test; paired data are compared with paired t-tests. Statistical 
significance was accepted at p<0.05. The co-efficient of variation describes the 
standard deviation of a sample divided by its arithmetic mean and is used as an 
index of reproducibility. Statistical calculations were performed using Microsoft Excel 
2007. 
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5. Results Part One: In vitro studies of Simvastatin and circulating endothelial 
progenitor cell number and function  
 
5.1 Study cohort demographics and cardiovascular risk profile 
 
A total of 9 white European and 9 South Asian men were recruited for the study. 
These subjects were well matched for age and systolic blood pressure. Mean 
haematological and biochemical parameters fell within ‘normal’ range as indicated by 
Leeds Teaching Hospitals NHS trust laboratories, although white cell count was 
higher in South Asian men. Biochemical parameters including LDL and blood 
glucose were well matched. BMI showed a trend of being greater in South Asian 
men. HOMA-IR, an index of insulin sensitivity, was calculated using fasting plasma 
glucose and insulin concentrations. South Asians were significantly insulin resistant 
when compared to white European counterparts (1.2 [0.19] vs. 0.51 [0.08]; p=0.003).  
 
Parameter 
 
Asian [SEM] 
 
White European 
[SEM] 
 
 
p value 
Age (years) 30.9 [1.18] 29.7 [1.12] 0.48 
Systolic BP (mmHg) 115.5 [2.3] 116.4 [2.5] 0.80 
BMI 24.1 [0.69] 22.4 [0.44] 0.05 
Waist:hip ratio 0.8 [0.01] 0.8 [0.01] 0.71 
Haemoglobin (g/dL) 13.8 [1.4] 15.4 [0.3] 0.28 
White cell count (109/L) 6.05 [0.17] 4.97 [0.21] 0.001 
Creatinine (µmol/L) 101.1 [3.6] 96.7 [1.9] 0.8 
ALT (iu/L) 23.9 [2.3] 20.3 [1.5] 0.22 
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Cholesterol (mmol/L) 4.55 [0.2] 4.43 [0.2] 0.7 
LDL (mmol/L) 2.91 [0.19] 2.82 [0.16] 0.72 
HDL (mmol/L) 1.17 [0.08] 1.21 [0.05] 0.73 
Triglycerides (mmol/L) 1.11 [0.16] 0.91 [0.08] 0.32 
Insulin (mU/L) 5.57 [0.8] 2.88 [0.34] 0.005 
Glucose (mmol/L) 4.8 [0.12] 4.6 [0.09] 0.38 
HOMA-IR score 1.2 [0.19] 0.51 [0.08] 0.003 
 
Table 3: Subject demographics and blood results for experiments with early 
outgrowth EPCs 
 
5.2 Pilot work 
 
In the initial stages of the project, we planned to administer oral Simvastatin 20mg 
daily for 1 month to 20 healthy South Asian men, and assess EPC function prior to 
and after Simvastatin exposure. Unfortunately, we were only able to recruit 5 
subjects and due to poor subject compliance, this part of the experiments had to be 
abandoned.  Further experiments were limited to obtaining blood samples and 
performing in vitro studies of EPCs exposed to clinically relevant concentrations of 
Simvastatin. 
 
Pilot work was conducted with early EPCs derived from two white European and two 
South Asian subjects. Simvastatin at concentrations of 0.1 µM and 1.0 µM was 
added to the EPC culture medium on day 3 and numerical and functional assays as 
previously described were conducted after 15 hours. Endothelial progenitor cell 
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death was consistently noted with Simvastatin 1.0 µM in South Asian group, as 
demonstrated by loss of adhesion to the fibronectin coated plate and alteration in 
morphology suggestive of cell death (see figure 18).  
 
 
Figure 18: Altered EPC morphology with Simvastatin 1.0 µM 
 
Further experiments were therefore conducted with 0.1 µM Simvastatin only and the 
results are as described below; as discussed earlier, this represents a clinically 
relevant concentration. 
 
Altered EPC 
morphology 
117 
 
 
5.3 Early outgrowth EPC numerical assay 
5.3.1 Enumeration 
Basal EPC numbers at day 4 were defined by dual staining with Dil-acetylated LDL 
and Ulex Europeus lectin-FITC conjugate. The number of cells, expressed in cells 
per high power field, was significantly reduced in SA males when compared to WE 
males (12 [2.4] vs. 27 [5.6]; p = 0.009) (See figure 19).  
 
 
Figure 19: Basal EPC numbers in SA and WE subjects. SA EPC count is 
significantly lower than WE subjects. 
 
Interestingly, HOMA – IR score negatively correlated with EPC numbers, as seen in 
figure 20 (R2 = -0.55, p < 0.05) 
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Figure 20 – Negative correlation between HOMA-IR score and number of EPCs per 
high powered field.  
 
 
Following treatment with 0.1 µM Simvastatin on day 3, a significant increase was 
noted in EPC numbers (cells/HPF) in SA group (10 [2.3] vs. 19 [4.0]; p=0.005), a 
change which was also seen in the WE group (26.7[5.6] vs. 38.5 [6.1]; p=0.005). The 
total EPC count recorded following Simvastatin treatment in SA subjects did not 
exceed the basal EPC numbers seen in WE subjects, though the difference was not 
statistically significant (19[4.0] vs. 26.7[5.6]; p=0.20) (See figure 21).  
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Figure 21: EPC numbers in SA and WE men following treatment with 0.1 µM 
Simvastatin. A significant increase in EPC numbers is seen in both groups. 
 
 
5.4 Early outgrowth EPC functional assays 
5.4.1 Migration in response to VEGF 
 
Early EPCs exhibited migration in response to vehicle medium (i.e. haptotaxis) and 
VEGF (i.e. chemotaxis). Early EPCs that had been treated with Simvastatin 0.1 µM 
also demonstrated migration to both vehicle medium and VEGF. Basal haptotaxis 
was initially analysed, as was the response to VEGF as a chemo-attractant factor. 
Cells that were treated with Simvastatin were then analysed similarly.  
 
 
p = 0.005 
p = 0.005 
P = 0.009 P = 0.02 
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There was a significant increase in migration in response to VEGF in both SA men 
(1.5 [0.36] vs. 2.6 [0.64]; p=0.01) and WE men (2.1 [0.65] vs. 3.8 [0.91]; p=0.007), as 
compared with basal haptotaxis. EPC pre-treated with Simvastatin 0.1 µM alone also 
demonstrated an increase in haptotaxis in both groups; this increase was significant 
in SA men (1.5 [0.36] vs. 2.4 [0.3]; p=0.04) but non-significant in WE men (2.1 [0.65] 
vs. 2.6 [0.64]; p=0.54) (See figure 22). 
 
 
Figure 22: Basal and Simvastatin pre-treated EPC migration towards VEGF. A 
significant increase in EPC migration is seen in both groups in response to VEGF, 
but only seen in SA EPCs following pre-treatment with Simvastatin.  
 
In order to assess specific migratory effect to VEGF, data was corrected for each 
individual subject for haptotaxis of cells to vehicle solution. Migration in response to 
VEGF was greater in WE men, though the increase was not significant (1.1 [0.4] vs. 
1.7 [0.52]; p=0.28). Cells that were treated with 0.1 µM Simvastatin were analysed 
similarly. Migration of cells treated with Simvastatin 0.1 µM to VEGF was 
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interestingly reduced in both groups, compared with non-statin exposed cells. The 
degree of reduction was lesser in WE EPCs (1.7 [0.52] vs. 1.1 [0.56]; p=0.43) when 
compared with SA EPCs (1.1 [0.4] vs. 0.35 [0.56]; p=0.26), though the difference 
was not statistically significant. 
 
 
Figure 23: Effect of Simvastatin 0.1 µM pre-treatment on EPC migration to VEGF. 
No difference is seen in overall migration to VEGF or following pre-treatment with 
Simvastatin. 
5.4.2 Adhesion of Early EPCs to fibronectin 
EPC derived from SA and WE men were plated at a concentration of 5 x 104 per well 
into 3 wells of a 24 well fibronectin coated plate. The plate was washed twice with 
DPBS after 1 hour, and the number of adherent cells was counted. At baseline, there 
was no significant difference in adhesion to fibronectin of non-stimulated EPCs 
derived from South Asian males to the white European subjects (13.7 [1.9] vs. 15.5 
[3.1]; p=0.61) (See figure 24). 
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Figure 24: Basal EPC adhesion to fibronectin. No difference is seen between SA 
and WE EPCs. 
 
 
However, following stimulation with Simvastatin, South Asian EPCs demonstrated a 
significant improvement in adhesion to fibronectin (13.7 [1.9] vs. 21.28 [3.1]; 
p=0.009), while in the WE group there was a smaller non-statistically significant 
increase noted (15.4 [3.0] vs. 21.54 [7.4]; p=0.26) (See figure 25). 
 
 
 
 
 
 
123 
 
 
Figure 25: Enhanced adhesion of EPCs following treatment with Simvastatin. A 
significant increase is seen in EPC adhesion in SA group but not in WE group. 
5.4.3 In vitro angiogenesis assay 
 
As previously discussed, early outgrowth EPCs are believed to release a number of 
paracrine factors that stimulate angiogenesis. In order to assess this further, 
conditioned medium derived from both un-treated and pre-treated (with Simvastatin 
0.1 µM) cells was used to perform an in vitro angiogenesis assay. HUVECs were 
suspended in this medium and then placed onto a thin layer of Matrigel, and tubular 
structures formed after 24 hours were counted.  
 
The number of tubules formed was significantly lower in the South Asian subject’s 
EPC conditioned medium when compared to matched white Europeans, as shown in 
figure 26 (1.1 [0.89] vs. 4.9 [1.5]; p = 0.049).   
0 
5 
10 
15 
20 
25 
30 
Control 0.1μM 
A
d
h
e
re
n
t 
c
e
ll
s
/h
ig
h
 p
o
w
e
r 
fi
e
ld
 
Simvastatin 
SA 
WE 
p = 0.26 
p= 0.009 
124 
 
 
Figure 26: Basal tubule formation in conditioned medium from SA and WE EPCs. 
Significantly fewer tubule are formed with SA EPC derived conditioned medium. 
 
However, conditioned medium derived from EPCs pre-treated with Simvastatin 
showed a non-significant increase in tubule formation in both South Asians (1.1 
[0.89] vs. 2.5 [1.8]; p=0.34) and WE subjects (4.9 [1.5] vs. 5.0 [1.7]; p=0.98) (See 
figure 27). Importantly, this conditioned medium did not contain Simvastatin. 
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Figure 27: Tubule formation in conditioned medium derived with or without pre- 
treatment of early outgrowth EPCs with Simvastatin. No increase in tubule formation 
was noted in either group following pre-treatment with Simvastatin. 
 
5.5 Discussion 
 
This section of the thesis presents an assessment of in vitro functional potential of 
early EPCs in South Asian men. Early EPC function has been assessed at baseline 
and following the treatment of cells with Simvastatin 0.1 µM. Before discussing the 
individual findings in detail, the overall findings in these groups of experiments will be 
summarised first. 
 
Limited work has been carried out assessing functional properties of early EPCs in 
South Asian men. We have, however corroborated findings of Murphy et al 132 
confirming a significant reduction in basal early EPC numbers in South Asian men 
compared to white European men. Our method of enumerating early EPCs involves 
p=0.049 
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counting adherent cells that are dual positive for DiI-acetylated LDL and Ulex 
Europeaus Lectin, whereas Murphy et al enumerated EPC-CFUs instead. 145 The 
subjects in both are healthy non-obese South Asian males compared with a well 
matched control group. Studies analysing early EPC numbers in groups of human 
subjects using dual staining in South Asian men are relatively limited, though work 
performed in white European subjects by Dimeller et al has shown this to be a 
reliable way of performing a numerical assay, with confirmatory phenotyping 
performed using FACS 167. Flow cytometry was not used to enumerate EPC using 
cell surface markers which could be viewed as a limitation of this study. However, 
our group has performed similar work and validated the conclusion of Murphy et al 
that CPC numbers are also reduced in South Asian men, using FACS analysis.133 
We have also demonstrated impairment in basal functional properties of South Asian 
EPCs, with reduced migration to VEGF and induced endothelial tubule formation as 
a measure of paracrine activity, when compared to white Europeans. However, the 
in vivo significance of these observations remains unclear, as will be mentioned at 
different points in the discussion. 
5.5.1 Basal South Asian EPC function 
 
5.5.1.1 South Asian EPCs demonstrate impaired migration 
Our work has demonstrated a reduction in migratory capacity to VEGF in early 
outgrowth EPCs derived from South Asians when compared with white European 
subjects. In vivo, this would translate into impaired capacity of the EPCs to migrate 
to site of vascular injury or tissue ischemia. VEGF has been demonstrated to be 
released following vascular injury and thus appears to be physiologically relevant as 
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a stimulus for migration, though it would be interesting to study the effect of other 
molecules such as SDF-1. Our group has previously demonstrated similar responses 
of EPCs to VEGF and IGF-1 (Dr Richard Cubbon: unpublished data). As VEGF and 
IGF-1 signal through the PI3k/Akt signalling pathway to promote migration,88 further 
mechanistic work will need conducting in future to analyse signalling properties in 
these cells. 
 
5.5.1.2 South Asian EPCs demonstrate normal adhesion 
 
Our finding of non-impaired EPC adhesion to fibronectin would suggest that South 
Asian EPC adhere optimally at sites of vascular endothelial damage. Work by 
Tepper et al 234 studied adhesion of EPCs derived from subjects with type II diabetes 
and control subjects to fibronectin. They found no significant difference in adhesion 
between the groups. Our findings in the insulin resistant SA group are in keeping 
with their findings, though it must be borne in mind that the diabetic phenotype is a 
lot more advanced and complex when compared to the insulin resistance phenotype 
in this study. This is in contrast to studies in mice where adhesion of diabetic EPCs 
was significantly reduced to numerous extracellular matrices including fibronectin.288 
Our findings in this study are in contrast to previous unpublished work by our group 
that demonstrated significantly impaired adhesion of early EPCs when seeded on 
Matrigel. However, the SA group whilst only showing a trend towards insulin 
resistance did not show any significant difference in the HOMA-IR scores from WE 
men. How these contradictory findings would therefore translate in vivo is unclear, 
and ideally future experiments should be conducted under shear stress to better 
mimic arterial injury. Also, the lack of difference in adhesive capacity in our groups 
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could be explained by the small sample size, and studies in a larger cohort may 
demonstrate a statistically significant difference. As discussed in the introduction to 
this thesis, adhesion of EPCs to denuded vessel wall is dependent to some extent 
on integrin expression 186, and future work into this could provide valuable insights 
into the adhesive capabilities of SA early EPCs. Attachment of circulating EPCs to 
denuded endothelium on an injured arterial wall is critical in mediating re-
endothelialisation, and understanding the exact mechanisms would aid future 
modulation of adhesive capacity of EPCs.  
 
5.5.1.3 South Asian EPCs demonstrate impaired paracrine function 
 
In vivo, early outgrowth EPCs are believed to release numerous paracrine mediators 
that stimulate local vascular cells to repair injured blood vessels161, 195. Hence, 
analysing this effect in vitro using HUVECs cultured in conditioned medium derived 
from early EPCs is helpful to assess the reparative properties of these cells. We 
found that tubule formation in Matrigel was significantly lower in HUVECs exposed to 
South Asian specimens. Work by other research groups has shown a majority of this 
effect to be dependent on VEGF161, though other secreted factors may also play a 
role. However, it must be noted that the Matrigel assay is a 2-dimensional assay 
which does not replicate the actual 3-dimensional process involving endothelial cells, 
pericytes and smooth muscle cells that occurs in vivo in response to shear stress. In 
our assay we have used conditioned medium containing paracrine mediators derived 
from early outgrowth EPCs as stimulatory factors for tubule formation. Data by 
different groups regarding the ability of EPCs to form tubules in Matrigel is variable 
and conflicting.289, 290 In addition, the pattern of tubule formation seen on microscopy 
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may not be representative of capillary network formation in vivo.291 While the release 
of paracrine mediators by early outgrowth EPCs has been clearly established in 
existing research 201, it may be worthwhile probing the specific alteration in selected 
growth factor (e.g. VEGF) secretion in future studies.  
5.5.2 Effect of Simvastatin on basal EPC function 
5.5.2.1 Simvastatin increases early EPC numbers  
 
In keeping with research by other groups167, we found a significant increase in EPC 
numbers in both ethnic groups following stimulation with Simvastatin 0.1µM. 
However, we believe that the finding of increased EPC numbers in SA men is novel. 
Interestingly however, this change did not numerically match basal EPC number in 
white Europeans, and was significantly lesser than EPC numbers following pre-
treatment of EPCs with Simvastatin in white Europeans. Given this increase in 
numbers, one may speculate that statins exert this effect by stimulating the release 
and expression of numerous angiogenic growth factors like VEGF and IGF-1, with 
resultant autocrine and paracrine effects. However, it appears that statins can induce 
differentiation of CD34 positive hematopoietic precursor cells into EPCs, even when 
critical aspects of VEGF/IGF-1 downstream signalling are inhibited167. Future work is 
required to dissect the mechanisms involved. 
 
5.5.2.2 Simvastatin treated EPCs may demonstrate reduced migration  
 
Migration to VEGF was assessed with EPCs that had been pre-treated with 
Simvastatin 0.1µM. Our findings demonstrate that un-treated EPC migration to 
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vehicle (haptotaxis) was reduced in SA men versus WE men, and increased 
significantly in both groups, as expected, in response to VEGF. On assessing 
migration of Simvastatin treated EPCs, a significant increase in haptotaxis was noted 
in SA group (compared to untreated EPCs); a similar increase was also seen in WE 
group. Interestingly, we found a reduction in net migration of Simvastatin treated 
EPCs to VEGF in both groups (i.e. after accounting for haptotaxis); the reduction 
however, was not statistically significant. 
 
The above findings are in contrast to work published by other groups. EPCs pre-
treated with Lovastatin demonstrated enhanced migration when compared to control 
groups.270 In a study group of 15 patients with angiographically evident coronary 
artery disease, a 3 week course of oral Atorvastatin augmented migration of 
circulating EPCs.292 It is important to note that subject ethnicity was not indicated in 
these studies, and as far as we are aware no such work has been conducted in SA 
men to date. Unpublished work by our group has shown reduced basal migration of 
untreated SA early EPCs to VEGF and IGF-1. It remains unclear how statins impact 
on EPC migration toward other physiologically relevant stimuli such as IGF-1, 
however. 
 
Surprisingly, in our study, a reduction in Simvastatin pre-treated EPC migration to 
VEGF was noted in both groups, though to a non-significant degree. A possible 
explanation for this could be that both VEGF and statins appear to promote PI3K/Akt 
signalling.88, 167 It is possible that the Simvastatin pre-treatment has maximally 
stimulated PI3K/Akt activity, and so VEGF is unable to produce its usual chemotactic 
effect, which, as outlined earlier, is PI3K/Akt dependent. Another possibility is that 
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the power of the study is insufficient to make an accurate analysis of the overall 
effect of Simvastatin on migration. Repeated analyses and other migration assays 
(e.g. scratch wound assay) are needed in order to more confidently define the impact 
of statins on early outgrowth EPC migration to VEGF. 
 
5.5.2.3 Simvastatin enhances EPC adhesion 
 
Following treatment with Simvastatin, early EPCs demonstrated an enhanced 
degree of adhesion to fibronectin. In particular, a statistically significant increase in 
EPC adhesive capacity was noted in South Asian specimens. An increase of similar 
magnitude was also seen in white European specimens, though this increase was 
not statistically significant.  
 
Adhesion of EPCs is thought to play a key role in their promotion of neo-
angiogenesis. Research assessing the adhesive capacity of early EPCs following 
treatment with statins is limited. Unpublished work by our group assessing EPC 
function in South Asian men demonstrated an incidental finding of significantly 
reduced adhesion of early EPCs to Matrigel following 24 hours of seeding. However, 
most adhesion assays are performed following an hour of seeding onto fibronectin or 
matrigel coated plates, and hence the results could be construed as inaccurate.234 
Previous work by Tepper et al assessing the function of EPCs derived from subjects 
with type 2 diabetes found no significant difference in adhesion to fibronectin when 
compared to control subjects234. Our study has shown similar results in an insulin 
resistant SA group.  
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Adhesion studies of EPCs treated with simvastatin is limited. Human EPCs pre-
treated with Lovastatin showed increased EPC adhesion in a dose dependent 
manner270. However, the ethnicity of the subject population in the study population 
was not specified. Our study has shown a significant increase in adhesion to 
fibronectin in South Asian subjects. Adhesion of EPCs is mediated by integrins – in 
particular β2 integrins.186  Further study of expression of these integrins and 
inhibition of their function with blocking antibodies, in our study population may 
provide valuable insights into statin-mediated effects upon EPC adhesion. 
 
5.5.3.3 Simvastatin enhances paracrine function 
 
As discussed above, tubule formation from HUVECs cultured in conditioned medium 
derived from early EPCs demonstrated significantly greater promotion of 
angiogenesis in white European subjects when compared to South Asians. We 
found that when HUVECs were cultured in conditioned medium derived from early 
EPCs pre-treated with simvastatin, there was an increase in tubule formation of 60% 
seen in south Asians, though this increase was not statistically significant. No 
material change was seen in HUVEC angiogenesis when exposed to conditioned 
medium from white European EPCs pre-treated with Simvastatin. 
 
The existing literature on the impact of statins on angiogenesis offers no clear data 
on their mechanism of action. Most of the in vitro work performed is with murine 
EPCs, but did not address the impact of statins on their secretory paracrine function. 
There appears to be no data to date on the effect of statins on EPC conditioned 
medium in humans.  
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Future work should address the inter-ethnic differences in secretion of specific pro-
angiogenic compounds by early EPCs at baseline and following treatment with 
Simvastatin; this may provide valuable insights into our observations and suggest 
methods of translating into novel therapeutic strategies. 
 
5.6 Common underlying mechanisms 
 
The in vitro studies presented in this chapter have highlighted numerous functional 
impairments in early EPCs derived from South Asian men. Early EPCs once 
released from the bone marrow home to sites of injury or ischemia, release paracrine 
factors, and mediate endothelial repair. Impairment in any of these steps could result 
in defective endothelial repair, a process likely to be a required in retarding the 
progression of atherosclerosis. From the work we have described above, two main 
factors seem to play an important role in impaired EPC function in SA men. 
5.6 1. Insulin resistance 
 
As discussed in the introduction to this thesis, insulin resistance forms a central role 
in a complex group of cardiovascular risk factors collectively termed metabolic 
syndrome. We have previously shown reduced EPC numbers in SA insulin resistant 
subjects.132 More recent work by Jialal et al has also shown the same in subjects 
with metabolic syndrome, though a majority of their subjects were female.293 Our 
study has corroborated these findings and gone on to show associated dysfunction 
of these cells. We have also shown the HOMA-IR score to be negatively correlated 
134 
 
to basal EPC numbers. While such indices of whole body insulin resistance are 
associated with increased cardiovascular risk, insulin resistance at a cellular level 
may also be relevant, by retarding EPC PI3K/Akt signalling, whilst sparing the MAP 
kinase signalling.122   However, the existence of insulin resistance at EPC level 
remains speculative. 
5.6.2. Blunted PI3 kinase/Akt signalling 
In addition to showing reduced basal SA EPC numbers, we have also demonstrated 
reduced migration of SA EPCs toward VEGF which could reflect impaired migration 
toward damaged vascular tissue in vivo. Once progenitors have mobilised in vivo, 
they migrate to site of injury and ischemia and initiate endothelial repair and 
angiogenesis. Tubule formation in vitro on Matrigel aims to reflect the angiogenic 
process in vivo, and in our studies required the release of paracrine mediators by 
EPC (producing conditioned medium). We have demonstrated reduced promotion of 
endothelial tubule formation by conditioned medium derived from SA EPCs. One of 
the key secreted molecules in early outgrowth EPC conditioned medium is VEGF, 
although many others are co-secreted.161 The mechanism of EPC VEGF secretion is 
unclear, although it is interesting to note that insulin resistance has been shown to 
reduce vascular cell and myocardial VEGF secretion via reduced PI3K/Akt 
signalling.294, 295 
 
The available evidence and our study included have shown that Simvastatin 
increases basal EPC numbers and may improve functional properties of early 
EPCs.167, 254 Previous work has shown this increase in numbers to be due to 
stimulation of the PI3k/Akt signalling pathway by Simvastatin167, and thus blunting of 
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this pathway could explain reduced basal signalling in untreated early EPCs, 
especially those derived from South Asian men. It may be speculated that 
Simvastatin increases EPC numbers by enhancing the expression of paracrine 
angiogenic growth factors such as VEGF and thus act through the PIK/Akt pathway, 
though unpublished work by Dimeller et al has shown this not to be the case.167 As 
was discussed in the introduction, isoprenylated proteins and Rho Kinases play a 
role in eNOS production. Blocking Rho kinases with atorvastatin and another 
pharmacological inhibitor HA 1077 did not increase EPC numbers, thus implying that 
statins are unlikely to exert its effects on EPCs through this mechanism.167 
 
It is noteworthy that while we have shown increased SA EPC numbers and 
enhanced adhesion to fibronectin following pre-treatment with Simvastatin, we did 
not notice a statistically significant increase in EPC migration. This is in contrast to 
available evidence where Simvastatin enhanced EPC migration, though this was not 
in a South Asian population group.242 It is likely that this is due to our small sample 
size. In addition, studies that have been performed with statins and EPCs are with 
different statins and murine EPCs.254  For example, work by Shao et al explored the 
effect of Fluvastatin on EPC migration as a part of their experiments assessing the 
effect of statins and SDF-1 on human EPC function and angiogenesis.296 They 
demonstrated enhanced migration with low dose Fluvastatin, while this was inhibited 
with a higher dose of Fluvastatin. This was further increased when EPCs were 
treated with both Fluvastatin and SDF-1 when compared to statin or SDF-1 alone. 
This is in contrast to our results with Simvastatin. They then proceeded to examine 
Akt phosphorylation following statin treatment, and demonstrated a statistically 
significant increase in Akt phosphorylation with low dose statins, while no increase 
136 
 
was noted with a higher dose of statin. Work with Cerivastatin by Vincent et al 
demonstrated reduced endothelial migration to chemotactic factors, though the 
migratory capacity of un-stimulated endothelial cells was preserved.275 Our basal 
EPC function results and those obtained after treatment with Simvastatin may 
support a role for PI3k/Akt signalling in impaired function of SA EPCs. However, this 
requires further work with western blot analysis of Akt protein expression, 
phosphorylation and activity in early EPCs.  
 
However, it must be borne in mind that while this might be one possible mechanism, 
other factors cannot be conclusively ruled out. In particular, early EPC dysfunction in 
South Asians could be related to enhanced apoptosis and premature senescence, 
as demonstrated and discussed later with late outgrowth EPCs. If this were to be the 
case, then the impaired basal functional properties of early EPCs may not be 
regarded as a true impairment, but instead be all due to enhanced early cell death. 
While we do not have this data at present, future studies could be designed to 
address this issue. 
 
5.7 Study limitations 
 
Our data, as with any scientific work, has both strengths and weaknesses. It is 
important to identify these limitations in order understand the implications of our 
observations and to plan future studies. 
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5.7.1 Defining ethnicity 
As evident from our preceding discussion, defining ethnicity accurately is difficult, 
and in most published papers is arbitrary. Criteria remain unclear, and can include 
parameters ranging from geographic location to religious beliefs. Using one 
particular criterion may promote standardisation; however this system would ignore 
numerous other heterogeneous factors within each ethnic group (culture and 
religion). This heterogeneity would no doubt impact cardiovascular risk. Furthermore, 
migration patterns would imply a greater spread of the population globally, resulting 
in difficulty applying commonly used descriptors to a fewer number of people in this 
ethnic group. In an attempt to avoid this difficulty in defining ethnicity, we opted to 
consider geographic origin and self defined ethnicity sufficient to represent our study 
population similar to previous studies. Of course, this would unfortunately exclude 
other parameters that may impact on cardiovascular risk (such as genetics), and 
given the lack of a clear solution to this, we decided that this would be the clearest 
and simplest way to define our study groups. 
5.7.2 Sample size 
Our study has a relatively small sample size which has potential implications for the 
entire study. The in vitro studies assess the numerical and functional properties of 
EPCs at basal level and following treatment with Simvastatin. While at basal level a 
few parameters show significant differences between these properties, those that 
have been described as being no different between the two groups or showing no 
correlation between various factors cannot be conclusively stated as fact. When the 
project was designed, the main context of the project was to generate hypothesis as 
to how differences in ethnicity and thus endothelial repair mechanisms in these two 
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groups could explain a difference in prevalence of cardiovascular events. In our 
study, we have collected a large amount of data for a small sample size, which we 
consider to be more effective than collecting a limited amount of information from a 
larger sample size. Furthermore, consumable expenditure for this study was limited, 
as was the availability of resources and time. We have mentioned this fact clearly 
where relevant, in addition to the small sample size and the requirement for further 
experiments.  
5.7.3 Defining EPCs 
In the introduction to this thesis, I have discussed the difficulty in clearly defining 
EPC phenotype based on surface markers and appearance in culture, as no unique 
marker has been identified.  
 
The extrapolation by the other groups of Asahara’s seminal work on ‘progenitor 
endothelial cells’ resulting in a definition of circulating EPCs as cells expressing 
endothelial and hematopoietic progenitor markers has confused the wider literature 
and is now agreed to be inappropriate.297 Studies have shown alteration in the 
number/function of these cells to be associated with cardiovascular disease; 
however no clear causal association has been demonstrated. Our study focuses on 
culture derived early outgrowth EPCs. We have previously discussed the confusion 
that prevails over the link between in vitro and in vivo studies. In addition, it is 
unclear if EPCs derived in culture are solely an artificially derived phenotype. As 
research has progressed over the years, other groups described these cells as being 
monocytic in origin. In particular, this group demonstrated the transfer of endothelial 
surface markers to monocytes by platelet microparticles that are generated in 
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vitro.163  However, whether monocytes that do not bear these ‘transferred’ surface 
markers exhibit properties such as angiogenesis in vivo is uncertain.  Furthermore, 
the in vivo therapeutic role of the cells derived in this project are yet to be defined; a 
series of infusion studies after arterial injury in immuno-deficient mice (akin to the 
next chapter) would go some way to addressing this issue. 
 
 
In our study, we have also examined the effect of Simvastatin on EPCs in vitro. 
While the results are interesting, there still remains the question as to what the in 
vivo relevance of this would be. We attempted to study this by administering oral 
Simvastatin to healthy male subjects, but encountered difficulties with subject 
compliance and recruitment and hence abandoned the study. Studies looking at oral 
administration of Simvastatin in C57BL/6 male mice have demonstrated an increase 
in circulating progenitor cells number.167 Similar results have been observed in 
human studies as well, though are mostly in patients suffering from coronary artery 
disease.271 
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6. Results part two - Late outgrowth endothelial progenitor cell function 
The work in this chapter forms part of a jointly authored manuscript which is currently 
under revision (see non-revised manuscript in appendix 1). I acknowledge the 
contribution of all authors to this work, and have highlighted the role of some authors 
in this chapter, where relevant. 
 
6.1 Subject demographics 
 
A total of 8 SA and 8 WE subjects were studied. Parameters such as systolic blood 
pressure and BMI appear statistically comparable. HOMA-IR score was significantly 
higher in SA when compared to WE (1.19 [0.22] vs. 0.44 [0.08]; p = 0.01). 
Interestingly, total cholesterol and LDL concentrations were both significantly higher 
in SA men. 
 
 
Parameter 
 
Asian [SEM] 
 
White European 
[SEM] 
 
 
p value 
Age (years) 30.6 [1.5] 29.4 [1.3] 0.54 
Systolic BP (mmHg) 116.3 [3.2] 115.8 [3.5] 0.91 
BMI (kg/m2) 24.2 [1.0] 22.3 [0.6] 0.12 
Waist :hip ratio 0.8 [0.0] 0.8 [0.0] 0.86 
Haemoglobin (g/dL) 15.4 [0.2] 15.4 [0.4] 0.94 
White cell count (109/L) 6.0 [0.2] 4.8 [0.2] 0.01 
Creatinine (µmol/l) 97.8 [0.2] 96.8 [2.5] 0.22 
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ALT (iu/L) 24.6 [2.8] 19.7 [1.3] 0.65 
Cholesterol (mmol/L) 4.9 [0.1] 4.4 [0.2] 0.02 
LDL (mmol/L) 3.1 [0.2] 2.7 [0.2] 0.04 
HDL (mmol/L) 1.2 [0.1] 1.2 [0.1] 0.53 
Triglyceride (mmol/L) 1.2 [0.2] 0.9 [0.1] 0.37 
Glucose (mg/dL) 4.7 [0.1] 4.6 [0.1] 0.81 
Insulin (mU/L) 5.6 [0.9] 2.7 [1.0] 0.004 
HOMA-IR score 1.19 [0.22] 0.44[0.08] 0.01 
 
Table 4 - Subject demographics and blood results for experiments with late EPCs 
 
6.2 Population doubling time 
 
Population doubling time was calculated as described in section 4.3.3. 
South Asian EPCs (n=7) demonstrated a significantly greater population doubling 
time when compared to WE subjects (n=6) (5.25 [0.81] vs. 2.92 [0.3]; p = 0.019). 
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Figure 28: Population doubling time in SA EPCs vs. WE EPCs. Significantly higher 
population doubling times are seen in the SA group. 
 
Interestingly, a positive correlation was noted between HOMA-IR scores and 
population doubling times (n=13), suggesting a trend toward association between 
insulin resistance and EPC proliferation (R2 0.31, p=0.15). 
 
Figure 29: Scatter plot and line of best fit demonstrating an association between 
HOMA-IR score and EPC population doubling times. Proliferation assays were 
performed in a subset of samples (SA n= 7, WE n=6) 
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The number of population doublings occurring per unit time (days) i.e. the growth 
rate of SA EPCs was significantly lower than WE subjects (0.16 [ 0.02] vs. 0.28 
[0.03]; p=0.014).  
 
 Figure 30: Late outgrowth EPC growth rate. A significantly lower growth rate is 
seen in the SA EPCs. 
 
 
6.3 EPC senescence 
 
At passage 4, cells were stained with β-galactosidase to measure senescence. The 
total number of cells counted per high powered field was noted, as were the number 
of cells that had stained blue. Results are expressed as a percentage of total cells 
that β-galactosidase staining. There was good inter-observer agreement when 
analysed by 2 separate observers (R2 0.99, p=0.95) 
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Figure 31: Inter-observer variability in measuring EPC senescence 
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Figure 32: β-galactosidase staining of late EPCs at passage 4. A greater number of 
EPCs stain blue in SA when compared to WE (A). A significantly greater percentage 
of β-galactosidase positive senescent cells are seen in South Asians (B) 
 
 
6.4 Molecular signalling pathways 
 
Previous unpublished work performed by our group has demonstrated reduced 
colony formation, migration to VEGF / IGF-1 and reduced angiogenic tubule 
formation by late outgrowth EPCs derived from SA men, compared with matched 
white European controls (see appendix 1). Given this, these experiments were not 
repeated, but mechanisms involved in this dysfunction were investigated further. 
 
Senescent cells % 
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6.4.1 Expression of phospho S1177-eNOS and eNOS 
Late outgrowth EPCs were harvested from fibronectin coated plates when confluent 
and were subject to western blot analysis of phospho-eNOS and eNOS protein 
expression.  
 
6.4.1.1 Expression of phospho-eNOS 
 
In order to standardise protein expression, the ratio of phospho-S1177eNOS to β-
actin expression was calculated for each sample. A significantly higher phospho-
eNOS : β-actin protein ratio was noted in WE men when compared to South Asian 
men (0.15 [0.01] vs. 0.05 [0.02]; p=0.015).  
 
A 
 
 
 
 
 
 
 
 
 
 
β-actin 
SA WE 
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Figure 33: Western blot analysis of phospho-eNOS protein in EPCs derived from SA 
and WE men. A representative immunoblot clearly demonstrates denser phospho-
eNOS bands in WE EPCs (A). A significant difference is observed between the 2 
groups (B). 
 
6.4.1.2 Expression of eNOS 
 
In order to standardise individual values, a ratio of total eNOS to β-actin was 
calculated. eNOS : β-actin ratio was significantly higher in WE men when compared 
to SA men (1.83 [0.62] vs. 0.11 [0.05]; p=0.018). 
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Figure 34: Western blot analysis of eNOS protein in EPCs derived from SA and WE 
men (expressed as eNOS: β-actin). A representative immunoblot clearly 
demonstrates denser bands in WE EPCs (A). A significant difference is observed 
between the 2 groups (B). 
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6.4.2 Expression of phospho- S473 Akt and total Akt 
6.4.2.1 Expression of phospho-S473-Akt 
 
A significantly higher expression of phospho-S473-Akt protein was noted in WE men 
when compared to South Asian men (0.81 [0.2] vs. 0.14 [0.05]; p=0.005).  
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
WE SA 
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Figure 35: Expression of phospho-Akt in South Asian vs. WE men. A representative 
immunoblot demonstrates denser bands in WE EPCs (A). Phospho-Akt expression 
is significantly greater in WE EPCs (B) 
 
 
6.4.2.2 Expression of Akt 
 
A significantly higher expression of total Akt protein was noted in WE men when 
compared to South Asian men (1.19 [0.13] vs. 0.69 [0.16]; p = 0.049). 
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Figure 36: Akt expression in SA and WE LEPCs. A representative immunoblot 
clearly demonstrates denser bands in WE EPCs (A), and this is significantly greater 
as well (B). 
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6.4.3 Polymerase chain reaction 
 
eNOS and Akt mRNA was quantified by PCR. eNOS mRNA concentrations were 
significantly higher in WE LEPCs when compared to SA LEPCs. However, there was 
no difference between Akt mRNA concentrations (n=6 in both groups). 
 
 
 
Figure 37: Akt and eNOS mRNA concentration in SA and WE LEPCs. eNOS mRNA 
concentrations in SA EPCs are significantly lower than in WE EPCs. No difference is 
seen in Akt concentrations 
6.4.4 EPC mediated in vivo arterial repair following femoral wire injury 
 
Late outgrowth EPCs derived from South Asian and white European men were 
cultured until confluent. They were then fluorescently tagged, detached and 
transfused into nude mice subject to femoral artery wire injury. The arteries were 
harvested on day 4 post transfusion, and stained with Evan’s blue to assess the 
degree of re-endothelialisation. Non-re-endothelialised sections of the artery 
remained blue, while re-endothelialised sections were marked by lack of staining. 
p < 0.05 p > 0.05 
Akt eNOS 
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Comparisons were also made to vessels from mice receiving vehicle only (i.e. 
medium without EPCs) after wire injury. 
 
EPCs derived from SA subjects demonstrated significantly impaired capacity to re-
endothelialise injured femoral arteries when compared to white European EPCs, with 
a significantly smaller area of the artery demonstrating endothelial regeneration 
(36.9% [4.5%] vs. 54.2% [8.4%]; p=0.03). Interestingly the percentage of endothelial 
regeneration was no different between vessels exposed to SA EPC and vehicle 
alone (acellular) (36.9% [4.5%] vs. 34.7% [5.7%]; p=0.70). Images were analysed as 
described in section 4.4.3. 
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Figure 38: Evans blue staining of representative injured conduit artery 4 days after 
EPC transfusion. The degree of endothelial regeneration is no different between 
vehicle (A) and SA EPCs (B), but is significantly greater with WE LEPCs (C). Re-
endothelialisation is significantly promoted by WE, but not SA LEPC (D). 
6.4.5 Confocal microscopy of injured vessel 
A subset of injured vessels were analysed using confocal microscopy. Fewer late 
EPCs derived from SA men were found adherent to the intima of the healing vessel 
when compared to WE late EPCs. 
 
 
 
p= 0.70 
p= 0.03 
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Figure 39: Representative images on confocal microscopy of fluorescently tagged 
late EPCs derived from SA and WE men. Fewer LEPCs are adherent to the intimal 
wall in mice receiving SA LEPC (A) when compared to WE LEPC (B). Red denotes 
CMDiI tracked LEPC; Blue denotes DAPI stained nuclei. 
 
6.4.6 Viral titre data and induced change in Akt content  
 
Given the above data, and the background literature presented in the introduction, 
we speculated reduced Akt signalling may promote SA EPC dysfunction and so 
elected to augment late EPC Akt activity in further in vivo studies. Using a 
constitutively active E17KAkt1 mutant delivered with lentiviral vectors we 
demonstrated 3-fold augmented Akt activity within SA EPC (see appendix 1).  
Prior to late EPC transfusion, Akt activity in native SA late EPCs and EGFP 
expressing SA late EPCs was also compared - no significant difference was found in 
the between the two.  
 
Intravenous transfusion of SA late outgrowth EPCs expressing EGFP was 
associated with no change in femoral artery re-endothelialisation in CD1 
immunodeficient mice. However, E17KAkt expressing SA late EPCs demonstrated 
A B 
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significantly augmented re-endothelialisation to a degree comparable with non-
transduced WE late EPCs (See figure 40).  
 
A  
 
 
B 
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Figure 40: Re-endothelialisation following transfusion of EGFP (A) and E17KAkt (B) 
transduced SA LEPCs. Re-endothelialisation is significantly enhanced with E17KAkt 
transduced EPCs to a magnitude comparable to non-transduced WE LEPCs (C). * 
denotes p < 0.05, NS denotes p≥0.05. 
 
 
6.5 Discussion 
 
This section of my thesis discusses functional properties of late outgrowth EPCs, 
which are considered by many to be the ‘true EPC’, and also to represent an 
attractive autologous cell-based therapeutic modality.298 In addition to this, we have 
attempted to assess the molecular mechanisms involved in late outgrowth EPC 
dysfunction in South Asian subjects by looking at basal protein expression and 
phosphorylation, with subsequent manipulation using lentiviral transduction. Once 
again, this is an area in EPC biology where limited information is available. In 
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particular, information relating to late outgrowth EPC biology and South Asian 
ethnicity is extremely scarce.  
 
6.5.1 South Asian EPCs demonstrate reduced proliferative potential 
 
Previous unpublished work by our group has shown the late outgrowth EPC colony 
number to be significantly lower in South Asian men. In keeping with these findings, 
we found the population doubling time of EPCs derived from SA males was 
significantly higher than WE counterparts. Cell cultures grow and multiply through a 
process of binary fission, with each cell splitting into two at a constant rate. 
Population doubling time refers to the time taken for a particular number of cells to 
double in total number. A higher population doubling time indicates a lower growth 
rate which in turn implies a reduced number of population doublings over a fixed 
period of time. Our findings may simply reflect the fact that the lower colony number 
in SA samples requires more rounds of LEPC division in order achieve a particular 
population size than WE samples, resulting in a more senescent slow-growing 
population at any point in time. 
 
Previous work by Zhang et al in cord blood derived late outgrowth EPCs 
demonstrated increased senescence following treatment with TNF-α, a pro-
inflammatory cytokine 299. Further analysis showed that chronic treatment of EPCs 
with TNF-α resulted in a dose dependent reduction in cumulative population 
doublings. In the results seen above, higher mean population doubling time seen in 
SA men would imply a slower growth rate and thus a lower aggregate of population 
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doublings. This could indicate a greater degree of senescence at the same passage 
stage in SA when compared with WE counterparts (see below).  
 
As is seen from the results, there may be a positive correlation between late EPC 
population doubling times and the HOMA-IR score. In addition, a link has been 
established between inflammatory markers such as TNF-α and insulin resistance212. 
From this available evidence, it could be hypothesised that high population doubling 
times in South Asian men may be explained by insulin resistance. 
6.5.2 South Asian EPCs are more senescent  
 
We have clearly shown in figure 32 that at passage 4, South Asian EPCs are 
significantly more senescent than white European EPCs. As described in section 
5.6.1, this is linked with a higher population doubling time in EPCs derived from 
South Asians.  
 
EPC senescence has been linked to a number of cardiovascular risk factors.279, 280 In 
this study, we have shown South Asian population groups to be insulin resistant, in 
keeping with studies conducted by other groups.21 As discussed above, pathway 
specific insulin resistance has been implicated in endothelial dysfunction.122 This 
results in selective down-regulation of the PI3k/Akt pathway, while maintaining or 
promoting signal transduction via the MAPK pathway. Excessive signalling via MAPK 
pathway has been implicated in defective EPC survival, proliferation and 
differentiation. In addition to this, a close link has been established between insulin 
resistance and increased inflammatory markers such as TNF-α.212 Chronic exposure 
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of EPC cultures to TNF-α has shown increased levels of senescence mediated via 
the p38 MAPK pathway.299  
 
In keeping with these effects, premature senescence of EPCs derived from South 
Asians could also be explained by insulin resistance. Whether or not senescence is 
related to other cardiovascular risk factors in South Asians is unclear, and certainly 
our cohort showed no significant difference in systolic blood pressure readings 
between the two groups, though there was a difference in LDL levels between the 
two groups. Studies using larger cohorts may be required to assess this further. 
Also, future work assessing p38 MAPK activity and it’s phosphorylation in South 
Asian EPCs could provide useful insights into enhanced senescence and EPC 
dysfunction in this group. In addition, studying other principle mediators of 
senescence (p16 and p53) would be interesting to study, along with ROS as a driver 
of senescence. 
 
6.5.3 South Asian EPCs demonstrate blunted expression and activation of pro-
angiogenic signalling molecules 
 
Previous unpublished work by our group has shown that late outgrowth EPCs 
derived from healthy South Asian men demonstrate impaired differentiation, 
migration toward VEGF and IGF-1 and reduced in vitro angiogenesis (appendix 1). 
These experiments were hence not repeated, but mechanisms involved in this 
impairment were analysed further. In particular, expression of Akt, phospho-Akt, 
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eNOS and phospho-eNOS was analysed further using Western blotting and 
polymerase chain reaction. 
 
We found that basal eNOS, phospho-eNOS, Akt and phospho-Akt protein 
expression were all significantly blunted in South Asian EPCs. This is a novel finding 
in late outgrowth EPCs derived from South Asian populations; in fact such changes 
have not been addressed to date in late outgrowth EPC from any insulin resistant 
cohort.. 
 
Murphy et al have previously demonstrated reduced circulating progenitor cell 
numbers, and impaired flow mediated dilatation in response to brachial artery shear 
stress.132. Vasodilatation in response to shear stress is mediated by NO, and as 
previously discussed; NO production secondary to shear stress is dependent on 
PI3k/Akt signalling. Furthermore, our group has also shown that exercise induced 
circulating progenitor cell mobilisation is blunted in SA men as a result of reduced 
NO bioavailability.133 In keeping with these findings, we have now shown reduced 
basal expression of eNOS and Akt in late outgrowth EPCs from SA men. Quon et al 
have demonstrated pathway specific insulin resistance as a mechanism for reduced 
NO production by selective downregulation of the PI3k/Akt pathway.122 In our study 
and in previous work, we have clearly demonstrated SA men to be metabolically 
insulin resistant, and can hypothesise this as a mechanism of blunted PI3K/Akt 
signalling in this group. Of course, our findings are derived from experiments on ex-
vivo expanded late EPCs, and it remains to be established regarding the in vivo 
relevance of these studies. However, cumulative data from our studies suggests 
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downregulation of PI3k/Akt signalling in vivo, resulting in reduced NO production 
which may cause blunted angiogenesis and vascular repair in SA men. 
 
6.5.4 South Asian late EPCs demonstrate impaired re-endothelialisation capacity 
following arterial injury 
 
We have clearly demonstrated impaired injured femoral artery re-endothelialisation 
following transfusion of native (non-manipulated) SA late EPCs when compared to 
WE late EPCs. This finding is novel, and to our knowledge there is no evidence to 
date other than our data demonstrating that human late outgrowth EPCs can 
promote vascular repair.  
 
Impaired vascular repair plays an important role in the pathogenesis of 
atherosclerosis. Circulating progenitor cells may mediate cellular repair in vascular 
injury and so be essential to maintain the integrity and function of the vasculature. 
Endothelial dysfunction is an early event in atherosclerosis, and studies assessing 
the pathogenesis of atherosclerosis in ApoE-/- mice have certainly demonstrated 
this. Seminal work by Wassmann et al in splenectomised ApoE-/- mice fed a high fat 
diet demonstrated a significant impairment in endothelium dependent vasodilatation 
when compared to wild type mice.239 This impairment was rescued by intravenous 
transfusion of mononuclear cells, CPCs or culture-derived early outgrowth EPCs 
derived from wild type mice.  
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We have demonstrated, in keeping with previous studies132, that South Asian 
subjects are insulin resistant. While data assessing murine vascular repair following 
transfusion of EPC derived from this particular group is unavailable, there is a 
plethora of evidence suggesting impaired EPC function in insulin resistant 
phenotypes.233, 288 Our group recently performed a study investigating the effects of 
insulin resistance on EPCs and endothelial regeneration in Insulin receptor knock out 
(IRKO) mice.233 In addition to demonstrating impaired mobilisation in response to 
VEGF and reduced bone marrow eNOS expression in IRKO mice, we demonstrated 
significantly delayed endothelial regeneration following femoral arterial injury in 
insulin resistant IRKO mice when compared to wild type mice. Vascular repair was 
rescued following transfusion of MNCs derived from wild type mice. This appears to 
be the only data to date that assesses the impact of insulin resistance per se on 
vascular repair, though experiments addressing insulin resistant diabetes have 
reached similar conclusions.220 
. 
 
While the work described above involved EPCs derived from mice, there remain 
limited studies assessing re-endothelialisation capacity of EPCs derived from insulin 
resistant humans. Sorrentino et al derived EPCs from subjects with diabetes and 
demonstrated severely blunted re-endothelialisation capacity when compared to 
EPCs derived from healthy subjects.220 This effect persisted even after 7 days of 
transplantation. EPCs derived from the subjects with diabetes also demonstrated 
significantly elevated levels of superoxide production and reduced NO availability.  
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Keeping in mind the high possibility of development of an immune reaction in mice 
following transfusion of human EPCs, we used immunodeficient nude mice for our 
work. Our findings are similar to the findings of Sorrentino et al 220, and we have 
clearly demonstrated impaired re-endothelialisation of injured femoral arteries 
following transfusion of EPCs derived from insulin resistant SA subjects. The 
underlying mechanism appears likely to be impaired PI3K/Akt signalling and possibly 
via reduced NO production, in view of our rescue of EPC mediated vascular repair 
after E17KAkt transduction.  Of course, we have not assessed the role of other 
factors such as oxidant stress or probed the reasons for altered PI3K/Akt signalling, 
and these could be pursued in future studies.  
 
6.5.5 Impaired re-endothelialisation capacity is rescued by constitutively active Akt 
expression in South Asian EPCs 
 
As we demonstrated impaired re-endothelialisation of injured conduit vessels 
following transfusion of South Asian EPCs which exhibited reduced PI3K/Akt 
signalling, we elected to upregulate Akt activity using lentiviral vector constructs. A 
significant improvement in EPC-mediated repair was noted following E17KAkt 
transduction, to a magnitude comparable to non-transduced WE EPCs. This 
corroborates our hypothesis that reduced PI3K/Akt signalling may mediate SA EPC 
dysfunction.  
 
Previous work by Ackah et al has demonstrated a crucial role for Akt in EPC 
function.88 In addition, loss of Akt1 has been demonstrated to result in increased 
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release of pro-inflammatory mediators resulting in atherosclerosis.300 While the 
concept of augmenting Akt activity in SA EPCs to improve their function appears 
promising, it is important to bear in mind that chronic hyperactivation of Akt signalling 
may be detrimental to EPC function. Work by Wang et al in mice with a mutant 
circadian rhythm gene demonstrated increased Akt signalling, which was associated 
with greater EPC senescence and impaired proliferation. 208 Inhibition of Akt 
signalling rescued impaired cellular function in these mice. In addition, Nishi et al 
demonstrated endothelial dysfunction due to excessive Akt activity following VEGFR-
1 deletion.209 
 
Our study is the first to demonstrate improvement in late outgrowth EPC function 
following promotion of Akt activity in insulin resistant human. While we have used 
lentiviral technology to modify EPCs in our study, we appreciate the difficulty of 
replicating this in a clinical setting due to safety concerns described later. Of course, 
Akt activity can be augmented in EPCs with statins, and this has been shown to 
improve their function.167, 254  However, these agents have many other 
pharmacological effects and much more work is required to determine their role in 
this capacity 254 Furthermore, it is unknown as to whether long term statin use and 
hence chronic Akt upregulation is beneficial or detrimental to EPC function. These 
caveats notwithstanding, it maybe that novel pharmacological agents could promote 
vascular repair, by normalising endothelial and/or progenitor PI3K/Akt signalling. 
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6.6 Study limitations 
 
As was observed earlier, this aspect of our study has certain limitations. As already 
discussed in chapter 4 defining ethnicity accurately is impossible, and the small 
sample size of these experiments limits statistical power and may not be reflective of 
the entire SA population group. These limitations remain applicable to this aspect of 
our study. 
 
6.6.1 Origin of and defining ‘late EPCs’ 
 
Despite extensive research being conducted in the field of endothelial progenitor cell 
biology, there is so far no clear agreement on what constitutes an ‘EPC’, how to 
define such cells and whether they exist in vivo. To this date, these issues continue 
to be a matter of debate, with different groups culturing and identifying EPCs by 
different methods.147  
 
From a functional point of view, while culture derived late outgrowth EPCs may 
represent true endothelial progenitors, the possibility that these cells might have 
acquired or lost properties during culture which could influence experimental results 
should not be ruled out. In other words, the results we have described above may, to 
some extent, be artefacts due to cell culture. This of course is relevant to any in vitro 
experiment. However, independent of the in vivo relevance of these data, it is 
apparent from our work that late outgrowth EPCs offer an attractive therapeutic tool, 
providing their reparative function can be restored. 
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The origin of late outgrowth EPCs also remains uncertain. These cells appear in 
culture after 14 – 21 days of plating mononuclear cells, at which point early EPCs 
have died. However, given the lack of a unique marker for late outgrowth EPCs the 
precursor of these cells remains uncertain and so cannot be sought in vivo. Case et 
al described cells expressing surface markers CD34,CD45,CD133, and VEGFR-2  to 
be hematopoietic progenitors and not EPCs.301 Work by Timmermans et al identified 
late outgrowth EPCs to lie within a cell fraction that express CD34 and lack CD45 on 
flow cytometry.155 From the available evidence, it appears late outgrowth EPCs are 
CD34+CD45-CD133-.  
 
Certain groups have described late outgrowth EPCs as different from HUVECs due 
to their greater proliferative potential and resistance to oxidative stress.302, 303 
However, contradictory reports have been published, which adds to the uncertainty 
of the origin of late EPCs.304, 305 To add to this uncertainty, some groups have 
speculated whether late outgrowth EPCs are in fact sloughed off mature endothelial 
cells that have expanded in culture. We have previously described these cells as 
CECs, which possess poor proliferative potential. 306 However, vessel wall derived 
mature ECs such as HUVECs also possess high proliferative potential, which could 
imply the origin of culture derived late EPCs to be CECs. However, there are no 
clear studies clarifying this, and hence this possibility remains uncertain. More 
recently, Mund et al attempted to define and characterise circulating endothelial 
cells.146 Polychromatic flow cytometry (PFC) has now shown these not to be 
endothelial cells but mostly platelet and extracellular vesicles. Upon culture, it 
appears that a proportion of these CECs bear high clonogenic potential, and appear 
to be true EPCs. However, this study also identified EPCs as bearing cell surface 
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markers CD34+CD146+CD45-, which was also present on mature CECs. It thus 
appears that despite advanced flow cytometric methods, it still remains difficult to 
accurately define circulating EPCs and CEC, except based on their clonogenic 
capacity.  
 
6.6.2 Potential problems with oncogene transfer using lentiviral vectors into EPCs 
 
The introduction of an oncogene into EPCs using lentiviral vectors poses potential 
problems if applied to clinical use. As late EPCs possess high proliferative potential 
and are capable of serial passages, there remains the possibility that these cells can 
form or contribute to tumour-like lesions. Lentiviral vectors bear an advantage in that 
they can integrate into the target cell genome in a stable fashion, with the added 
capability of transducing non-dividing cells. However, using HIV as a lentiviral vector 
bears the risk of viral replication into wild type-recombinants or interaction between 
lentiviral vectors and subsequent wild type viral infection.307, 308 In addition to this 
exists the possibility of insertional oncogenesis if vectors with long terminal repeats 
(LTR) are used. These problems are addressed by using self-inactivating (SIN) 
lentiviral vectors which consist of inactive long terminal repeats (LTR)309 that prevent 
vertical and horizontal transmission of the wild type virus. However, there still 
remains a risk of the SIN vectors forming competent viral transcripts capable of 
encapsidation and integration into the host cell genome.307 This risk would need 
addressing when lentiviral vector mediated gene delivery is considered for clinical 
use. So far there do not appear to be any human clinical studies, probably due to the  
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lack of sufficient number of preclinical models to predict the likelihood of insertional 
oncogenesis.310 Furthermore, most mouse models that have used lentiviral gene 
delivery are short studies, which could make it difficult to predict the likely long term 
outcomes if similar studies are conducted in humans. Designing such a clinical study 
would require careful analysis of the potential risks of oncogenesis versus the 
benefits. SIN vectors may bear promise, but more studies need to be conducted 
before clinical application.  
 
In addition to the problem addressed above, we have used constitutively active Akt 
in our experiments. We have previously discussed the potential problems with over-
expression of Akt leading to enhanced EPC senescence. Wang et al studied Per2m/m 
mice (a circadian regulatory gene) and demonstrated enhanced senescence in these 
specimens to be due to over-expression of Akt.208 To add to this, Nishi et al 
demonstrated that premature senescence in VEGFR-1 deleted endothelial cells was 
secondary to Akt activation, implying a detrimental role of endothelial cells in 
postnatal angiogenesis in the event of excessive Akt activation.209 This should be 
borne in mind when titrating the ‘dose’ of constitutively active Akt if performing in 
vitro experiments. Furthermore, Akt over-expression has been linked to certain 
cancers311, 312, which may pose a risk if in vitro studies are translated into clinical 
trials in the future.  
 
6.7 Study implications 
 
From the data presented in this chapter, it is evident that there appears to be a link 
between SA ethnicity, insulin resistance and impaired endothelial progenitor Akt 
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signalling and endothelial progenitor function. While this is evident in a research 
setting, the clinical implications of this are not clear.  
 
Unpublished work by our group has shown late outgrowth EPCs derived from SA 
men demonstrate impaired migration to angiogenic stimuli, impaired adhesion to 
fibronectin and impaired in vitro angiogenesis. We have gone on to show that this is 
mechanistically related to impaired PI3K/Akt signalling. We translated this into an in 
vivo model of vascular injury, and demonstrated impaired re-endothelialisation at 
baseline, with a rescue of reparative function following restoration of Akt activity. This 
data is novel in demonstrating that human late outgrowth EPC can promote vascular 
repair, but are profoundly dysfunctional in a group at high risk of cardiovascular 
disease. While the actual existence of culture derived late EPCs in vivo remains 
unproven, our work still provide data around which future cardiovascular cell based 
therapies can be designed. However, whether isolating sufficient numbers of EPCs 
and optimising their function sufficiently to treat patients with vascular disease is 
feasible remains an issue to be addressed in future. Finally, we have identified a 
common pathophysiological mechanism that leads to EPC dysfunction in late (and 
potentially early) outgrowth EPCs from humans at risk of cardiovascular events. 
These data will undoubtedly generate further hypotheses around which future 
therapeutic studies can be designed. 
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7. Conclusions and future work 
 
In summary, my thesis above has demonstrated the following findings -  
 
1. Basal early EPC abundance is reduced and function is impaired in metabolically 
insulin resistant SA men, when compared to matched WE men. 
2. Simvastatin exposure in vitro increases early EPC number in SA and WE men and 
may improve some indices of EPC function in cells derived from SA men. 
3. Human late outgrowth EPC can incorporate in to the vessel wall and promote 
vascular repair after transfusion into immuno-deficient mice with arterial injury.  
4. Late outgrowth EPC function is impaired in SA men. In particular, they exhibit 
early senescence and impaired capacity to promote re-endothelialisation in murine 
conduit artery injury studies. 
5. Restoration of Akt activity in SA EPCs by lentiviral introduction of constitutively 
active Akt rescues their capacity for vascular repair. 
In section 7.1, we shall discuss the common underlying themes linking some of 
these findings and also discuss future work which may translate our findings toward 
clinical relevance. 
 
 
7.1 Common underlying themes 
 
In chapter four we have demonstrated in a cohort of SA men that metabolic insulin 
resistance is associated with early outgrowth EPC dysfunction. Though the number 
of parameters we have evaluated to assess early EPC function are only a few, we 
have performed these keeping in mind the putative role of progenitors in vivo. It is 
speculated that following tissue injury or ischemia, the CPCs are mobilised from the 
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bone marrow, home to the site of injury and then release paracrine mediators that 
aid re-endothelialisation and healing at the site of injury, or themselves incorporate 
into new vessels.174 Our group has previously demonstrated reduced number and 
mobilisation of CPCs in SA men, with the reduction in basal abundance being 
inversely correlated to the HOMA-IR score.133, 313 The in vitro studies in this thesis 
have extended such observations to culture derived EPCs. In particular, we have 
shown reduced basal EPC number, reduced EPC migration and reduced paracrine 
stimulation of endothelial angiogenesis. When translated in vivo, this could imply 
impaired mobilisation, homing and incorporation into new vessels. However, the lack 
of clear evidence as to whether cultured EPCs are in fact CPCs seen in vivo adds to 
the confusion of accurately interpreting the relevance of these results.  
 
Treatment of early EPCs with Simvastatin, as shown above, resulted in increased 
EPC numbers, along with an improvement in adhesive capacity of SA early EPCs. 
Such increased have been previously been shown to be equipotent to physiologically 
relevant concentrations of the angiogenic cytokine VEGF, and is mechanistically 
related to increased PI3K/Akt activity.167 This increase in EPC abundance using 
Simvastatin could add to the list of their pleiotropic effects, though remains of 
uncertain clinical relevance in isolation, even if EPCs are proven to exist in vivo. 
 
While the in vivo relevance of in vitro studies of EPCs remains unclear, late 
outgrowth EPCs appear to represent an attractive autologous therapeutic tool. These 
cells not only have the capacity to proliferate significantly, but are also 
morphologically similar to endothelial cells, bear functional properties similar to ECs 
and share similar gene expression profiles.157, 164, 165 Given this, we elected to 
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analyse various functional properties of late EPCs derived from South Asian men. In 
addition to our previous findings (Appendix 1), we have clearly demonstrated 
reduced proliferative capacity and increased senescence of SA LEPCs. In an 
attempt to explain these observations, we went on to demonstrate reduced 
expression of the key pro-angiogenic molecules eNOS and Akt. In keeping with a 
mechanistic role of reduced Akt activity, re-endothelialisation following conduit artery 
injury was impaired, and rescued by increasing Akt activity using lentiviral 
manipulation of SA EPCs. These results are in keeping with the possibility that 
pathway specific insulin resistance, with impaired cellular PI3K/Akt signalling, is of 
relevance to LEPC derived from a group of insulin resistant humans. 
 
In the introduction to this thesis, I discussed ‘pathway specific’ insulin resistance as 
an important concept linking whole body insulin resistance, insulin resistance at the 
vascular endothelial cell level, and the development of atherosclerosis. This results 
in selective downregulation of endothelial PI3K/Akt signalling pathway, while 
maintaining normal or enhanced activity of the MAP kinase pathway. As NO 
production is stimulated by the PI3K/Akt pathway, impairment of its activity results in 
reduced NO bioavailability. NO is a critical molecule in regulating angiogenesis in the 
setting of tissue ischemia.314 In addition to being an anti-atherosclerotic molecule315, 
it attenuates senescence 141 and enhances EPC migration316, which are key factors 
in vascular repair. Furthermore, EPC mobilisation to VEGF is absent in eNOS 
knockout mice, indicating a role of NO in this process.176 
 
From the results we have seen with late EPCs (and possibly early EPCs), increasing 
the activity of the PI3 kinase / Akt pathway increases EPC number, enhances EPC 
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function and promotes vascular repair. While these findings most certainly are 
hypothesis generating, their application in disease preventing strategies remains to 
be tested. Of course, these findings could be used to direct future translational 
research.  
 
7.2 Future work 
7.2.1 In vivo effect of Simvastatin on SA EPCs 
Our study has shown enhanced EPC number and function following in vitro 
treatment of South Asian early EPCs with Simvastatin. While these findings are 
intriguing and novel in a South Asian population, they may not necessarily reflect 
changes that could occur in a clinical setting following oral Simvastatin. Dimmeler et 
al demonstrated a significant increase in c-kit/sca-1 cells in the bone marrow and 
EPC numbers in the periphery following administration of 20mg/kg Simvastatin to 
C57BL/6 male mice.167 While we attempted to study these in vivo effects by 
administering oral Simvastatin to healthy SA men, difficulties encountered with 
subject compliance required that the study be terminated. Of course, we only 
planned to recruit 20 subjects based on power calculations. This sample size may 
still be construed as too small to reflect the entire SA population group, so studies 
involving a larger cohort may be more enlightening. The cost implications and time 
required in evaluating important functional parameters should be kept in mind, which 
could be difficult in a large study group. However, there still remains the issue that 
these cells are not established to exist in vivo and the appropriateness/relevance of 
their use as a surrogate cardiovascular endpoint is unclear. 
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7.2.1.1 Brachial artery flow mediated dilatation following Simvastatin  
 
Previous work by our group has shown a positive correlation between brachial artery 
flow mediated dilatation and endothelial progenitor cell function, suggesting reduced 
NO bioavailability underlies reduced CPCs in SA men.132, 133, 313  Studying an 
individual parameter such as flow mediated dilatation (FMD) following treatment with 
Simvastatin could provide interesting insights into its in vivo effects on endothelial 
function. Murphy et al studied vascular function in 24 SA and 25 WE men 
demonstrating a reduced FMD and blunted basal NO bioavailability in forearm blood 
flow studies in the insulin resistant SA group132;their FMD data was recapitulated by 
Cubbon et al.133 Flow mediated dilatation study is a validated technique to infer 
endothelial NO production secondary to shear stress. In addition, changes recorded 
in brachial artery FMD reflect vasomotor changes in coronary arteries.317 A reduction 
in FMD is reflective of underlying endothelial dysfunction, which is a precursor to 
atherosclerosis and subsequent development of CAD.  
 
In keeping with the above findings, and the results described with early EPCs treated 
with Simvastatin in this thesis, designing a study based around our pilot study of oral 
Simvastatin in a larger study cohort of SA men would provide valuable information as 
to the in vivo effects of therapeutic doses of statins normally used in patients with 
hypercholesterolemia or coronary artery disease. Furthermore, FMD would offer a 
more validated outcome measure than early outgrowth EPC number/function in 
isolation. Assessing basal and Simvastatin induced changes in vascular function 
using FMD as a marker would be of great interest in linking altered EPC indices with 
changes in vascular function in vivo. 
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7.2.2 Endothelial repair following conduit artery injury  
 
In chapter 5, we have described the effect of transfused human late EPCs on 
endothelial repair following conduit artery injury in immunodeficient mice. The 
findings we have described are novel in SA populations, and in addition, have 
allowed us to define out a likely mechanism of endothelial progenitor dysfunction. 
 
Existing EPC transfusion studies have assessed the effect of transfusion of early 
EPCs on vascular repair.237 In our in vitro studies, we have demonstrated basal early 
EPC dysfunction in insulin resistant SA men, with some improvement following 
treatment with Simvastatin. It would be interesting to assess the effect of statin pre-
treatment on early EPC mediated conduit artery repair. Work by Sorrentino et al 
clearly demonstrated a significant reduction in re-endothelialisation following 
transfusion of early EPCs from diabetic subjects when compared to non-diabetic 
subjects; this was rescued by Rosiglitazone therapy. 220 Similar results have been 
seen in early EPCs derived from pre-hypertensive and hypertensive patients. 318 We 
have shown that by up-regulating Akt in late EPCs, conduit artery repair can be 
augmented significantly in SA EPCs to a degree comparable to basal repair seen 
with WE late EPCs. Combining these two results together, and using similar 
methods to our late EPC work, early EPCs could be transfused into nude mice and 
re-endothelialisation can be assessed. Using a statin as pharmacological method of 
improving early EPC function, possibly via promoting PI3K/Akt activity, it would be 
possible to probe its effects on vascular repair in vivo. Of course, detailed 
assessment of PI3K/Akt signalling in EPC treated with statin or vehicle would be 
required to link altered signalling with altered function.  
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7.2.3 Other mechanisms of EPC dysfunction 
 
While our work has offered some interesting observations regarding EPC functional 
impairment both in vitro and in vivo in SA men, it would be useful to assess other 
mechanisms that may be involved. In particular, an interesting avenue of future 
research would be to address why Akt activity is reduced in SA late EPCs. 
Determining this could lead to safer means of restoring EPC function, and thus avoid 
the potential problems that could arise using viral delivery of constitutively active Akt. 
Our work here has concentrated mostly on the PI3 kinase/Akt pathway. EPC function 
is closely linked with NO production176, and promotion of PI3K/Akt signalling is not 
the sole means of augmenting NO bioavailability.  
 
Reactive oxygen species play a role in NO degradation, and so evaluating oxidant 
stress as a regulator of EPC function in SA men would be helpful. While EPCs have 
been shown to be relatively tolerant to oxidant stress due to expression of anti-
oxidant enzymes, excess ROS generation may play a role in endothelial progenitor 
cell dysfunction.217, 219, 319 In addition, they appear to play a critical role in progenitor 
mobilisation and tissue reperfusion in hind limb ischemia models.218, 320  
 
We have shown SA EPCs to be more senescent in culture, and senescence has 
been shown to be related to oxidative stress.321  Enhanced EPC apoptosis may also 
play a part in EPC dysfunction, and FACS assessed cell surface Annexin expression 
may be a useful way of evaluating this. Detailed study of ROS subtypes and 
subsequent modification with selective anti-oxidants in vitro may provide a platform 
to define the relevance of ROS to SA late outgrowth EPC dysfunction. 
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7.2.4 Sample size and standardisation of assays 
 
While our findings are interesting and hypothesis generating, our study cohort is 
small and the most relevant sub-studies should ideally be repeated in a larger 
sample of South Asian and White European men. However, given the financial 
constraints and limited resources, performing such work will be difficult. If studies are 
to be continued to be conducted in small samples, assays would benefit from 
standardisation amongst research groups to aid comparison and future meta-
analysis. 
 
7.3 Future potential therapeutic strategies 
 
Our study has not only corroborated previous findings by our group, but has also 
extended these data by demonstrating rescue of endothelial progenitor cell function 
by augmenting Akt activity. This presents a potential therapeutic target to enhance 
autologous EPC function, and thus neovascularisation, should cell-based therapies 
reach the clinical arena. 
 
Previous research has suggested the mechanism of impaired mobilisation and 
migration of diabetic EPCs to be dependent on NO.229 However, the therapeutic 
strategy used by this group to modify EPC function by enhancing NO production 
using hyperoxia is difficult to replicate in a clinical setting. In addition, other groups 
have shown that NO production is dependent on PI3 kinase/Akt signalling.206 We 
have shown improvement in EPC function by targeting this pathway. This result is of 
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particular significance, given our subjects are insulin resistant, and the concept of 
pathway specific insulin resistance downregulating NO production via the PI3K/Akt 
pathway would apply here.122 In particular, we have shown that increasing Akt 
activity in SA EPCs enhances their capability to promote re-endothelialisation. 
However, as has been previously discussed, chronically activated Akt may be 
detrimental 208, and so the longer term implications of our findings to progenitor 
function are unclear. While our data from Simvastatin exposure of early EPCs 
appears promising, we did notice cell death at higher concentrations, which could 
imply a role of Akt over-activation, although we have not formally assessed this. 
Studies assessing the effect of long term statin use in patients with coronary artery 
disease identified statin use as an independent predictor of reduced CPC and EPC 
numbers.322 From this data, it could be that while short term use of statins may 
improve EPC function transiently, prolonged use and high doses of statins could be 
detrimental to EPCs in a clinical setting. This deduction is purely hypothetical and 
can be investigated in future studies. 
 
We have demonstrated enhanced vascular repair following arterial injury using 
lentiviral vector delivery of constitutively active Akt. While the results are novel and 
appear promising, there remain potential problems which we have highlighted in 
section 6.6.2. These hurdles will need to be adequately dealt with the confirm safety 
of the application of this research technique in clinical practice.  
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7.4 Concluding remarks 
 
 
When we commenced this project, our aims were to assess EPC number and 
function in SA men, to corroborate previous findings by our group, assess effects of 
Simvastatin on EPC function, identify mechanisms of EPC dysfunction and modulate 
these mechanisms to improve this function. 
 
Our data has not only corroborated our previous work 132, 133, but has also clearly 
demonstrated impaired capability of  EPCs derived from healthy SA men to promote 
vascular repair, when compared to white European men. These subjects were all 
apparently healthy, non-obese with normal lipid profile and normal blood pressure, 
though South Asian men were insulin resistant. Early EPC function was impaired in 
SA men, and some indices improved significantly with Simvastatin exposure in vitro. 
While similar findings have been described in human EPCs before, these findings 
are the first to be reported in South Asian men.  
 
In addition, we have systematically studied the re-endothelialisation capacity of late 
outgrowth EPCs derived from WE and SA men.  Beyond demonstrating for the first 
time that human late EPCs can promote arterial repair, we also found that SA EPCs 
were dysfunctional in vivo and this could be rescued by restoration of Akt activity. 
This finding is both novel and exciting, and opens numerous avenues in modulating 
EPC function in subjects at risk of cardiovascular events as part of developing cell-
based cardiovascular repair therapies.  
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Finally, our work has continued to demonstrate numerous aspects of endothelial 
progenitor dysfunction in SA populations. This could bear direct relevance to the 
higher prevalence of cardiovascular disease in South Asians. Hopefully our data in 
combination with future research will aid development of new strategies in the 
prevention and management of cardiovascular disease in this high risk population. 
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Abstract 
Late-outgrowth endothelial progenitor cells (LEPC) are putative mediators of 
endogenous vascular repair, and represent an attractive tool for future cell-based 
cardiovascular repair strategies. However, progenitor function is impaired in potential 
target populations. We have conducted detailed analysis of in vitro and in vivo LEPC 
pro-angiogenic function in insulin resistant South Asian (SA) men and matched 
European controls. SA LEPC exhibited impaired colony formation, migration and in 
vitro angiogenesis, associated with markedly decreased expression of the pro-
angiogenic molecules Akt and eNOS. Transfusion of control LEPC into 
immunodeficient mice after wire-induced femoral artery luminal injury augmented re-
endothelialization; however, neither SA LEPC, nor vehicle, augmented re-
endothelialization. Lentiviral vector gene delivery of constitutively active Akt1 
(E17KAkt), but not enhanced green fluorescent protein (EGFP) control, to SA LEPC 
was associated with augmented Akt content and activity, and rescue of in vivo re-
endothelialization capacity. These data support the role of human LEPC as a 
platform for future cell based vascular repair therapies, and suggest a mechanism by 
which autologous progenitor function can be promoted in subjects likely to benefit 
from cardiovascular repair therapies.  
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Introduction 
LEPC possess the functional properties of vascular endothelium, whilst exhibiting a 
progenitor hierarchy and the capacity for significant ex vivo expansion (1). These 
properties and the capacity to easily derive autologous cells without the need to 
introduce multiple potentially oncogenic genes ex vivo, makes their translation as a 
cardiovascular repair therapy appealing. A large body of evidence supports 
progenitor dysfunction in diabetes and insulin resistance, disorders linked with 
persistently poor cardiovascular mortality and morbidity (2). Our previous work has 
demonstrated impaired vascular function and a reduction in basal and exercise 
mobilized circulating progenitor cells in healthy insulin resistant South Asian (SA) 
men as a result of reduced nitric oxide (NO) bioavailability (3,4). Indeed, many other 
studies have shown vascular dysfunction and insulin resistance from childhood 
onwards in people of South Asian ethnicity, and in later life this group is at high risk 
of major vascular events, which may be amenable to cell based preventative or 
therapeutic intervention in future (5-7).  
Results 
We recruited a cohort of apparently healthy SA men and matched white European 
(WE) controls (n=12 per group) to assess basal abundance and function of LEPC, 
prior to assessing strategies to optimize the therapeutic efficacy of progenitors. 
Groups were well matched for demographic factors and established cardiovascular 
risk factors, though insulin resistance was apparent in the SA cohort (Table 1).  
LEPC colony formation was markedly reduced in SA men (Figure 1a, Supplemental 
data), suggesting a lower abundance of circulating progenitors; endothelial 
phenotype was confirmed using standard assays (see Supplemental data). The 
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proliferative rate and migration toward physiologically relevant stimuli (Vascular 
Endothelial Growth Factor [VEGF] and Insulin-like Growth Factor-1 [IGF1]) were 
blunted in SA LEPC (Figure 1b-c, Supplemental data). VEGF stimulated in vitro 
angiogenic capacity, measured by tubular structure formation on Matrigel, was also 
significantly reduced (Figure 1d, Supplemental data). Senescence, assessed using 
acidic beta-galactosidase staining, was more prevalent in SA LEPC populations 
(Figure 1e, Supplemental data). Concentrations of the pro-angiogenic molecules 
protein kinase-B (Akt) and endothelial nitric oxide synthase (eNOS) were markedly 
reduced in SA LEPC at protein level (including the ‘activated’ S473 phosphorylated 
form)(Figure 1f-i). eNOS, but not Akt, mRNA was less abundant in SA LEPC (see 
Supplemental data). 
In order to probe the in vivo relevance of our in vitro studies, equal numbers of LEPC 
were transfused intravenously into CD1 immunodeficient mice immediately after 
wire-induced luminal injury of the common femoral artery, with vehicle medium 
serving as control. After 4 days re-endothelialization was assessed using Evans blue 
staining of the injured and contralateral non-injured vessel to indicate persistent 
endothelial denudation (Figure 2a). LEPC derived from WE subjects significantly 
augmented re-endothelialization, whereas the femoral arteries of mice exposed to 
SA LEPC were indistinguishable from those receiving vehicle (Figure 2b). Confocal 
microscopy of a subset of vessel preparations revealed markedly fewer adherent 
fluorescently tagged LEPC in the intima of specimens previously treated with SA 
LEPC (see representative images in Figure 2c-d).     
Based upon the upstream location of Akt relative to eNOS, and literature 
demonstrating the critical role of both molecules in angiogenesis (8-10), we elected 
to augment LEPC Akt activity in SA LEPC using lentiviral vector gene delivery of a 
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constitutively active Akt1 mutant (E17KAkt – Supplementary data) (11,12). Self-
inactivating lentiviral vectors (LVHVSLS2 and LVSinCSGWdlNot1) were used to 
introduce E17KAkt or EGFP (control), with viral titers chosen to augment SA LEPC 
phospho-Akt S473 content approximately three-fold, in order to achieve levels 
comparable to control European LEPC (Supplementary data). E17KAkt expressing 
SA LEPC exhibited increased phospho-Akt S473 content, Akt activity as measured 
using a cell free GSK phosphorylation assay, and phospho-eNOS S1177 content 
(Figure 3a-c). Akt activity in EGFP expressing and native SA LEPC was comparable 
(Figure 3c). Intravenous transfusion of EGFP expressing SA LEPC was associated 
with unchanged femoral artery re-endothelialization, whereas E17KAkt expressing 
LEPC augmented re-endothelialization to a magnitude comparable to non-
transduced European cells (Figure 3d). Confocal microscopy of injured femoral 
artery specimens from mice exposed to EGFP expressing SA LEPC revealed 
persistent in vivo expression of EGFP in tracked LEPC (see Supplemental data).      
Discussion 
Our data are the first to demonstrate the dysfunction of LEPC derived from 
apparently healthy South Asian men using a detailed array of in vitro and in vivo 
assessments; furthermore, these functional deficits have been linked to molecular 
abnormalities relevant to vascular repair. In particular, by demonstrating improved 
SA LEPC function after lentiviral augmentation of Akt activity, we have causally 
implicated this molecule in the EPC dysfunction related to South Asian ethnicity. 
Moreover, our work provides the first demonstration of rescued in vivo LEPC function 
in cells derived from subjects at high risk of major cardiovascular events, an 
important step in optimizing future cell based cardiovascular repair strategies.   
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LEPC are recognized as representing an attractive form of autologous cell based 
cardiovascular repair therapy, given their close mimicry of endothelial phenotype and 
capacity for significant ex vivo expansion and manipulation (1). Indeed, they have 
already been demonstrated to augment myocardial angiogenesis and stimulate 
beneficial left ventricular remodeling in large animal models of myocardial infarction 
(13). Hence, these cells may offer the prospect of preventing or retarding 
cardiovascular morbidity in groups of patients at high risk of adverse events. As far 
as we are aware, our data is the first to demonstrate that human LEPC are capable 
of conduit artery repair, an important proof of principle for human autologous cell 
based vascular repair therapy. 
A growing body of evidence supports the elevated cardiovascular risk associated 
with South Asian ethnicity, compared with European ethnicity (6,14); insulin 
resistance and diabetes have been strongly implicated in this phenomenon. Our 
previous work has demonstrated important abnormalities in the vascular biology of 
apparently healthy, but insulin resistant, South Asian men (3,4). Endothelial 
dysfunction/damage were suggested by impaired flow mediated vasodilatation and 
elevation of circulating endothelial microparticles, whilst marked reductions in 
circulating progenitor subsets were apparent. Furthermore, physiological mobilization 
of progenitors appeared reduced in SA men, as a result of reduced nitric oxide 
bioavailability (3). Our current data complements these observations, demonstrating 
clear perturbation in the function of ex vivo expanded LEPC and mechanistically 
implicating impaired Akt signaling in this process. The causality of such impaired 
signal transduction in SA LEPC is unclear, though abundant data support the role of 
Akt, and downstream eNOS, signal transduction in promoting vascular repair and 
abrogating atherogenesis (8-10,15,16). Importantly our data also support the 
215 
 
capacity of E17KAkt to augment phospho-eNOS S1177, a surrogate of eNOS 
activity, and so nitric oxide generation. 
If LEPC are to become a therapeutically useful cardiovascular repair tool, it is likely 
they will be introduced in patients at the highest risk of cardiovascular morbidity and 
mortality. Our data is therefore important in demonstrating that in a group of high 
cardiovascular risk subjects, LEPC function is impaired and can be ‘normalized’ by 
modulation of Akt signaling. It is tempting to speculate that our observations may 
also extend to insulin resistant subjects within other ethnic groups, though this 
hypothesis requires ongoing assessment. It is also important to direct future studies 
toward identifying the causation of reduced Akt content and signaling in SA LEPC, 
since this may hint at more effective strategies to augment LEPC function ex vivo, or 
even modulate endogenous vascular repair.  
In conclusion, we have demonstrated that LEPC derived from healthy, but insulin 
resistant, South Asian men exhibit profound blunting of vascular reparative function 
in vitro and in vivo, which is mechanistically linked to reduced Akt signaling. By 
augmenting Akt signaling using lentiviral vector gene delivery, we have corrected 
these functional deficits, and so have demonstrated a potential means of augmenting 
the efficacy of cell based autologous vascular repair in this group at high risk of 
major vascular events.   
 
Materials and Methods 
Subject recruitment: Healthy white European and South Asian men were recruited by 
poster advertisement. Ethnicity was defined by subjects from a list used in UK 
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healthcare monitoring (17); subjects defining their ethnicity within subdivisions of 
‘Asian or British Asian’ were defined as South Asian; those within the subdivisions of 
‘White’ were defined as white European. Subjects were eligible for inclusion if aged 
18-40, free from any chronic illness, not taking prescription medication, non-smokers 
within the past year and free from hypertension (BP>160/90mmHg), diabetes and 
hypercholesterolaemia (Total cholesterol>7mmol/L). A total of 12 white European 
and 12 South Asian men were included. All participants provided written informed 
consent, according to the declaration of Helsinki; ethical approval was provided by 
the Harrogate and Leeds (Central) research ethics committees. 
LEPC culture: Peripheral blood mononuclear cells (PBMC) were harvested using 
density gradient centrifugation (Ficoll), and suspended in EGM-2 medium with EGM-
2 Bullet kit (Lonza) and 10% Fetal Calf Serum (FCS). Cells were seeded on 
fibronectin and medium replaced daily for the first week, then on alternate days. After 
3-4 weeks cells with cobblestone morphology developed in LEPC colonies (18); cells 
exhibited contact inhibition and were capable of serial passage. Endothelial 
phenotype was confirmed using flow cytometry, demonstrating co-expression of the 
vascular endothelial growth factor receptor-2 (KDR) and platelet-endothelial cell 
adhesion molecule (CD31) in >90%. 
Flow cytometry: LEPC were washed twice in phosphate buffered saline (PBS), then 
incubated with FcR blocker (Miltenyi Biotech). Appropriate concentrations of FITC 
conjugated anti-CD31 (Miltenyi Biotech), PE conjugated anti-KDR (R&D systems), or 
equivalent isotype control non-fluorescent antibodies were added. Cells were 
analyzed using a FACSCalibur cytometer with CellQuest software (Becton 
Dickinson).  
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Migration: 4×104 LEPC suspended in basal EGM2 medium (1% FCS, without other 
additives) were placed in the upper compartment of modified Boyden chamber 
apparatus. The lower compartment contained EGM2 with 50ng/ml Vascular 
Endothelial Growth Factor (VEGF165), 50ng/ml Insulin like Growth Factor-1 (IGF-1), 
or vehicle alone (control). Wells, in triplicate, were incubated for 24 hours. 
Membranes were fixed in 70% ethanol before mechanical removal of cells on the 
upper surface, and Haematoxylin/Eosin staining; migrant LEPC were enumerated in 
10 high power fields (HPF: 1430x1060µm). 
In vitro angiogenesis: LEPC (5×104 cells/ml in EGM-2 with 50ng/ml VEGF165 and 1% 
FCS) were seeded in triplicate on Matrigel plates for 24 hours. Tubule formation was 
defined as participation in contiguous circular structures; mean number of tubular 
structures per HPF was calculated from 10 HPF. 
Senescence: Sub-confluent 3rd passage LEPC were studied using a senescence 
associated β-galactosidase staining kit (Cell Signaling); senescent EPCs were 
counted by two blinded independent operators (inter-observer agreement: r=0.99) 
using Image J software (National Institutes of Health, USA) and expressed as % total 
cells. 
Western blotting: 30mcg total protein from cellular lysates was loaded onto 4-12% 
SDS-PAGE gels (Invitrogen) and electrophoresed under reducing conditions before 
transfer to PVDF membranes. Membranes were probed with primary antibody (anti-
Akt [Cell Signaling], anti-eNOS [BD], anti-phospho S473 Akt [Cell Signaling], anti-
phospho S1177 eNOS [BD], or anti-beta-actin [Santa Cruz]) overnight in 5% 
skimmed milk in TBS-Tween buffer, followed by HRP-conjugated secondary 
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antibody for an hour. Proteins were visualized using enhanced ECL kit (Amersham 
Biosciences). 
Polymerase chain reaction: Total RNA was extracted from cells using TRIZOL 
(Sigma). Equal quantities of RNA were reverse transcribed using reverse 
transcription kit (AB Systems) following manufacturer’s protocol. Real-time PCR was 
performed using the following primers using SYBR based assay (AB systems: 
7900HT), and beta-actin normalization: 
eNOS forward, 5’-CTG-GAG-CAC-CCC-ACG-CT-3’ 
eNOS reverse, 5’-AGC-GGT-GAG-GGT-CAC-ACA-G-3’ 
Akt1 forward, 5’-CCT-TCC-TCA-CAG-CCC-TGA-AGT-3’ 
Akt1 reverse, 5’-CCG-GGA-CAG-GTG-GAA-GAA-C-3’ 
Beta-actin forward, 5’-CGT-GAA-AAG-ATG-ACC-CAG-ATC-A-3’ 
Beta-actin reverse, 5’-TGG-TAC-GAC-CAG-AGG-CAT-ACA-G-3’ 
Akt activity: Akt kinase activity was analyzed by non-radioactive 
immunoprecipitation-kinase assay according to manufacturer’s protocol (Cell 
Signaling Technology). 30mcg cell extracts were incubated with immobilized Akt 1G1 
monoclonal antibody. After extensive washing, the kinase reaction was performed at 
30°C for 30 min in the presence of 200µM cold ATP and GSK-3 substrate. Phospho-
GSK-3 was measured by Western blot, using phospho-GSK-3α/β (Ser-21/9) 
antibody. 
Animals: 9-13 week old (weight 25-33g) male immuno-deficient CD1 nude mice 
(Charles River Labs) housed in isolators with 12 hour light-dark cycle were used in 
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all experiments; standard diet was provided ad libitum. Experiments were performed 
under license from the UK Home Office, observing standard animal welfare 
regulations. 
Vascular injury and analysis: As published (19), mice were anaesthetized with 
isoflurane prior to femoral arteriotomy and three 1.5cm passages of a 0.014-inch-
diameter angioplasty guidewire (Hi-Torque Cross-IT 200XT, AbbotVascular, USA); 
the vessel was then ligated, and skin closed. The contralateral artery underwent 
sham operation, without arteriotomy or wire injury. Animals received postoperative 
buprenorphine 0.25mg/Kg. 3x105 CMDiI (Invitrogen) labeled LEPC in EBM2 (or 
EBM2 without cells, as control) were transfused into the external iliac vein 
immediately after injury. Injured and contralateral femoral arteries were explanted 4 
days later after injection of 50µL Evans Blue dye via the inferior vena cava and 
perfusion fixation with 4% paraformaldehyde in PBS. Re-endothelialization was 
assessed in en face specimens, defined as the region of absent Evan’s blue staining 
in relation to a total area of a 5mm section of vessel, commencing 5mm distal to the 
aortic bifurcation; vessels were then mounted with Vectashield DAPI for confocal 
microscopic (Zeiss LSM 510 META Axioplan 2) assessment of adherent LEPC. All 
murine studies and analysis were performed by researchers blinded to ‘treatment’ 
allocation.  
SIN-Lentiviral vector production and transduction: pSINCSGWdlNot1 was a kind gift 
of Dr. Yashiro Idea (Mayo Clinic, Minnesota, USA) (20). The EGFP cassette of 
pSINCSGWdlNot1 was replaced by E17KAkt to generate pHVSLS2. The SIN-
lentiviral vectors were generated in accordance to established protocols (21), and 
were titred using QuickTiter™ Lentivirus Titer Kit (Lentivirus-Associated HIV p24 
ELISA kit [Cell Biolabs]) in accordance with manufacturer’s protocol. Semi-confluent 
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LEPC were transduced at one moi (multiplicity of infection) of appropriate lentiviral 
vector for use 4 days later. 
Statistical analysis: Data are presented as mean (standard error of mean) and 
groups compared with Student’s t-tests or paired t-tests as appropriate. Statistical 
significance is defined as p<0.05. 
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Figure 1: In vitro characterization of LEPC abundance and function 
 
In South Asian men, compared with white European controls, LEPC: A) colony 
formation is reduced (n=8); B) population doubling time is prolonged (n=8); C) 
Migration to VEGF and IGF-1 is impaired (n=8); D) In vitro angiogenesis is reduced 
(n=8); E) Senescence is increased (n=8); F-G) Total and phospho-S473 Akt are 
reduced (n=7); H-I) Total and phospho-S1177 eNOS are reduced (n=7). All data are 
displayed as mean ± SEM; p<0.05 is denoted by *. 
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Figure 2: In vivo assessment of LEPC mediated arterial re-endothelialization  
 
A) Injured (top) and non-injured (bottom) femoral arteries demonstrating endothelial 
denudation, indicated by Evan’s blue staining, in the injured vessel (Scale bar 
denotes 5mm); B) Femoral artery re-endothelialization is augmented in mice 
receiving WE, but not SA LEPC, nor vehicle (n=7 in all groups; data is displayed as 
mean ± SEM); C-D) Representative confocal microscopic images of injured intima, 
showing sparse tracked LEPC in vessel from mouse receiving SA LEPC (C) and 
abundant tracked cells in vessel of mouse receiving WE LEPC (D) [Scale bars 
denote 100µm; Blue – DAPI, Red – CMDiI cell tracker labeled LEPC]. p<0.05 is 
denoted by *; p≥0.05 is denoted by NS. 
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Figure 3: In vitro and in vivo assessment of LEPC expressing constitutively active 
Akt 
 
A) Phospho-S473 Akt content is increased in E17K expressing cells, relative to 
EGFP expressing, or untreated SA LEPC (representative immunoblots included; n=6 
in all studies); B) Phospho-S1177 eNOS is increased in E17K expressing cells, 
relative to EGFP expressing, or untreated SA LEPC (representative immunoblots 
included; n=6 in all studies); C) Akt activity is increased in E17K expressing cells, 
relative to EGFP expressing, or untreated SA LEPC (representative immunoblots 
included; n=6 in all studies); D) Lentiviral vector mediated gene delivery of 
constitutively active Akt1 (E17kAkt), but not EGFP, to SA LEPC rescues capacity to 
re-endothelialise injured femoral artery, when compared with unmodified WE LEPC 
(n=6 in E17KAkt and EGFP groups, and n=7 in all other groups). All data are 
displayed as mean ± SEM; * denotes p<0.05. 
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Table 1: Demographic and cardiovascular risk data 
 South Asian White European p value 
Age (years) 30.9 (1.2) 29.7 (1.1) NS 
Body Mass Index (Kg/m2) 24.1 (0.7) 22.4 (0.5) NS 
Waist-Hip ratio 0.85 (0.01) 0.84 (0.01) NS 
Systolic Blood Pressure (mmHg) 116 (2.3) 116 (2.5) NS 
Diastolic Blood Pressure (mmHg) 70 (1.6) 69 (1.6) NS 
Total Cholesterol (mmol/L) 4.6 (0.1) 4.7 (0.1) NS 
Triglycerides (mmol/L) 1.1 (0.1) 1.2 (0.1) NS 
Glucose (mmol/L) 4.8 (0.1) 4.6 (0.1) NS 
Insulin (mu/L) 5.6 (0.8) 2.9 (0.3) 0.009 
HOMA-IR 1.2 (0.2) 0.6 (0.1) 0.008 
 
All data are expressed as mean (SEM). NS denotes non-significant. 
 
 
 
 
